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Abstract
Suppressing mutant p53 using RNA interference: Investigating a novel potential 
gene therapy strategy for Colorectal Cancer
Colorectal cancer is a common disease that kills half of those affected within five 
years of diagnosis. A pathway of successive genetic mutations leads to tumour 
progression and p53 has an important and frequent role to play in the late stage of 
this carcinogenesis. Single nucleotide p53 mutations may lead to a gain of malignant 
function which may render colorectal cancers less responsive to adjuvant 
chemotherapy regimes. The technology of RNA interference (RNAi) allows targeted 
gene silencing and vectors are available that allow stable and prolonged suppression 
of the protein product under investigation.
I hypothesised that inhibiting mutant p53 in colorectal cancer cells may reduce 
malignant potential and augment response to adjuvant therapies. The aim was to 
utilise RNA interference via the pSUPER (oligoengine) plasmid to achieve stable 
down regulation of mutant p53 protein levels in a panel colorectal cancer cell lines in 
culture and to consequently study the effects of this on cell proliferation and response 
to chemotherapeutic agents.
In total over one hundred clones were produced and analysed, with clonal 
populations created in three separate cell lines, each of which showed successful 
down regulation of the mutant p53 protein.
The effect of mutant p53 suppression on the rate of cell proliferation in the SW620 
cell line was studied. Whilst some of the clonal populations with down regulation of 
mutant p53 expression did show a markedly reduced proliferation rate, this was not 
consistent across all suppressed clones. Some with no alteration in mutant p53 levels 
also exhibited a degree of slowed proliferation.
Two SW620 clones with significant suppression of their mutant p53 protein levels 
demonstrated an IC5o value half that of the parent population when treated with 
oxaliplatin. Thus, half the amount of this chemotherapeutic agent was needed to 
produce the same effect when the mutant p53 protein had been suppressed. The 
results with the second agent, 5- fluorouracil, were less consistent. Whilst there was a 
general trend towards lower IC5o values in the down regulated clones, this was not 
always the case.
The overall conclusion from our work is that suppression of mutant p53 may 
improve the chemotherapy response of colorectal cancer cells, especially to 
oxaliplatin. However, these experiments show that extrapolating beyond the results 
obtained for an individual clone can be misleading and that large numbers of clone 
replicates must be studied before appropriate conclusions can be drawn.
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Chapter 1. Introduction
Colorectal cancer is a common disease that still kills half of those affected within 
five years of diagnosis. A pathway of successive genetic mutations leads to tumour 
progression and p53 has an important and frequent role to play in the late stage of 
this carcinogenesis. Single nucleotide p53 mutations may lead to a gain of malignant 
function above and beyond that witnessed with loss of the wild-type p53 phenotype. 
This may render colorectal cancers less responsive to adjuvant chemotherapy 
regimes. The technology of RNA interference allows targeted gene silencing and 
vectors are available that allow stable and prolonged suppression of the protein 
product under investigation. This thesis will examine whether these vectors can be 
successfully used on colon cancer cell lines in vitro to suppress mutant p53 and 
hence abrogate any ‘gain of function’ effects. It will then consider whether such 
suppression effects cell proliferation and improves responsiveness to 
chemotherapeutic agents within these cell lines.
This introduction considers colorectal cancer as a clinical disease; detailing its 
epidemiology, aetiology, natural history and staging. The current methods for 
screening, diagnosing and treating the disease are reviewed and survival statistics are 
considered. The mechanism of action of chemotherapy is detailed along with 
consideration of some the agents used in colorectal cancer treatment and the current 
role chemotherapy plays in the neo-adjuvant, adjuvant and palliative settings.
The genes and pathways implicated in inherited and sporadic colorectal cancer 
tumorigenicity are reviewed with establishment of the role p53 plays within this 
network. The study then focuses in on the TP53 gene itself, reviewing some of the
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extensive research of the past thirty years into the gene’s structure and function. The 
implications of TP53 mutations in colorectal cancer and the effects on prognosis and 
treatment will be discussed. The nature and relevance of ‘gain of function’ p53 
mutations will be highlighted with a review of the published work on this topic to 
date. The technology of RNA interference and its role in the laboratory and clinical 
settings to date will also be considered.
This section will conclude with the hypothesis and the aims for this MD thesis being 
presented.
1.1 Colon cancer as a disease
1.1.1 Epidemiology
Colorectal cancer is a major cause of mortality and morbidity in the Developed 
world. Worldwide an estimated 1.24 million new cases of colorectal cancer were 
diagnosed in 2008, accounting for more than 9% of all new cancer cases [1]. In 2008 
there were 39,991 new cases of large bowel cancer registered in the UK, resulting in 
around 110 new cases of colorectal cancer being diagnosed each day. Around two- 
thirds of these (25,551) arise in the colon and one-third (14,440) in the rectum. In 
2010, there were 16,013 deaths from bowel cancer in the UK [2-5]. The lifetime risk 
for men of being diagnosed with colorectal cancer in the UK is estimated to be 1 in 
15 and for women 1 in 19. In the UK colorectal cancer is now the third most 
common cancer in women after breast and lung cancer whereas in men it also ranks 
third after prostate and lung cancer [6-8].
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The occurrence of colorectal cancer is strongly related to age, with 86% of cases 
arising in people who are 60 years or older. The data shown in Figure 1.1 indicates 
that until age 50, men and women have similar rates for colon cancer, but in later life 
male rates are higher. In numerical terms, there are more male cases of bowel cancer 
in almost all age-groups up to the age of 84, after which female cases are in the 
majority, even though their rates are lower, as women make up a larger proportion of 
the elderly population. Overall the male to female ratio is 11:10. The incidence of 
rectal cancer is higher in men whilst the incidence of colon cancer is higher in 
women [2-5].
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Figure 1.1: Colorectal Cancer: Average Number of New Cases Per Year and Age-Specific
Incidence Rates, UK, 2006-2008.
Published by Cancer Research UK. 
http://info.cancerresearchuk.org/cancerstats/tvpes/bowel/
The lifetime risk of a man in Great Britain developing colorectal cancer has almost 
doubled between 1975 and 2008, from 3.5% (or 1 in 29 men) to 6.9% (or 1 in 15).
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In women the risk has increased from 3,9% (or 1 in 26 women) to 5.4% (or 1 in 19 
women).
Incidence rates vary across the country, particularly in men. Incidence rates are as 
low as 50 per 100,000 men in London, which along with the South East and the East 
of England, has rates below the England average. However, in the North East the 
incidence rate is more than 65 per 100,000 men and along with the North West and 
the West Midlands, it has rates significantly higher than the England average. Female 
incidence rates across the country are much closer to the England average with 
London being the only region which is significantly lower at 35 per 100,000 women
[9].
There is a deprivation gradient for male colorectal cancer patients, with incidence 
rates 11% higher in the most deprived groups than in the affluent groups [10].
Bowel cancer is the third most common cancer worldwide after lung and breast with 
almost 60% of all colorectal cancers occurring in the more developed regions. 
Globally there are large variations in rates, with the lowest rates in Africa, Asia and 
Latin America and the highest in Western Europe, Northern America and 
Australasia[l]. Japan is an exception to other countries in the Eastern Asia region 
with age-standardised rates similar to other highly developed countries. Countries 
that have had a rapid ‘westernisation’ of diet, such as Japan, have also seen a rapid 
increase in the incidence of colorectal cancer. Consumption of meat and dairy 
products in Japan increased ten-fold between the 1950s and 1990s [11, 12]. 
Epidemiological studies report a rapid increase in risk for colorectal cancer in 
migrants moving from low to high risk countries [13] and the rates for second
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generation migrants can be double that of first [14]. The risk of colorectal cancer also 
decreases after migrating from a high to a lower risk country. The magnitude of 
incidence variation worldwide, together with migration data, suggest that many cases 
of colorectal cancer could be prevented.
In Europe, the incidence of colorectal cancer is increasing, particularly in southern 
and eastern Europe, where rates were originally lower than in western Europe [15, 
16]. In the USA, the incidence rose until the mid-1980s but in the last two decades 
rates have fallen for both men and women [17].
Although patients diagnosed with early stage disease have a high cme rate, many 
patients present later when long term survival is poor. The five-year relative survival 
rates for both male and female colon and rectal cancer have doubled between the 
early 1970s and the mid 2000s. In the early 1970s, five-year relative survival for 
male colon cancer was 22% (23% for women) and this rose to 50% (51% for 
women) in the mid 2000s. Over the same time period, the five-year survival rates for 
male rectal cancer rose from 25% to 51% and from 27% to 55% for female rectal 
cancer [18]. Ten-year survival rates are only a little lower than those at five-years 
indicating that most patients who survive for five years are cured from this disease.
1.1.2 Aetiology
1.1.2.1 Genetics
The development of colorectal cancer results from the interactions of an individual’s 
genotype and the environmental influences which they encounter during their lives. 
As it is a common cancer, many people are quite likely by chance alone to have at 
least one affected relative [19], as the number of affected relatives increases, so does 
the risk of the individual developing the disease [20]. There is a spectrum of genetic
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risk from those with no particular’ genetic disposition through to those who will 
almost inevitably develop colorectal cancer. There are various degrees between these 
extremes where the contribution of inherited genetic risk plays a variable role. In 
order to stratify these risks into categories for screening strategies, the genetic 
inheritance related to colorectal cancer is considered as high, high-moderate or low- 
moderate risk.
High risk patients, 3 - 5% of the total cases [21], are those in whom a family member 
is known to have one of the ‘inherited bowel cancer syndromes” i.e. Familial 
Adenomatous Polyposis (FAP), MUTYH-associated polyposis (MAP), juvenile 
polyposis (JPS), Peutz-Jeghers syndrome (PJS) or Hereditary Non-Polyposis Colon 
Cancer (HNPCC) aka Lynch Syndrome. These high penetrance genetic disorders are 
identified on the basis of one or more of the following criteria:
• A family history consistent with an autosomal dominant cancer syndrome.
• Pathognomonic features of a characterised polpyposis syndrome personally 
or in a close relative.
• The presence of a germline pathogenic mutation in a colorectal susceptibility 
gene.
• Molecular features of a familial syndrome in a colorectal cancer arising in a 
first-degree relative.
The lifetime cancer risk for theses syndromes ranges from 10-100% and so the 
intensity of surveillance reflects that elevated level of risk and the natural history of 
the resultant neoplasia [22],
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In FAP family members, annual flexible sigmoidoscopy and alternating colonoscopy 
should be offered to mutation carriers from diagnosis until polyp load indicates a 
need for surgery. Patients should be advised to undergo prophylactic surgery (ideally 
panproctocoloectomy) between the ages of 16 and 25 year's, but the exact timing of 
surgery should be guided by polyp numbers, size and dysplasia alongside 
consideration of educational and child-bearing issues [23].
In Lynch syndrome (HNPCC) family members, total colonic surveillance, at least 
biennially, should commence at age 25 years and continue to age 70-75 years, or 
until clinical co-morbidity makes it clinically inappropriate. Colonoscopic 
surveillance for individuals with proven MMR gene mutations has been shown in 
retrospective case-control comparisons to provide an average of seven years of extra 
life [24].
The high-moderate risk category comprises:
• People with three or more affected relatives in a first-degree kinship with 
each other (none less than 50 years old, otherwise they would fulfil high risk 
criteria) or
• Two affected relatives less than 60 years, or with a mean age less than 60, in 
first degree kinship with each other.
People in the high-moderate risk category merit low intensity surveillance 
comprising 5-yearly colonoscopy commencing at age 50 until age 75years.
The low-moderate risk group comprises those with only one affected relative less 
than 50 years old or only two affected first degree relatives aged 60 or older. These 
individuals are recommended for a once-only colonoscopy at age 55; with further
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surveillance under-taken only if adenomatous polyps are encountered at this 
investigation [25].
The low risk group encompasses all those in whom the above family history criteria 
are not satisfied. Although the risk of developing the disease may be up to twice that 
of the average population, there is no evidence to support routine invasive 
surveillance in this group. The risks of colonoscopy as a procedure are not offset by 
the detection rate of new cancers in asymptomatic patients [26].
1.1.2.2 Lifestyle Factors
A high intake of dietary fibre, in particular cereal fibre and whole grains, is 
associated with a reduced risk of colorectal cancer [25], It is hypothesised that 
reduced intestinal transit time and the effects of dilution could reduce the exposure of 
the large intestine mucosa to potential pathogens [27]. The effects of wheat fibre on 
mucosal cell turnover, [28] epidemiological [29] and dietary questionnaire studies 
[30] all back up this hypothesis. The effects of red meat have been examined in many 
epidemiologic studies; most, though not all, associate an increase in colon cancer or 
adenoma risk with greater intake of red meat. In the European Prospective 
Investigation into Cancer and nutrition (EPIC) study; the absolute risk of developing 
colorectal cancer within 10 years for a 50 year old participant was 1.71% for the 
highest category of red and processed meat intake compared with 1,28% for the 
lowest category of intake [31]. It is suggested that animal fats cause an increased 
excretion of bile salts in the faeces but also promote the growth of bacteria that can 
degrade bile salts into carcinogens [32]. Secondary bile acid secretion is increased 
after cholecystectomy and this was said to correlate with a rise in colorectal cancer- 
incidence [33]. However, a more recent study refutes this finding [34].
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Calcium binds bile acids and two large scale, double-blind, randomised controlled 
trials have shown that dietary calcium supplementation can bring about a moderate 
reduction in the risk of recurrent colonic adenomas. However a Cochrane review 
concluded there was insufficient evidence to recommend the general use of calcium 
supplements to prevent colorectal cancer [35]. Diets lacking in vegetables have been 
shown to increase risk [36]. Isiocyanates in cruciferous vegetables (e.g. broccoli) 
may help induce apoptosis in neoplastic cells [37, 38]. High glycaemic dietary load 
and high intake of refined carbohydrates have been shown to increase risk, 
potentially secondary to insulin resistance [39, 40].
There is a consistent inverse relationship between exercise and colon cancer risk in 
all studies, though the effects are greater in men than women [41]. Elevated BMI 
also seems to independently increase risk of both adenomas and colorectal cancer 
[42]. A recent meta-analysis has confirmed the link between smoking and colorectal 
cancer, with relative risk increased proportionate to daily consumption, age at 
initiation, duration and total number of pack years [42]. The relationship between 
alcohol and cancer has been controversial, but most evidence indicates that high 
intake of alcohol increases risk of colorectal cancer. A pooled analysis of 8 
prospective cohort studies, which included nearly 500,000 participants, yielded a 
multivariate risk of colorectal cancer of 1.24 (95% Cl 1.07-1.42) for consumption of 
>30 g/day of alcohol compared to low intake [43]. There is substantial evidence that 
the use of non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin are 
associated with a reduced risk of colorectal cancer and adenomatous polyps [44, 45].
Chapter One - Introduction 9
Use of Hormone Replacement Therapy (HRT) in post-menopausal women has been 
associated with a reduced risk of developing colorectal cancer. In the Women’s 
Health Initiative trial (16,608 participants); relatively short-term use of oestrogen 
plus progestin was associated with a decreased risk of colorectal cancer [46]. There 
were 43 invasive colorectal cancers in the hormone group and 72 in the placebo 
group (hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.003). 
However, the increased risk for other types of cancer and cardiovascular effects 
indicate that HRT cannot safely be used for chemoprevention [47].
1.1.3 Natural History / Pathology
In normal colon tissue, stem cells at the bottom of crypts divide continuously in an 
asymmetric fashion, adding cells to the crypt’s proliferative area [48]. These 
intermediary cells will either differentiate further into goblet cells or migrate towards 
the lumen [49]. In malignant tissue, genomic alterations disrupt normal division, 
resulting in symmetric division, with the possible result that both daughter cells may 
preserve the clonogenic traits of the stem cell. If apoptotic activity is not adequate, 
this leads to the build up of altered stern cells and the risk of clonal expansion [49], 
see Figure 1.2. Aberrant crypt foci are one of the foremost pre-malignant lesions seen 
in colorectal cancer. Dysplastic aberrant crypt foci are the precursors of adenomatous 
polyps. Once developed the small adenoma enlarges and becomes increasingly 
dysplastic. Low grade dysplastic adenomas exhibit mild to moderate architectural 
irregularities. High grade dysplastic adenomas show heightened changes in glandular 
patterns and / or extreme cytological irregularities. High grade dysplasia is the 
catalyst for malignant transformation [50]. Histologically, adenomas are classified
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as tubular, tubulo-villous or villous, with increasing villous content and neoplastic 
tendency respectively [51].
Although the majority of adenomas diagnosed are polypoid or exophytic, the flat 
adenoma (defined as an adenoma where the depth of dysplastic tissue is no more 
than twice that of the mucosa) is now a recognised entity. These lesions may account 
for up to 40% of adenomas, are premalignant and may have a greater tendency 
towards malignant transformation than polypoid adenomas [52].
Figure 1.2: Model for colon cancer initiation from stem cells.
Reproduced from Chandler and Lagasse, Stem Cell Research and therapy 2010 [53].
Accurate, detailed and consistent pathology reporting for colorectal cancer is 
important for estimating prognosis and planning further treatment in terms of 
adjuvant therapy. The Dukes’ classification was first published in 1932 and is still 
utilised today [54]. This simple classification based on pathological findings was 
modified further by Dukes in 1958, sub-dividing group C to detail apical node 
involvement [55], as shown in Table 1.1. An adaptation by the Americans Astler and
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Coller in 1954 further divided stages B and C [56], as shown in Table 1.2. These 
staging systems are still widely quoted, but the TNM (Tumour, Node, Metastasis) 
classification, produced by the American Joint Commission on Cancer (AJCC) and 
currently in its 7th edition, is the internationally preferred method for reporting and 
staging colorectal cancers [57], which is demonstrated in Table 1.3 and Table 1.4
Table 1.1: Duke’s Original Classification [55]
Stage Description
A Limited to the bowel wall
B Through the bowel wall
C Regional lymph nodes metastasis
(later divided into Cl Apical node negative and C2 where the node is positive)
Table 1.2: Modified Astler-Coller (MAC) staging system [56]
Stage Description
A Limited to the mucosa
B1 Tumour extending into but not through the muscularis propria
B2
Tumour penetrating through the serosa but no involvement of
lymph nodes
B3 Tumour invades adjacent structures
Cl Same as B1 plus regional nodal metastasis
C2 Same as B2 plus regional nodal metastasis
C3 Same as B3 plus regional nodal metastasis
D Distant metastasis
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Table 1.3. The TNM Classification of Colorectal Cancer (7th Edition) [57J
Primary tumor (T)
TX Primary tumor cannot be assessed
TO No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through the muscularis propria into the pericolorectal tissues
T4a Tumor penetrates to the surface of the visceral peritoneum
T4b Tumor directly invades or is adherent to other organs or structures
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Metastasis in 1-3 regional lymph nodes
Nla Metastasis in 1 regional lymph node
Nib Metastasis in 2-3 regional lymph nodes
Nlc Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional nodal metastasis
N2 Metastasis in 4 or more lymph nodes
N2a Metastasis in 4-6 regional lymph nodes
N2b Metastasis in 7 or more regional lymph nodes
Distant metastasis (M)
MO No distant metastasis
Ml Distant metastasis
Mia Metastasis confined to 1 organ or site (eg, liver, lung, ovary, nonregional node)
Mlb Metastases in more than 1 organ/site or the peritoneum
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Table 1.4: Stage of disease according to TNM classification
Stage T N M Dukes
Modified
Astler-
Coller
0 Tis NO MO — —
I T1 NO MO A A
T2 NO MO A B1
IIA T3 NO MO B B2
IIB T4a NO MO B B2
IIC T4b NO MO B B3
IIIA T1-T2 Nl/Nlc MO C Cl
T1 N2a MO C Cl
IIIB T3-T4a Nl/Nlc MO C C2
T2-T3 N2a MO C C1/C2
T1-T2 N2b MO C Cl
me T4a N2a MO C C2
T3-T4a N2b MO C C2
T4b N1-N2 MO C C3
IVA Any T Any N Mia — —
IVB Any T Any N Mlb — —
Another factor that can affect the outlook for survival is the grade of the cancer. 
Grade is a description of how closely the cancer resembles normal colorectal tissue 
microscopically. The scale used for grading colorectal cancers goes from G1 (well 
differentiated) to G4 (poorly differentiated). The grade is often simplified as either 
"low-grade" (G1 or G2) or "high-grade" (G3 or G4). Low-grade cancers tend to grow
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and spread more slowly than high-grade cancers. Most of the time, the outlook is 
better for low-grade cancers than it is for high-grade cancers of the same stage.
Invasion and spread of colorectal cancer eventually renders it a terminal disease. This 
may occur directly or via the lymphatic or haematogenous routes. Direct radial 
spread may involve the small intestine, stomach, pelvic organs or abdominal wall 
whilst a retroperitoneal extension may invade the ureter, duodenum, or the posterior 
abdominal wall. The lymphatic spread of colonic cancer progresses usually from the 
paracolic nodes along the main colonic vessels to the nodes associated with either 
cephalad or caudal vessels, eventually reaching the para-aortic glands in advanced 
disease. The most common site for blood-borne spread of colorectal cancer is the 
liver, presumably arriving by the portal venous system. Up to 37% of patients may 
have detectable liver metastases at the time of operation, and around 50% of patients 
will develop overt metastatic disease at some stage [58],
1.1.4 Screening
Prior to introduction of the UK bowel cancer screening programme, colorectal cancer 
often presented either as an emergency (approximately 20% of patients) e.g. 
obstruction, perforation or bleeding, or as an incidental finding on routine tests 
performed for another reason e.g. investigating iron deficiency anaemia [59].
However, a meta-analysis of four randomised controlled trials evaluating mass 
screening using the faecal occult blood test (FOBt) demonstrated a 15% reduction in 
bowel cancer specific mortality in the trials using biennial screening [60]. Following 
these demonstrations of mortality reduction, the Department of Health commissioned
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a pilot screening programme to assess the feasibility of using biennial FOBt 
screening as a population screening tool for bowel cancer in the UK.
The initial UK Pilot programme ran from 2000-2002 and three pilot screening rounds 
for men and women aged 50-69 years were successfully implemented in Coventry 
and Warwickshire in England and in Tayside, Grampian and Fife in Scotland. These 
pilots achieved uptake of screening close to the 60% target, and concluded that key 
parameters of test and programme performance observed in randomised studies of 
FOBT screening can be repeated in population based pilot programmes. For every 
1000 individuals returning at least one test kit during the first phase of the screening 
pilot in England, there were approximately three positive results, 958 negative results 
and 39 unclear results after the first test kit. After a possible two further tests for 
individuals with unclear results, there was an overall total of approximately 16 
positive results and 980 negative results per 1000 individuals returning at least one 
test kit. Approximately 16 out of every 1000 participants returning a test kit were 
offered a colonoscopy, with uptake of colonoscopy reaching 78%. Cancer was 
detected in approximately 10% of individuals undergoing colonoscopy, with 
adenoma being detected in 40% and nothing abnormal being detected in 50% of 
individuals [61].
Following a second round of pilot studies conducted between 2003 - 2005, [62] the 
NFIS UK Bowel Cancer Screening Programme started to offer biennial screening to 
those aged 60 - 69 nationally in April 2006, and is now available across England 
with a target of completing all initial invitations for screening by the end of 2012.
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The NHS is also planning to introduce flexible sigmoidoscopy screening for all men 
and women when they reach the age of 55.This follows a multicentre randomised 
controlled trial which found that flexible sigmoidoscopy was a safe and practical test 
which, when offered only once to the appropriate age group conferred a substantial 
and lasting benefit [63].
1.1.5 Presentation and Diagnosis
The left side of the colon is affected more often than the right, with tumours in the 
sigmoid colon, recto-sigmoid junction and the rectum, accounting for over half of the 
total cases, as demonstrated in Figure 1.3. In 4-5% of cases there are synchronous 
lesions at the time of presentation [59].
Right side Left side
Hepatic Flexure 
3%
Splenic Flexure 
2%
Ascending Colon 
8% Transverse Colon Descending 
Colon 3%
Rectosigmoid 
Junction 7%
Caecum
14%
Sigmoid Colon 
20%
Appendix
1% Rectum
27%Anus
2%
Other and Unspecified Sites 
8%
Figure 1.3: Bowel cancer (Cl 8-21), Percentage Distribution of Cases within the Large
Bowel, Great Britain, 2007-2009.
Published by Cancer Research UK. info.cancerresearchuk.org/cancerstats/types/bowel/
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Patients with left sided / rectal tumours (approximately 75%) typically present with a 
change of bowel habit, colicky abdominal pain and per rectum bleeding. Right sided 
cancer typically presents with anaemia, as the liquid nature of the faeces and the 
wider diameter of the colon make obvious tumour related symptoms unusual. 
Guidelines have been developed to classify those at high risk warranting urgent 
investigation based on change in bowel habit, rectal bleeding in the absence of anal 
symptoms, palpable abdominal or rectal masses, and anaemia [64].
It is recommended that patients with higher-risk symptoms should be fast-tracked 
either in special clinics or with urgent appointments in routine clinics. Patients so 
referred should be investigated with sigmoidoscopy (flexible or rigid) plus a high 
quality double contrast barium enema, or colonoscopy, or CT colonography. With 
the exception of patients with peritonitis who require emergency surgery, all patients 
with colon or rectal cancer should have pre-operative staging by CT scan to 
determine the local extent of the disease and the presence of lung or liver metastases. 
Patients with rectal cancer should also have MRI scans of the pelvis to stage the 
tumour and assess involvement of adjacent organs. Endorectal ultrasound scanning 
should be performed to assess T1 rectal cancers when local excision is being 
considered [65].
For the purpose of this summary so far colonic and rectal cancers have been 
considered as a single disease process, however it is debated whether they should be 
considered as separate entities. Differences exist with respect to age and gender 
dynamics as well at tumour progression and adjuvant treatments. However, there is a 
good correlation between cancer incidence rates for both the sites observed in 
different ethnic populations and the shared similar aetiology, type of precancerous
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lesions as well as mode of spread all give evidence to them being two variants of the 
same malignant process.
1.1.6 T reatment options
1.1.6.1 Surgery
Radical resection of a colonic tumour along with the appropriate vascular pedicle and 
accompanying lymphatic drainage is the most appropriate operation to gain local 
control [66]. This approach is appropriate for 80-90% of patients with localised colon 
carcinoma. As surgery is the only definitive curative treatment, technique is 
important to ensure a good outcome. Adequate lymphadenectomy is critical. In 
addition to the therapeutic benefits of preventing local progression and subsequent 
development of symptoms due to mesenteric recurrence, lymphadenectomy is critical 
in the staging of patients with colon carcinoma. In colon cancer, the status of 
recovered lymph nodes is one of the main parameters used for adjuvant therapy 
recommendations.
1.1.6.2 Adjuvant treatments
At present, only chemotherapy and radiotherapy have an established role as adjuvant 
treatment for colorectal cancer. Chemotherapy is discussed in section 1.2.
1.1.6.3 Radiotherapy
Radiotherapy is a potential adjuvant treatment only for those tumours localised in the 
rectum. There is unequivocal evidence that neo-adjuvant radiation reduces the risk of 
local recurrence in resectable rectal cancer [67, 68].
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Patients with resectable rectal cancer should be considered for preoperative short 
course radiotherapy (25Gy in 5 fractions in 1 week), with surgery performed within 1 
week of completion of radiation.
When local staging indicates that radiotherapy (with synchronous chemotherapy) 
would be appropriate to downstage the tumour and facilitate surgical resection, a 
dose of 45Gy in 25 fractions over 5 weeks, is recommended. If the addition of 
radiotherapy to surgery is deemed necessary for rectal cancer, it should ideally be 
given pre-operatively. However, in cases with well established predictive factors of 
local recurrence (e.g. evidence of tumour at the circumferential resection margin, 
mesorectal lymph node involvement and extramural vascular invasion), post 
operative radiotherapy and chemotherapy should be considered for patients who did 
not receive pre-operative radiotherapy. A dose of 45Gy in 25 fractions over 5 weeks 
with a planned boost dose of 5.4-9Gy in 3-5 fractions is recommended [65],
A planned radiotherapy volume using three or four fields given pre-operatively is 
recommended for rectal cancers as this results in less morbidity and mortality [67, 
68].
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1.1.7 Five Year Survival
The proportion of patients surviving for five years or more after their initial cancer 
resection is significantly influenced by the Dukes’ stage of the original tumour, as 
shown in Table 1.5. Ten year survival rates hardly differ from these figures, as the 
vast majority of patients surviving for at least five years are considered cured from 
the disease.
Table 1.5: Five-year relative survival of colorectal cancer patients (diagnosed 1996-2002)
by stage at diagnosis, England.
Adaptedfrom National Cancer Inteligence Network (NCIN). 
www. ncin. org. uk/publications/data_ briefings/colorectalcancersurvivalbystage. aspx
Duke’s Stage at 
diagnosis Percentage of Cases
Five-year Relative 
Survival
A 8.7% 93.2%
B 24.2% 77.0%
C 23.6% 47.7%
D 9.2% 6.6%
Unknown 34.3% 35.4%
Chapter One - Introduction 21
1.2 Chemotherapy
Most chemotherapeutic drugs achieve their cytotoxicity by inhibiting mitosis, or 
inducing apoptosis, therefore exhibiting their greatest action against any rapidly 
dividing cells. These agents are largely non-selective, in that they impact on both 
enlarging tumours and other fast dividing cells, such as those responsible for hair 
growth and for replacement of the intestinal epithelium - leading to the side effect 
profiles which can be associated with these agents.
As chemotherapy affects cell division, tumours with high growth fractions are more 
sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing 
cell division at any time. Chemotherapy also affects well differentiated tumours more 
effectively since mechanisms regulating cell growth are usually still preserved. With 
succeeding generations of tumour cells, differentiation is typically lost, growth 
becomes less regulated, and tumours become less responsive to most 
chemotherapeutic agents. Near the centre of some solid tumours, cell division has 
effectively ceased, making them insensitive to chemotherapy. Another problem with 
solid tumours is the fact that the chemotherapeutic agent often does not reach the 
core of the tumour.
Chemotherapy may be administered with a curative intent or it may be used 
palliatively to decrease tumour load and increase life expectancy, a better toxicity 
profile generally being expected for the latter. Multiple agents are often used in 
combination therapy; the differing mechanisms of action minimise single-agent 
resistance and side effect profiles are generally reduced.
Chemotherapy may be used pre-operatively (neoadjuvant) to shrink the primary 
tumour, thereby rendering local therapy (surgery or radiotherapy) less destructive or
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more effective. Alternatively it can be utilised post-operatively to treat any residual 
tumour cells and reduce recurrence rates, or palliatively in the treatment of advanced 
disease not amenable to surgical resection.
Performance status is used to ascertain an individual’s capability to withstand a 
chemotherapy regime or to assess whether dose reduction is required. Only a fraction 
of the cells in a tumour die with each treatment (fractional kill), so the drug treatment 
is administered in cycles, with the frequency and duration of treatments limited by 
toxicity to the patient.
1.2.1 Fluorouracil (5-FU)
5~FU is a fluoropyridimine and an analogue of uracil with a fluorine atom at the C-5 
position in place of hydrogen. The fluoropyridiamines were developed in the 1950s 
following the observation that rat hepatomas used the pyrimidine uracil, one of the 
four bases found in RNA, more rapidly than normal tissues, indicating that uracil 
metabolism was a potential target for antimetabolite chemotherapy [69]. The 
mechanism of cytotoxicity of 5-FU has been ascribed to the disincorporation of 
fluoronucleotides into RNA and DNA and to the inhibition of the nucleotide 
synthetic enzyme thymidylate synthase (TS). Fluorouracil rapidly enters the cell 
using the same facilitated transport mechanism as uracil [70]. 5-FU is converted 
intracellularly to several active metabolites: fluorodeoxyuridine monophosphate 
(FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate 
(FUTP). These active metabolites disrupt RNA synthesis and the action of TS. The 
rate-limiting enzyme in 5-FU catabolism is dihydropyrimidine dehydrogenase 
(DPD), which converts 5-FU to dihydrofluorouracil (DHFU). More than 80% of 
administered 5-FU is normally catabolised primarily in the liver, where DPD is
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abundantly expressed [71]. One approach to improving 5FU bioavailability and 
specificity has been to design 5~FU pro-drugs that avoid this DPD-mediated liver 
degradation. Capecitabine is an oral fluoropyrimidine that is absorbed unchanged 
through the gastrointestinal wall and is converted to 5'-deoxy-5-fluorouridine 
(S'DFUR) in the liver by the sequential action of carboxylesterase and cytidine 
deaminase [72]. S'DFUR is then converted to 5-FU by thymidine phosphorylase 
and/or uridine phosphorylase, both of which have been reported to be significantly 
more active in tumour tissue than in normal tissue. This might account for the 
observed tumour-selective activation of capecitabine when compared to 5-FU [73].
1.2.2 Oxaliplatin
Oxaliplatin is a anti-neoplastic, platinum-based chemotherapeutic agent, complexed 
with a 1,2-diaminocyclohexane (DACH) and an oxylate group, to try and reduce 
toxicity and circumvent potential drug resistance (when compared with the earlier 
platinum compounds such as cisplatin). Within approximately two hours of 
intravenous administration, oxaliplatin is metabolised to platinum biotransformation 
products. It is thought these then interact with DNA to form both inter and intra­
strand cross links, resulting in the disruption of DNA synthesis and leading to 
cytotoxic effects [74]. Specifically, Oxaliplatin reacts with DNA, forming adducts at 
the N7-position of guanine and to a lesser extent adenine [75]. This results in 
platinated intrastrand crosslinks between two guanines or a guanine adjacent to an 
adenine. Comparison of cisplatin and oxaliplatin binding to DNA by X-ray 
crystallography reveals that the DACH moiety of oxaliplatin and its bulky adduct 
creates a greater distortion in the major groove of DNA [76]. This elicits a distinct 
cascade of DNA repair processes and bypasses the DNA mismatch repair (MMR)
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system [77]. At doses resulting in equivalent cytotoxicity, oxaliplatin forms fewer 
DNA adducts, suggesting oxaliplatin lesions are more lethal than cisplatin lesions. 
This is supported by observations of increased DNA strand breaks and apoptosis in 
cells treated with oxaliplatin when compared with cisplatin. The oxalate-leaving 
group is also important as it is more readily displaced relative to other platinums, 
contributing to high plasma protein binding and less renal clearance [78]. Resistance 
to oxaliplatin can occur via three mechanisms: i) diminished drug accumulation; ii) 
decreased adduct formation; and iii) increased DNA repair.
1.2.3 The role of chemotherapy in the management of colorectal cancer.
Chemotherapy has an increasing role in the management of colorectal cancer and has 
been a major contributing factor to the significant improvements in prognosis over 
the last two decades. Overall, adjuvant chemotherapy appears to confer a 5 - 10% 
improvement in absolute survival [79].
1.2.3.1 Node positive disease:
Large meta-analyses of historical data from randomised trials have demonstrated that 
post-operative systemic single-agent chemotherapy improves survival for patients 
with Duke’s C tumours. The standard regimens were based on 5-flourouracil (5-FU) 
modulated by folinic acid (FA), and given for 6 months. Pooled data suggest that 5- 
FU/FA regimens can increase disease-free survival at 5 years from 42% to 58% and 
overall survival by as much as 13% (from 51% to 64%), when compared with 
surgery alone [80]. National guidance makes no distinction between colon and rectal 
cancer, and advises that all patients with node positive disease are offered 
chemotherapy, if they are deemed fit enough to tolerate its side effects.
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More recently, oral forms of 5-FU (uracil-tegafiir and capecitabine) have been 
licensed for this indication, on the basis of the results of two large randomised trials 
comparing their efficacy and safety with bolus 5-FU/FA in the postoperative 
adjuvant setting [81, 82]. Both confirmed that the oral drugs were at least as effective 
as the standard intravenous treatment. For example in the X-ACT study, after a 
median follow-up of 3.8 years, 35% of patients in the capecitabine arm had 
experienced disease recurrence or died, compared with 39% in the 5-FU/FA arm. 
With regard to survival, 80% and 77% of patients were alive in the capecitabine and 
5-FU/FA arms, respectively, with no apparent differences in quality of life [82]. 
These agents are also associated with less toxicity and greater patient convenience. In 
April 2006 they received approval by NICE for adjuvant use.
There is overwhelming evidence of additional benefit from the use of combination 
therapy, specifically regimes based on oxaliplatin and 5-FU. Two phase III, 
randomised controlled trials that compared oxaliplatin containing regimens with 
standard treatment have been published [83, 84]. The first was the Multicenter 
International Study of Oxaliplatin / 5-fluorouracil and leucovorin in the Adjuvant 
Treatment of Colon Cancer (MOSAIC) trial. This study included 2246 participants, 
60% with stage III and the remainder with stage II colon cancer. The second was the 
National Surgical Adjuvant Breast and Bowel Project (NSABP C-07) trial, involving 
2492 patients, 71% with stage III and the remainder with stage II colon cancer. In 
both trials the addition of oxaliplatin to 5-FU/FA, albeit administered via different 
regimes, led to a statistically significant reduction in rate of relapse when compared 
with 5-FU/FA monotherapy. Analysis of disease-free survival at 3 years showed a 
hazard ratio for recurrence of 0.77 (95% Cl, 0.65 to 0.91) in the MOSAIC trial
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(median follow-up 37.9 months), and 0.79 (95% Cl, 0.67 to 0.93) in C-07(median 
follow-up 34 months). Toxicity was acceptable with low rates of persistent severe 
(greater than grade 1) neuropathy (<1%) and no excess of treatment associated 
fatality in the oxaliplatin containing arms. Oxaliplatin has been approved by NICE 
for this indication.
The challenge is now to determine for the individual patient which of these 
alternative approved treatments is the more appropriate for use as adjuvant therapy in 
node positive colorectal cancer. The benefit, in terms of improved likelihood of 
disease free survival from the use of oxaliplatin, should be set against the side effects 
and acceptability of the regimen. In general, a higher risk, otherwise fit patient 
should be offered oxaliplatin based adjuvant therapy as their risk of death from 
cancer significantly outweighs their risk of death from other causes.
1.2.3.2 Node negative disease
The magnitude of benefit for adjuvant chemotherapy in Duke’s B tumours is smaller. 
Some studies of 5-FU based treatment have failed to demonstrate any benefit at all. 
Examples include the IMPACT B2 study, a pooled analysis of 1,016 patients with 
stage B2 colon cancer randomised to chemotherapy versus observation which 
showed no significant improvement in overall survival (OS 0.83, Cl 0.72-1.07) [85]. 
In contrast, a grouped analysis of the National Surgical Adjuvant Bowel Project 
(NSABP) trials C-01 and 04, which included 2,151 Duke’s B patients, concluded that 
the findings supported the use of adjuvant FU+LV as an acceptable therapeutic
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standard in patients with Duke’s B and C carcinoma of the colon [86]. The more 
recently reported UK QUASAR 1 study has also shown a modest benefit with bolus 
5-FU/FA of around a 4% improvement in overall survival, and confirmed that this 
was cost-effective, especially in the under 70 age group. This data together suggests 
a small (5% or less) absolute increase in survival, for patients with Duke’s B cancers, 
from adjuvant single agent chemotherapy. The MOSAIC trial included node negative 
patients, and a smaller but statistically significant incremental benefit to the addition 
of oxaliplatin was demonstrated.
1.2.4 Chemotherapy for advanced and metastatic colorectal cancer
A number of meta-analyses of palliative chemotherapy have shown improved 
survival with chemotherapy compared with best supportive care. The evidence 
indicates that early single agent chemotherapy prior to clinical deterioration for 
advanced disease improves survival by 3 to 6 months and either improves or 
maintains quality of life [87]. More recently combination chemotherapy with 
intravenous 5-FU plus either irinotecan or oxaliplatin has been shown to offer 
survival benefits in both first and second line situations. Current NICE guidance 
supports the use of all three of the active drugs (a fluoropyrimidine, oxaliplatin and 
irinotecan) and as such has deemed them cost effective [88].
Therefore, when offering multiple chemotherapy drugs to patients with advanced and 
metastatic colorectal cancer the following combinations of chemotherapy have NICE 
approval:
• FOLFOX (folinic acid plus fluorouracil plus oxaliplatin) as firstline treatment 
then single agent irinotecan as second-line treatment or
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• FOLFOX as first line treatment then FOLFIRI (folinic acid plus fluorouracil 
plus irinotecan) as second-line treatment or
• XELOX (capecitabine plus oxaliplatin) as first-line treatment then FOLFIRI 
(folinic acid plus fluorouracil plus irinotecan) as second-line treatment.
Raltitrexed is only licensed for patients with advanced colorectal cancer who are 
intolerant to 5-fluorouracil and folinic acid, or for whom these drugs are not suitable.
1.2.5 Targeted Monoclonal Antibody Therapy
The most recent developments are with targeted monoclonal antibodies used in 
conjunction with chemotherapy. Bevacizumab (Avastin), an antibody to the vascular 
endothelial growth factor, has been shown to confer an additional benefit of 4.7 
months in median survival, compared to irinotecan and 5-FU alone, in the first line 
setting [89], Cetuximab (Erbitux), an epidermal growth factor receptor inhibitor, 
appeal's capable of overcoming drug resistance in second and third line situations 
[90]. Both these agents are licensed and at the time of writing are subject to a NICE 
appraisal. The preliminary guidance suggests that they are unlikely to be approved on 
the grounds of cost-effectiveness. It is hoped that the results of the numerous 
ongoing clinical trials with these and other molecularly targeted drugs, will 
demonstrate sufficient benefit to render them financially viable.
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1.3 The role of genetics in colorectal carcinogenesis
Cancer cells are characterised by their ability to proliferate in defiance of normal 
controls and by their potential ability to invade other tissues. It has become clear 
during the revolution in cancer research in recent decades, that cancer is in essence a 
genetic disease. The regulation of cell growth, division and death is usually carefully 
controlled, with multiple safeguards to protect the cell from the potentially lethal 
effect of cancerous mutations. Therefore a series of genetic mutations are necessary 
within a given cell before an invasive cancer can develop. Alterations in three 
categories of genes are responsible for tumorigenesis: oncogenes, tumour suppressor 
genes and DNA repair genes.
Oncogenes are mutated forms of the proto-oncogene normally found within the cell. 
They render the gene constitutively active or active under conditions in which the 
wild type gene is not. Oncogenic activations can result from chromosomal 
translocations, gene amplifications or from subtle intra-genic mutations (missense 
mutations) affecting crucial residues that regulate the activity of the gene product. 
Oncogenic mutations are typically dominant in nature, requiring mutation to only 
one allele, to express the oncogenic phenotype.
Tumour suppressor genes are affected in the opposite manner, with genetic mutations 
leading to reduced activity of the gene product. This can occur as a result of 
nucleotide deletions, insertions or missense mutations leading to altered or truncated 
forms of the protein product. Mutations in both alleles are generally required to 
confer a selective advantage to the cell. This situation commonly arises when an 
intragenic mutation occurs, followed by a gross chromosomal loss of the other allele.
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Oncogene and tumour suppressor gene mutations both drive the neoplastic process 
by increasing tumour cell number through the stimulation of cell division or the 
inhibition of cell death.
DNA maintenance genes are involved in the repair of DNA lesions incurred as a 
result of extrinsic cell damage or intrinsic replication errors and are therefore 
required to maintain the fidelity of DNA sequences. The first somatic mutation in an 
oncogene or tumour suppressor gene that causes a clonal expansion initiates the 
neoplastic process. Subsequent somatic mutations result in additional rounds of 
clonal expansion and thus tumour progression. Individuals with germline genetic 
mutations have a Tread start’ on the neoplastic process as they only require one 
further allelic mutation to contribute to cancer formation. Such individuals often 
develop multiple tumours at an earlier age than individuals whose mutations have all 
occurred somatically.
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1.4 Colorectal cancer - the genes / pathways involved
Cancer progression results from a series of genetic alterations leading to the 
progressive disordering of the normal mechanisms controlling growth. Colon cancer 
provides an excellent opportunity to study the stages of an evolving malignancy 
because tumours at various stages of development can be obtained for analysis. Early 
lesions may be by removed at colonoscopy or, in the case of more advanced tumours, 
tissue may be provided from an anatomical surgical resection.
In addition, the presence of hereditary syndromes associated with increased 
incidences of colon cancer (i.e. FAP and HNPCC) has allowed the concurrent study 
of inherited and sporadic genetic alterations to be considered. This has enabled the 
detection of shared mutations in affected families and therefore localisation and 
ultimately the identification of implicated genes.
Clinical and histopatholgical data suggest that most colon cancers arise from small 
pre-existing benign tumours (adenomas), which increase in size and dysplasia over 
several decades to eventually become large invasive and then metastatic neoplasms. 
In 1975, the term “adenoma to carcinoma sequence” was coined by Morson and 
colleagues at St. Marks in London to describe this histological progression [91]. In 
1990, Fearon and Vogelstein published a model linking the accumulation of 
sequential genetic defects, with the clinical multi-step model of progression from 
adenoma to invasive carcinoma [92], The main candidate genes responsible for the 
various stages were consequently identified as APC, K-RAS, DCC and p53.
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Further work has indicated that this original model may be an oversimplification of 
colorectal carcinogenesis. Firstly the sequential model of mutation accumulation was 
questioned, with a study demonstrating that only 6.6% of tumours were found to 
contain mutations in APC, K- RAS and p53, with 38.7% of tumours containing 
mutations in only one of these genes. The heterogeneous pattern of tumour mutations 
suggested that alternative patterns to colorectal cancer may exist and that the widely 
accepted genetic model of cancer development may not represent the majority of 
colorectal tumours [93].
Hence, the Vogel stein model now appears to represent one pathway, amongst a 
number of complex and integrated routes, towards the development of colorectal 
cancer. In Figure 1.4, the classic Fearon and Vogelstein model is shown in red 
alongside other hypothesised routes towards colorectal cancer development.
TGFfiRII, Bax, MMR genes. 
Tcf-4. IGF2R. E2F4 frameshifrs
Normal
Epithelium
(Chromosomal
Cancerinstability)
? progressionFlat
adenoma
Late
adenoma
UCACRC
Sporadic
Low grade 
dysplasia
Early
Adenoma
Late
Adenoma
High grade
dysplasia
Intermediate
Adenoma
Early MHAP/ 
Serrated adenoma
Hypermutable phenotype
Cydin D1
tPa
CEA
Nm23
MMP
E-cad her in
CD44
Figure 1.4: Model for genetic alterations in the development of colorectal cancer. 
Reproduced from Narayan and Roy (2003) [94]
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Each of the key genes implicated in colorectal cancer pathogenesis will now be 
discussed in more detail through the following sections.
1.4.1 APC
The Adenomatous Polyposis Coli (APC) gene is a tumour suppressor gene located 
on chromosome 5q21. The APC gene product is a 312 kDa protein localised in both 
the cytoplasm and the nucleus [95, 96]. Somatic APC mutations are an early and 
perhaps rate-limiting event in the development of most adenomas and are present in 
approximately 70-80% of sporadic colorectal carcinomas [97-99].
The APC gene is abnormal in the germline of patients with familial adenomatous 
polyposis (FAP). This is an autosomal dominant syndrome in which hundreds of 
colorectal adenomas develop in affected person by the third or fourth decade of life, 
each of which can progress to carcinoma. FAP is found in about 1 in 12,000 
individuals and accounts for approximately 0.5% of all colorectal cancers. 
Heterozygous germline mutations typically result in a truncated protein. Adenoma 
progression is initiated by a somatic loss of the second wild-type APC allele as 
predicted by the Knudson two-hit hypothesis for tumour suppressor genes. [100- 
103].
The APC tumour suppressor gene has been implicated in the regulation of cell-cell 
adhesion, cell migration, chromosomal segregation and apoptosis in the colonic crypt 
[72-74].
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Although the APC protein more than likely has multiple critical cellular functions, 
the best established role for APC in the cancer process is as a major binding partner 
and regulator in the p-Catenin dependent Wnt signalling pathway. APC acts as a 
negative regulator of B-catenin. It stimulates B-catenin phosphorylation by GSK3 
and its subsequent ubiquitination and degradation by the proteosome. The lack of 
functional APC protein or the deletion of its B-catenin binding domain, leads to 
over-activity of the B-catenin TCF7L2 transcriptional activation pathway and 
therefore promotes proliferation of the intestinal cell [104, 105], see Figure 1.5.
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Figure 1.5: The role of the APC pathway in colorectal cancer 
Reproduced from Fukata and Abreu, Nature Medicine, 2010 [106]
1.4.2 KRAS
KRAS is a member of a family of homologous oncogenes (the others being HRAS 
and NRAS) and is located on chromosome 12pl2. It encodes a small 21kDa protein 
(p21ras). Approximately 40% of sporadic colorectal tumours are found to contain
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mutations of the KRAS oncogene. The majority of KRAS mutations are gain-of- 
function missense mutations limited to codons 12, 13 and 61 [107].
Mutations of KRAS tend to occur at a relatively early stage in colorectal 
tumorigenesis. Whereas approximately 10% of adenomas less than 1cm contain the 
mutated, activated KRAS oncogene, this increases to 40-50% of adenomas greater 
than 1cm [108]. Ras proteins are thought to function downstream of multiple 
receptor tyrosine kinase (TRK) growth factors, such as the epidermal growth factor 
receptor (EGFR) family, as shown in Figure 1.6. This has become clinically relevant 
with the development of the targeted anti-EGFR monoclonal antibody Cetuximab. 
The results of the CRYSTAL trail demonstrated a significant improvement in the 
efficacy parameters of Cetuximab, when combined with the FOLFORI 
chemotherapy regime, in patients expressing wild-type KRAS. In contrast, no 
difference in efficacy was evident between treatment aims in the mutant KRAS 
subgroup [109].
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Figure 1.6: The KRAS pathway 
Reproduced from www.discoverymedicine.com
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Several studies have shown that patients who have a KRAS mutation in their 
colorectal tumour have a significantly poorer prognosis than those without a KRAS 
mutation [110, 111]. KRAS mutation is associated with an aggressive tumour 
phenotype and therefore detecting this mutation at an earlier disease stage may be of 
clinical importance.
1.4.3 The TGF-p Pathway
Loss of heterozygosity (LOH) of chromosome 18q is observed in 70% of CRCs; 
50% of large, late-stage adenomas; and fewer than 10% of small, early stage 
adenomas [108]. Two chromosome 18q Tumour Suppressor Genes (TSGs) that are 
mutated in a fraction of colorectal cancers with 18q LOH are the SMAD2 and 
SMAD4 genes. Both genes encode proteins that function downstream of the TGF-p 
receptor complex, and the function of the SMAD2 and SMAD3 proteins is regulated 
by TGF-p-mediated receptor phosphorylation. Phosphorylation of SMAD2/3 allows 
the proteins to traffic to the nucleus and complex with the SMAD4 protein, and this 
complex can then bind to specific sequence elements and regulate gene transcription, 
as demonstrated in Figure 1.7. Mutations that inactivate SMAD4 are found in 10- 
15% of CRCs, and SMAD2 mutations are found in 5% of CRCs [112].
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Figure 1.7: The TGFppathway 
Reproduced from wwiv.proteinlounge.com
Loss of 18q function appears to be implicated in the late stages of the pathogenesis of 
colorectal neoplasia, being infrequent in small adenomas but present in nearly 100% 
of hepatic metastases from colorectal primaries. Chromosome 18q LOH has also 
been associated with relatively poor prognosis in Duke’s B staged disease [113, 114].
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1.4.4 The Mismatch Repair (MMR) System, HNPCC and micro-satellite 
instability (MSI).
The Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome is an 
autosomal dominant condition which probably accounts for up to 5% of all colorectal 
cancers in developed countries. An excess of colon cancer and a defined spectrum of 
extra-colonic cancers, diagnosed at an early age constitute the clinical definition, 
which is strictly detailed in the ‘Amsterdam criteria’ [115, 116]. The syndrome arises 
as a result of germline mutation in one of several DNA mismatch repair genes (e.g. 
hMSH2, liMLHl, hPMSl, hPMS2, liMShS, hMSH6).These genes control the repair 
of DNA base pair mismatches and are responsible for ensuring correct DNA 
synthesis during replication. Microsatellites are the result of base-pair substitutions 
and frame-shift mutations and result in short, tandemly repeated nucleotide 
sequences e.g. CACACACA. Microsatellites are found in a great number throughout 
the genome and owing to their repetitive nature, are prone to errors in replication. 
Micro satellite Instability (MSI) occurs when a germline microsatellite allele has 
undergone a somatic change in length. Nucleotide mismatches in micro-satellites are 
common but are usually rapidly corrected by the mismatch repair (MMR) genes. 
Hence defects in the MMR mechanism leads to widespread mismatch repairs, MSI 
and tumorgenicity. Approximately 15% of sporadic colon cancers result from MSI, 
rather than the classic chromosomal instability (CIN), with associated allelic 
mutations, loss of heterozygosity and aneuploidy as discussed thus far. In sporadic 
colon cancers the loss of expression of the MMR gene is often caused by aberrant 
methylation, and hence epigenetic silencing, resulting in deficient protein expression 
[117]. MSI associated tumours appear to have distinct clinical and pathological
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features to those arising from CIN. They are more common proximal to the splenic 
flexure and occur more frequently in women [118]. Although the tumours tend to be 
larger and more poorly differentiated than their CIN counterparts, they have longer 
overall and cancer-specific survival, than stage matched patients exhibiting CIN 
[119]. Hepatic metastases from colorectal cancer rarely exhibit MSI [120].
1.4.5 Flat / depressed carcinomas
Flat and depressed lesions are defined as visible non-exophytic, flat and/or depressed 
mucosal lesions with a height less than half the diameter of the lesion [121]. These 
lesions are typically smaller in size than their polypoid counterparts, and are usually 
located on the right side of the colon [122]. Multiple reports from the Japanese 
literature suggest that flat and depressed adenomas are associated with a higher 
incidence of advanced histopathology, which includes high grade dysplasia and intra- 
mucosal adenocarcinoma, in relatively small tumours [123, 124]. The tumorigenicity 
of flat cancers remains uncertain but it is possible they follow a potentially different 
genetic pathway to those outlined for polypoid lesions. For instance, KRAS 
mutations occur at a lower frequency in flat lesions than in sporadic polypoid 
adenomas [125].
1.4.6 Other Genes Implicated in Colorectal Cancer
The MYC (also referred to as c-MYC) protein is a transcription factor that regulates 
genes with roles in cell-cycle progression, survival and various aspects of cellular 
metabolism in normal and neoplastic cells, as displayed in Figure 1.8. High copy
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amplification of the CMYC gene is observed in approximately 5-10% of colorectal 
cancers, although moderate increases in MYC gene copy number and c-MYC protein 
expression may be found in more than 30% [126].
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Figure 1.8: The c-MYC pathway 
Reproduced from Pelengaris et al, 2002(127]
Many other genes that have been implicated in the tumorigenicity of colorectal 
cancer are shown in Table 1.6 alongside their estimated frequency of alterations:
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Table 1.6: Selected recurrent somatic mutations in oncogenes and tumour-suppressor
genes
Adapted from Fearon (2011) [128].
Gene Type of mutation Estimated frequency of alterations
Oncogenes
KRAS Point mutations (codons 12, 13, 61) 40% (>75% of mutations are at codon 
12)
NRAS Point mutations (codons 12, 13, 61) <5%
P1K3CA Point mutations activating kinase activity 15-25%
BRAF Point mutations activating kinase activity 
(e.g., V600E) 5-10%
EGFR Gene amplification 5-15%
CDK8 Gene amplification 10-15%
CMYC Gene amplification 5-10%
CCNEl Gene amplification 5%
CTNNB1 Stabilizing point mutations and in-frame 
deletions near N terminus <5%
NEU
(HER2) Gene amplification <5%
MYB Gene amplification <5%
Tumor-suppressor genes
TP53 Point mutation, allele loss 60-70% (>95% of point mutations are 
missense)
APC Frameshift, point mutation, deletion, allele 
loss
70-80% (nearly all mutations lead to 
truncated proteins)
FBXW7 Nonsense, missense, deletion 20%
PTEN Nonsense, deletion 10%
SMAD4 Nonsense, missense, allele loss 10-15%
SMAD2 Nonsense, deletion, allele loss 5-10%
SMAD3 Nonsense, deletion 5%
TGFpIlR Frameshift, nonsense 10-15% (>90% of MSI-H CRCs have 
mutations)
TCF7L2 Frameshift, nonsense 5% (mutations in both MSI-H and
MSS CRCs)
ACVR2 Frameshift 10% (>80% of MSI-H CRCs have 
mutations)
BAX Frameshift 5% (often one allele in 50% of MSI-H 
CRCs)
Abbreviations: CRC, colorectal cancer; MSI-H, high-frequency microsatellite instability; MSS, 
microsatellite stability.
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1.5 p53
There is evidence for a malfunction in the p53 pathways in most cancers [129] and 
the mutation of the TP53 gene that encodes p53 is one of the most frequent genetic 
changes seen in malignant cells.
Consequently p53 is one of the most studied proteins in the whole of contemporary 
biology, with almost 62,000 citations on the ‘PubMed’ database (March 2012).
This massive interest in a single protein reflects the central role of p53 in the 
regulation of cell growth and differentiation and the frequency with which 
abnormalities of p53 function occur in human tumours.
1.5.1 The story so far....
It became clear in the early lOTO’s that RNA tumour viruses were able to cause 
cancer by their remarkable ability to capture and alter the expression of host genes 
that promote cellular growth. In 1979, David Lane and Lionel Crawford (Imperial 
College London) were studying the oncogenic activity of the small DNA virus 
simian virus 40 (SV40). Studies of virally transformed cancer cells showed that the 
oncogenicity was due to the virally encoded T antigen. Lane and Crawford’s paper 
showed that in virally transformed cancer cells the T antigen was tightly and 
specifically bound to a 53,000 molecular weight host protein that would become 
known as p53 [130]. Shortly following this, Linzer and Levine (Princeton) 
independently identified p53 through similar studies of virally transformed cells and 
also found the protein to be over-expressed in uninfected embryonic cancer cells 
[131]. In the same year, De Leo et al showed that the humoral response of mice to 
some methylcholanthrene-induced tumour cell line such as MetliA was directed
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toward the p53 protein [132]. Later, it was found that animals bearing several types 
of tumours elicited an immune response specific for p53 [133].
In the early eighties p53 was considered to be a likely oncogene, though its function 
and likely significance remained undiscovered. However, two important observations 
made during this period were that p53 is induced by DNA damage [134] and the 
identification of p53 gene alterations in virus-induced leukaemia’s and tumour cell 
lines independently [135, 136].
A major paradigm shift occurred when it was demonstrated that wild-type p53 cDNA 
clones were in fact able to suppress transformation of rodent cells in culture while 
the point mutant version of p53 obtained from tumour cell lines were transforming. 
It was found that p53 point mutations were common in colorectal carcinomas and 
other tumours and in most cases one allele was mutated whereas the other was lost. 
In addition, inherited p53 mutations were found in the familial Li-Fraumeni 
syndrome (an autosomal dominant inherited syndrome in which affected individuals 
inherit a mutated p53 allele and are susceptible to a whole range of multiple 
sarcomas and carcinomas at a young age.) These findings in combination led to the 
recognition of p53 as a tumour suppressor gene [137].
In the following years, the induction of p53 in response to DNA damage was further 
substantiated and p53 was dubbed the “guardian of the genome” [138], Studies of the 
effects of wild type p53 on human tumour cells showed that p53 could curb cell 
cycle progression and induce cell death by apoptosis. The generation of p53 null 
mice in 1992 and the demonstration of their dramatically increased tumour incidence 
further proved p53’s tumour suppressive function [139]. Meanwhile, molecular 
studies revealed that p53 was a transcription factor with DNA binding specificity.
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The first p53 target gene discovered was the cell cycle inhibitor p21/WAFl in 1993, 
linking p53 with cell cycle arrest [140],
The identification of MDM2 as a p53 antagonist and critical regulator of p53 in 1997 
led to the discovery that p53 stability is regulated partly through degradation in the 
proteasome [141, 142]. Since this time many further genes involved in the complex 
and closely regulated p53 pathway have been discovered and studied. Although p53 
has been exstensively studied since its discovery approximately 33 years ago, there is 
still considerable work to be done before the potential production of efficient anti­
cancer drugs that are based on targeting p53 in cancer cells.
1.5.2 Structure of p53
The p53 protein and its corresponding gene were named in reference of its mass of 
53 kilodaltons. The gene is located on chromosome 17 at position pi3 and is a 
phosphoprotein made of 393 amino acids. p53 is a modular protein with several 
regions with distinct, but inter-dependent functions, hence it has been described as 
having a four domain structure, as shown in Figure 1.9.
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Figure 1.9: p53 protein structure. 
Reproduced from Anzola and Burgos, 2003 [143]
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Amino Terminus
The acidic amino terminus comprises the first 42 amino acids and constitutes a 
transcription activation domain. This area promotes expression of various 
downstream target genes in response to an activating stimulus. p53 possesses a 
hydrophobic interface in its N-terminal domain which interacts with the basal 
transcriptional machinery to promote up-regulation (or sometimes suppression) of 
p53 responsive genes through control of transcription of mRNA production. This 
region is also critically involved in regulating the stability and activity of p53 via 
interactions with proteins such as MDM2. Negative regulators of p53 mediated 
transcription, also target some of the same p53 amino acids critical to positive 
regulation of transcription activation.
SH3 binding domain
Sandwiched between the transcription activation and the DNA binding domains (see 
Figure 1.9), is a region containing repeated proline residues, typical of a polypeptide 
that can interact with signal transduction molecules that contain a SH3 binding 
domain, allowing p53 activity to be influenced. Through this domain p53 activity can 
be influenced by various signalling molecules including the c-abl oncogene.
Sequence specific DNA binding domain
The sequence-specific DNA-binding domain (DBD) of p53 is localised between 
amino acids 102 and 292. This region is a protease resistant and independently- 
folded domain, containing a Zn2+ ion. The domain folds into a four-stranded and five
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stranded anti-parallel B sheet that in turn is a scaffold for two a-helical loops that 
enable the region to interact directly with the DNA. More than 90% of the missense 
mutations of p53 occur in the regions of the gene encoding this domain [144]. 
Critical amino acid residues may be mutated resulting in defective contacts with the 
DNA and loss of the ability of p53 to act as a transcription factor. Alternatively, p53 
mutations may structurally alter the conformation of the p53 protein in this region 
thereby disrupting its binding ability. The consequence of these events is the loss of 
the ability of p53 to specifically bind DNA in a sequence specific manner.
Tetramerisation domain
In order for DNA binding to occur, tetramerisation of the 3D structure of the protein 
must occur. Amino acid residues 324-355 are responsible for this configuration and 
are therefore determined the tetramerisation domain.
Carboxy-T erminus
The carboxy-terminus consists of 26 predominantly basic amino acids, which form a 
region with key regulatory properties. The p53 protein requires a structural change to 
activate it for sequence-specific binding to DNA. The non DNA binding or latent 
form of p53 can be activated by alterations in the carboxy-terminus, regulating the 
ability of p53 to bind to specific DNA sequences at its central DBD. For example, 
deletion of this domain, phosphorylation by a protein kinase at residue 378 and short 
single strands of DNA binding to this region all activate site-specific DNA binding 
by the central domain. The c-terminal domain helps promote the re-association of 
single to double stranded DNA or RNA. It also binds preferentially to DNA ends and
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to internal deletions loops in DNA, as generated by replication errors that are then 
detected and fixed by mismatch repair processes [145].
1.5.3 Function
p53 functions as a transcription factor resulting in altered expression of a range of 
target genes involved in cell cycle inhibition, DNA repair, senescence and apoptosis. 
p53 protein levels are normally closely regulated to maintain appropriate control of 
cell growth and development. Mutations of p53 or factors leading to its inappropriate 
expression are associated with tumorigenesis. Normally there is a careful balance to 
be achieved between factors relating to increased synthesis and expression and those 
controlling the protein’s degradation. p53 becomes activated when cells are stressed 
or damaged. Such cells pose a threat to the organism as they are more likely than 
undamaged cells to contain mutations and exhibit abnormal cell cycle control and 
therefore have a greater risk of becoming cancerous. The p53 protein shuts down the 
multiplication of stressed cells inhibiting their process through the cell cycle.
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Figure 1.10: p53 responds to a plethora of stress signals and regulates diverse responses. 
Reproduced from Bieging and Attardi (2011) 1146]
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1.5.4 Activation and stabilisation
Regulation of p53 has been described at the level of transcription, translational and 
post-translational mechanisms and the latter can regulate conformational changes and 
various covalent and non-covalent modifications which alter levels and p53 activity. 
More than 36 different amino acids within p53 have been shown to be modified in 
various biochemical and cell culture studies (Figure 1.11). p53 protein levels in the 
cell are normally kept at a low concentration by its high turnover and thus has a 
relatively short half life in unstressed cells (~ 20 minutes) [147].
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Figure 1.11: Overview of p53 Posttranslational Modifications.
Reproduced from Kruse and Gu (2008) [148]
The major sites of p53 phosphorylation (P), ubiquitination (Ub), and acetylation (Ac) are 
shown with the corresponding major modifying enzymes and signals. Furthermore, 
additional phosphorylation and acetylation sites, as well as major sites of methylation (Me), 
sumoylation (S), neddylation (N8), glycosylation (O-Glc), and ribosy/ation (ADP), are 
indicated.
Phosphorylation of p53 is classically regarded as the first crucial step of p53 
stabilisation and this occurs rapidly, in response to various stress stimuli, to activate
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p53. This modification by phosphorylation is initiated by a broad range of kinases, 
including ATM/ATR/DNA-PK and Chkl/Chk2. Phosphorylation of serine residues 
within the N-terminal p53 transactivation domain was among the first 
posttranslational modifications of p53 identified and has been extensively 
investigated in in vitro biochemical assays, in tissue culture studies, and recently by 
using site-specific knock-in animals. N-terminal phosphorylation at SeiT5 (mouse 
Seri 8) and Ser20 (mouse Ser23) have been generally thought to stabilize p53 by 
inhibiting the interaction between p53 and Mdm2 [149, 150].
The tight control of cellular p53 levels is primarily achieved through its ubiquitin- 
mediated proteasomal degradation [151]. Three independent studies identified the 
mouse double minute protein 2 (Mdm2) as the principle endogenous E3-ligase with 
high specificity for p53 [141, 142, 152]. The MDM2 protein leads to the mono- 
ubiquitination of p53; subsequently several copies of the small peptide ubiquitin are 
then attached to the protein. This ubiquitin chain acts a flag, labelling the protein for 
degradation.
Although the level of p53 is elevated in the absence of Mdm2, p53 is still degraded 
in the cells of Mdm2 null mice, suggesting the existence of alternative, Mdm2 
independent pathways for p53 degradation in vivo [153]. The recently discovered E3 
-ligases COP 1, Pirh2, Arf-BPl and others, have clearly been shown to contribute to 
the efficient control of p53 levels in tissue culture and in in-vitro biochemical 
experiments [154-156].
There are multiple layers of regulation that connect Mdm2 function with p53 
stability dining stress responses. Several DNA damaging agents including UV, 
topoisomerase inhibitors and non genotoxic stresses such as hypoxia, induce a p53
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response by specific inhibition of MDM2 transcription. A prominent physiological 
regulator of Mdm2 is the tumour suppressor ARF [157]. ARF interferes with the 
Mdm2-p53 interaction, thereby acting to stabilise and activate p53. The low steady- 
state levels of ARF in normal cells are dramatically induced upon oncogenic stress, 
which suppresses abnormal cell proliferation by triggering p53-dependent growth 
arrest or apoptosis [158].
The other prominent regulator of Mdm2 activity is MdmX. Like Mdm2, MdmX is a 
critical negative regulator of p53 [159].
Genetic evidence in humans suggests that ATM and CHK 2 are key players in the 
pathway of response to ionising radiation (IR). The ATM gene is mutated in the 
genetic disorder ataxia telangiectasia which is characterised by hypersensitivity to 
ionising radiation and predisposition to cancer. CHK 2 was found to be mutated in 
patients with Li-Fraumeni syndrome who do not carry a p53 mutation. Cells deficient 
for ATM or CHK 2 show a defect in their ability to synthesise p53 after exposure to 
IR, strongly supporting a role for these kinases in this damage response [160].
Transcriptional co-activators CBP/p300 and PCAF enhance p53 mediated 
transcription and are therefore considered important for p53 mediated growth arrest 
and apoptotic functions [161].
Increasing cellular levels of p53 alone do not initiate transcriptional activation. The 
extreme C-terminus of the protein controls the DNA binding sequence at the 
protein’s core domain and hence the transcriptional activity. The folded 3- 
dimensional shape of the C-terminus usually inhibits DNA binding to the centre of 
the protein. A multitude of covalent and non-covalent modifications cause a
Chapter One - Introduction 51
conformational change in this region allowing binding to occur. Phosphorylation, 
ubiquitination, methylation, sumoylation, neddylation and acetylation all target and 
modify the C-terminal of p53, thereby affecting the ability of p53 to bind DNA 
[149].
1.5.4,1 The p53 Response 
Cell Cycle inhibition
p53 acts as a transcriptional activator directly stimulating p21 expression. This in 
turn inhibits cyclin dependent kinases (CDKs). CDKs are key regulators of the cell 
cycle. For example, they ensure that DNA replication (S phase) follows on smoothly 
from the resting phase Gl. Through its down regulation of various CDKs, p21 
inhibits both the Gl to S and the G2 to mitosis transitions in the cycle. Cells depleted 
for p21 are deficient in both Gl and G2 arrest and in the coupling of DNA synthesis 
and mitosis. The same phenomenon is demonstrated in p53 null cells. Further 
potential mediators of G2 arrest regulated by p53 include GADD45, 14-3-3, 
sigmaB99, meg 10 andreprimo [162].
Apoptosis
Some cells in which p53 has become activated subsequently undergo programmed 
cell death. Numerous apoptotic genes that are transcriptionally activated by p53 have 
been identified, suggesting that the p53 apoptotic response is multi-faceted. The first 
apoptotic target of p53 identified was the Bax gene - a member of the BCL-2 family 
[163]. Transcription of the Bax gene has been shown in some human cells to be 
directly activated by p53 binding sites in the regulatory region of the gene. There are 
other pro-apoptotic members of the same family that have been shown to be
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activated by p535 i.e. Noxa and PUMA (p53 upregulated modulator of apoptosis) 
[164, 165], These proteins are all located within the mitochondria.
Apoptosis via loss of mitochondrial integrity may also be controlled by several genes 
coding for redox-controlling enzymes which were identified as p53 induced genes 
(PIGs) in a colon cell line undergoing p53 mediated apoptosis. It is hypothesised that 
these PIGs produce reactive oxygen species (ROS) which damage mitochondria and 
initiate apoptosis [166].
It has been suggested that p53 itself can localise to the mitochondria presenting a 
potential additional transcription independent way of mediating apoptosis.
p53 has also been implicated in the membrane death receptor induced pathway of 
apoptosis. DR5 / KILLER and FAS are two of the death receptors observed to be up 
regulated by p53 [167]. Activation of PIDD, a death domain containing protein, by 
p53, also induces apoptosis and is likely to function through the death receptor 
pathway [168].
Genetic Stability
p53 participates in DNA damage repair. It can bind primarily to damaged sections of 
DNA or can function indirectly via target genes that participate in ‘nucleotide- 
excision5 repair of DNA, chromosomal recombination and chromosomal segregation.
GADD45 binds proliferating cell nuclear antigen (PCNA) and could serve to inhibit 
DNA synthesis thus allowing DNA repair to proceed [169],
P53R2, a ribonucleotide reductase gene, is another transcriptional target of p53 that 
plays a role in DNA repair [170].
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Inhibition of Blood Vessel formation
Angiogenesis into a malignant cell mass is essential for advanced tumour 
progression. p53 usually stimulates genes which suppress new blood vessel 
formation. Therefore cells in which p53 is inactivated would therefore be more likely 
to recruit new blood vessels, providing an important growth advantage at a late stage 
in tumour development. This corresponds with the stage of tumorigenesis when most 
natural p53 mutations occur.
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1.6 The p53 pathway and its relevance to colon cancer.
In 1988 it was noted that allelic loss of the chromosome 17p region, containing the 
p53 gene, was frequently observed in polypoid colorectal cancers [171]. The first 
reports implicating p53 gene mutations in the development of colorectal cancer 
followed shortly thereafter [172, 173]. Early work showed that the growth of 
colorectal cancer cell lines in vitro could be suppressed by the introduction of wild- 
type p53, thus establishing the tumour suppressor properties of the gene [174]. 
Mutation of p53 is thought to increase the protein half-life and is therefore often 
associated with over-expression in the nucleus. In 1990, Rodrigues et al carried out 
immunohistologic staining of primary colorectal carcinomas with antibodies specific 
for p53. They demonstrated gross over-expression of the protein in about 50% of 
colorectal cancer cases. Conversely, benign adenomas were all negative for p53 
over-expression [173]. The functional loss of p53 in colorectal cancer has been 
proposed as a late event in the transformation from adenoma to carcinoma [175].
An overview of fourteen studies, that each reported data on at least 50 colorectal 
cancer cases, estimated the frequency of p53 mutations at 45 % (1186 samples out of 
2659) [176]. This is consistent within the range reported by other authors of 23-61 % 
[177-180]. Information on 1517 p53 mutations held in the UMD-p53 database [181, 
182] indicates that 80% of the mutations are GC to AT single point transitions, 
occurring predominantly at CpG dinucleotides. These mutations are thought to arise 
by endogenous processes related to the deamination of 5-methylcystosine. Mutations 
in five hotspot codons (175, 245, 248, 273 and 282) account for approximately 43% 
of all p53 mutations in colorectal cancer [176, 181]. Three of these (codons 175, 248 
and 273) contain a CpG dinucleotide. In 2002, Bazan et al confirmed that mutations
Chapter One - Introduction 55
at codons 248 and 273 were the most frequently seen, with incidences of eleven and 
six percent respectively [183].
The prognostic significance of having a colorectal tumour containing mutated p53 
has been the subject of intensive study and ongoing controversy. Several groups 
reported strong associations between p53 mutation and poorer prognosis in cohorts 
of more than 200 patients [177, 184], although both found the association was 
confined to distal tumours. However other large scale studies reported no association 
between p53 mutations and patient survival [176, 185, 186]. There has also been a 
lack of consensus regarding the significance of specific types of p53 mutation. In 
1995, Goh and colleagues reported that mutations in the evolutionary conserved 
regions of p53 were associated with worse prognosis than those outside these 
domains [184]. In contrast, Kressner et al (1999) reported that mutations in the non- 
conserved region had the worst prognosis [180]. Borresen-Dale and colleagues 
(1998) found that mutations affecting the L3 zinc-binding domain had a significantly 
shorter cancer-related survival [177]. Different groups have suggested different 
prognostic significance depending on the ethnic group [187], site of tumour site in 
the colon [188] and stage of disease [189, 190]. The discrepancies in these findings 
are likely to represent the use of different mutation screening methods, as well as to 
the composition of the tumour series investigated, particularly with regard to tumour 
site, stage and the use of adjuvant therapies.
In order to try and resolve the issue of p53 mutations and prognostic implications in 
colorectal cancer, a large scale meta-analysis of all relevant previous studies, was 
performed by Munro et al in 2005 [191]. They performed a systematic review of 168
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previous reports, incorporating a total of 18,766 patients. As with previous authors, 
they encountered problems with publication bias, heterogeneity of results and 
variability in assessment of p53 status and reporting of results. A trim and fill method 
was used to correct for publication bias and heterogeneity was minimised by using 
well-defined clinical subgroups of outcomes. Overall, patients with abnormal p53 
were at increased risk of death: relative risk (RR) in studies using 
immunohistochemistry 1.32 (95% confidence interval, 1.23-1.42) and with mutation 
analysis 1.31 (95% confidence interval, 1.19-1.45). The adverse impact of abnormal 
p53 was greater in patients considered to have lower baseline risk of dying. That is, 
when taking the baseline median risk of death of 35%, and creating two arbitrary 
groups either side of this as good or bad prognosis patients, those considered to have 
good prognosis had a RR of death of 1.63 (95% c.i 1.40-1.90) and those with poor 
prognosis RR 1.04 (95% c.i. 0.91-1.19). Munro concluded that abnormalities in p53, 
whether assessed immunohistochemically or by sequence analysis, appear to be of no 
value in predicting response to 5FU-based chemotherapy. However, rectal tumours 
containing proven mutations in p53 are less likely to respond to radiation, or chemo- 
radiation, than rectal cancers without evidence of mutant p53.
The TPS3 colorectal cancer international collaborative study on the prognostic and 
predictive significance of p53 mutation was also published in 2005 and refitted some 
of Munro’s findings [192]. This study included data from a total of 3,583 colorectal 
cancer patients (from 17 different countries) with information on p53 gene mutation 
status. A significantly higher frequency of mutations (P < .001) was found in distal 
colon and rectal tumours (both groups, 45%) compared with proximal tumours 
(34%), confirming the findings of previous studies [176]. p53 mutations were
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associated with lymphatic invasion in proximal tumours and showed trends for 
association with advanced Duke’s stage (all sites) and with lymphatic (rectal 
tumours) or vascular invasion (distal and rectal tumours).
Previous in vitro studies had shown that disruption of p53 causes colorectal cancer 
cells to be more resistant to the apoptotic effects of FU [193]. The Russo et al. study 
found that colorectal cancer patients with wild-type p53 have significantly better 
survival when treated with chemotherapy compared with those treated with surgery 
alone, regardless of tumour site. In contrast, for patients with mutated p53, only those 
with proximal colon cancers showed significantly better survival when treated with 
chemotherapy compared with those treated by surgery alone. The results suggest that 
use of chemotherapy can influence survival depending on p53 mutation status; 
though this may be dependent on tumour site. Previous studies showing site-related 
differences in the frequency of p53 mutations and other genetic or epigenetic 
alterations have also suggested that these findings could translate into differential 
survival benefits from chemotherapy [194, 195].
The role of p53 in the cellular response to oxaliplatin has also been investigated 
using various in vilro models [196, 197]. These studies showed that human 
colorectal cancer cell lines lacking functional p53 were generally more resistant to 5- 
FU and oxaliplatin than the p53 wild-type cell lines analysed and that 5-FU and 
oxaliplatin sensitisation to Fas-mediated apoptosis required wild-type p53. 
Furthermore a retrospective clinical study in 2010 showed that p53 expression 
altered disease free survival when adding oxaliplatin to the adjuvant treatment 
regime of stage III colon cancer patients [198].
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1.7 Gain-of-function mutations of p53.
p53 mutations have been linked to increased cell growth [199], enhanced 
tumourgenicity [200] and poor prognosis in a wide variety of tumour types. 
Disturbances in spindle checkpoint mechanisms [201] and increased tumour 
invasiveness [202] have also been demonstrated. It has been shown that p53 
mutational status adversely affects cellular responses to chemotherapeutic agents 
when compared with cells lacking any detectable p53.
Unlike other tumour suppressor genes, whose inactivation occurs mainly by 
deletions, p53 is a frequent target of single nucleotide missense mutations, 
accounting for approximately 74% of all p53 mutations in human cancers [203]. 
Contrasting with wild-type p53, which under normal conditions has a short half-life 
curtailed when it is targeted by Mdm2 for degradation, mutant p53 proteins are 
outside this negative feedback loop and accumulate to high levels in cancer cells 
[204]. The large percentage of missense mutations, combined with the elevated level 
of expression of the tumour-derived p53 mutants, suggests that mutant proteins 
perform a vital oncogenesis role and are therefore selectively over expressed [205]. 
The p53 point mutations primarily occur in the conserved central region of the gene, 
coding for the DNA binding core domain (DBD). There are two classes of p53 DBD 
mutants: conformational and contact. The conformational mutants alter the global 
structure of the protein whilst the contact site residues bind directly with the DNA 
helix and accordingly are important for the transcriptional activation function of p53. 
Mutations in virtually every amino acid in this region (containing approximately 200 
in total) have been documented, with some ‘hot spot’ mutations occurring at a 
markedly higher frequency than others. The resulting protein products are flill-
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length, with a single amino acid change, and are considered unable to recognise wild- 
type p53 consensus DNA binding sites [206].
1.7.1 Dominant - negative inhibition of wild type p53 function
It was originally hypothesised that the poor outcome associated with p53 mutations 
resulted from functional inactivation of the wild type p53 allele in a heterozygous 
genotype - so called dominant-negative inhibition. The proposed methodology 
behind this loss of tumour suppressive function was based upon the tetrameric nature 
of the p53 protein. It was felt that hetero-tetramers consisting of combinations of 
mutated and wild type proteins, may lead to abolition of the DNA-binding capacity 
of the whole complex. Tetramisation of the wild-type protein is mediated by the 
oligomerization region (residues 319 - 360). This region is fully functional in core 
domain mutants. Interestingly the 273 (R to H) mutants, which seems to retain 
almost all of their wild type conformation (98% folding of wild-type p53) has a very 
weak dominant-negative activity [207].
However, despite possible dominant-negative function of missense p53 mutants, in 
approximately 50% of human tumours harbouring such mutations, the remaining 
wild-type allele is mutated or lost, suggesting that complete loss of normal p53 
promotes tumorigenesis further [208]. It has long been shown in knockout mouse 
model studies, that homozygous p53 null genotype is associated with tumour 
development, as anticipated with loss of tumour suppression function. However the 
tumour spectrum is fairly restricted, to primarily sarcomas and lymphomas, with 
carcinoma formation being rare [139]. In contrast, transgenic strains that produced 
over-expression of mutant p53, from exogenous promoters, resulted in accelerated 
tumour development with an increased incidence of carcinomas [209-212].
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These findings lead to the theory that mutant p53 may also actively promote 
tumorigenesis independent of wild-type p53 function. This phenomenon became 
known as the “gain-of-function” model. The hypothesis being that p53 mutants can 
transactivate or repress a range of specific target genes, and the action of these genes 
mediate the various oncogenic effects of these mutants.
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Figure 1.12: Proposed mechanisms for the role ofp53 mutations in tumorigenesis.
Reproducedfrom Cad well and Zambetti, 2001 [2131.
A - Loss of function. The wild-type p53 tetramer (green) is transcriptionally active in 
response to cellular stresses and induces the expression of downstream targets. An 
inactivating mutation (purple) or deletion of p53 (purple dotted line) results in a complete 
loss-of function that eliminates the p53 mediated stress response. B - Dominant-negative. 
Some p53 mutants (orange) oligomerise with wild-type p53 (green) and inhibit 
transcriptional activity’. C - Gain-of-function. Other p53 mutants (fuchsia) possess new 
functions not shared by wild-type p53.
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1.7.2 The mouse models of mutant p53 gain of function
In 2004, two independent research groups published data that added considerable 
weight and credibility to the “gain-of-function” properties of mutant p53 proteins. To 
ascertain the physiological effects of p53 point mutations, transgenic mouse models 
were created with mutated p53 alleles engineered into the endogenous p53 locus. 
This allowed direct comparison of p53 heterozygotes (+/-) and p53 null (-/-) mice, 
with those containing p53 mutant alleles (M/-,M/-) expressed from endogenous 
promoters, under physiological conditions. These experiments improved on previous 
studies in which strong promoters had driven expression of the mutant transgene to 
very high levels, thus not accurately mimicking the occurrence of p53 mutations in 
human tumours.
Tyler Jacks group engineered two conditional point mutant p53 alleles into the 
endogenous murine locus, encoding the contact mutant p53R270H and the structural 
mutant p53 . These correspond to the human codons 273 and 175 and represent
two of the three most commonly mutated codons in human cancer. They found that 
M/- mice develop tumour spectra distinct from p53 null mice. Since the effects of 
any dominant-negative action had been negated, the increased incidence of 
carcinomas, adenomas etc. were deemed to result from a gain-of-function action of 
the mutant protein. The M/+ mice were also found to provide a more appropriate 
model to recapitulate the human familial Li-Fraumeni syndrome than do p53 +/- or - 
/- mice. They found that p53 mice developed primarily carcinomas whereas the 
highest tumour incidence in the p53RI72H/+ group were osteosarcomas, indicating that 
different p53 point mutations may confer subtly different functions. Tumour cells 
derived from the mutant p53 mice were discovered to respond to shRNA mediated
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knockdown of their mutant p53 with a reduced rate of proliferation. This data in 
combination provided strong support for the protumorigenic effects of point mutant 
p53 [214].
Lozano’s group published a very similar study with a further knock in p53R172H 
mutant. They found increased rates of metastases in the heterozygous mutants 
compared with the +/- mice but did not see the variation of tumour spectra 
demonstrated in the Tyler Jacks paper. They concluded this may result from the 
differing mouse strains utilised in the two experiments [215].
Both groups studied the interaction of mutant p53 with its two family member 
proteins p63 and p73, since it had been previously suggested that down regulation of 
these proteins may provide a mechanism for the gain-of function [216, 217]. 
Independently each team demonstrated that mutant p53 co-immunoprecipitated with 
p63 and p73. Levels of both proteins were low in the mutant tumour cell lines and an 
increase in p63 and p73 target gene expression occurred following knock down of 
mutant p53 with siRNA. Further work by Flores and Jacks involved the generation of 
p53+/- p63+/- and p53+/- p73+/- combination mice to further analyse the role of p63 
and p73 in tumorigenesis. Mice heterozygous for mutations in both p53 and p63 or 
p53 and p73 displayed higher tumour burden and metastasis compared to p53+/- 
mice [218]. Hence strengthening the argument that p53, p63, p73 interactions may 
have an important role to play in p53 gain-of-function.
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1.7.3 Mechanisms of gain-of function (GOF)
The interaction of Mutant p53 with p63 and p73.
A pivotal GOF mechanism is the ability of common p53 mutants to bind and 
inactivate p53 family members’ p63 and p73. There is a substantial amount of data to 
support the role of the transactivation-potent variants of p63 and p73 in suppressing 
tumorigenesis. Analysis of mouse models demonstrated that p63 and p73 can 
partially compensate for deletion of Trp53 as Trp53+/— Trp63+/— mice and 
Trp53+/-Trp73+/- mice have reduced survival and increased metastatic rate 
compared with Trp53+/— mice (Flores et al 2005). Therefore, inhibition of p63 and 
p73 function is considered a key mechanism for mutant p53 gain of function [219]. 
Evidence supporting this notion has come from the recently developed knock-in 
mouse model in which p53R172H was shown to bind p63 and p73 in tumour derived 
cell lines, consequently inhibiting their abilities to induce cell-cycle arrest and 
suppress focus formation [220]. The capacity of different p53 mutants to bind p73 
has been shown to be significantly influenced by the site of mutation as well as by 
the single nucleotide polymorphism at codon 72 [221]. The p73 binding capacity is 
correlated with the ability of p53 mutants to protect cells from chemotherapeutic 
agents, and, accordingly, with less favourable response to chemo-radiotherapy in 
patients with head and neck cancer [221]. Therefore, targeting the interaction of 
mutant p53 with p63 and p73 seems a promising strategy for cancer therapy. Short 
peptides that disassemble p53R175H Rom p73 restore the activity of p73 and re­
sensitize cells that harbour mutant p53 to chemotherapy [222]. Similarly, the small 
molecule RETRA, which interferes with mutant p53-p73 interaction, hinders the
Chapter One - Introduction 64
growth of cells that express mutant p53 and their ability to form tumours in mice 
[223].
Transcriptional regulation by mutant n53
Modulation of gene transcription by mutant p53 is well documented as an important 
gain of function mechanism. The earliest evidence emerged with the demonstration 
that a functional transcription-activation domain of p53 is required for mutant p53 
dependent activation of MDR1 and protection from drug induced apoptosis. Since 
then, the transcriptional regulation of numerous genes has been implicated in mutant 
p53 gain of function: a summary of which is detailed in Table 1.7.
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Table 1.7: Selected list of genes that are transcriptionally regulated by mutant p53. 
Reproduced from Brosh and Rotter 2009 [224].
Phenotypic effects Corresponding gene(s) Effect
Enhanced proliferation NF-Y target genes (such as CCNA, CCA/87, CDK1. CDC25Q Upregulatcd
MAP2K3 (mitogen-activated protein kinase kinase 3) Upregulatcd
MAD1L1 (MAD1 mitotic arrest deficient-like 1) Upregulatcd
FOS, also known os c-fos Upregulatcd
PCNA (proliferating cell nuclear antigen) Upregulatcd
MYC, also known as c-myc Upregulatcd
E2FS Upregulatcd
ASMS (asparagine synthetase) Upregulatcd
ARHGEF2 (Rho/Roc guanine nucleotide exchange factor (CEF) 2; also known as CEF-Hl) Upregulatcd
ID2 (inhibitor of DNA binding 2) Downregulated
MCM6 (minichromosome maintenance complex component 6) Upregulatcd
/CFlR(tnsulin-like growth factor 1 receptor) Upregulatcd
CXCll (CXC-chcmokine ligand 1; also known asCROl) Uprcgutated
Inhibition of apoptosis EGR1 (early growth response J) Upregulatcd
and/or chemoresastance ATF3 (activating transcription factor 3) Downregulated
LGALS3 (lectin, gahetoside-binding, soluble; also known as CoIectin-3 Upregulatcd
FAS, also known os CD95/APO-1 Downregulated
MSTl (macrophage stimulating 1; also known as MSP) Downregulated
BCL2L1, also known os bcl-xL Uprcgulated
DHCR24 (24-dehydrocholesterol reductase; also known as setadin-1) Upregulatcd
NFKB2 (nuclear factor-KB2) Upregulatcd
ABCBl (ATP-binding cassette, sub-family B (MDR/TAP), member 1; also known as MDRl) Upregulatcd
IGF2 (insulin -bke growthfactor 2) Upregulatcd
BAGl (8CL2-ossocioted athanogcnc) Upregulatcd
OUT(deoxyuridine triphosphatase; also known as dUTPase) Upregulatcd
Other effects TGFBR2 (transforming growth factor, beta receptor II) Downregulated
ARHGD1A (Rho GDP dissociation inhibitor (GDI) a) Upregulatcd
RAN GAP 1 (Ran GTPese activating protein 1) Upregulatcd
PXN (paxitlin) Uprcgulated
KIF20A (kinesln family member 20A) Upregulatcd
ALOX15 (arachidonate 15 lipoxygenase) Uprcgulated
ribosomal proteins RPL37, RPLPl, end RPS2 Upregulatcd
Limitless replication TERT (telomerase reverse transcriptase) Uprcgulated
Invasiveness, inflammation 
and angiogenesis
NFkB target genes (such as CXCL1, interleukin ip (IL16). IL6, IL8, MMP3) Uprcgulated
WISP2 (WNT1 inducible signalling pathway protein 2; also known as cyclin 5) Upregulatcd
VEGFA (vascular endothelial growth factor A) Uprcgulated
• Rotter V.et ol-. unpublished data. CDC2 SC.cell division cycle 25C: CDK1, cyclin dependent kinase 1: MMP J. matrix metalloproteinase 3.
Mutant p53 stabilisation.
Efficient GOF action by mutant p53 requires elevated levels of the mutant protein in 
the affected cell. Mutant p53 is not intrinsically stable; rather changes that occur in 
tumour cells result in this stabilisation. Hence, mutant p53 protein levels are low in
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mutant p53 knock in mice but increase substantially in a fraction of tumours that 
emerge in such mice [220].
The simplest explanation for mutant p53 stabilization is that mutant p53 lacks the 
ability to transactivate wtp53 target genes. The Mdm2 gene is a classical positive 
transcriptional target of wtp53, and this drives a negative feedback loop that helps 
maintain wtp53 levels very low in unstressed cells. However, mutant p53 fails to 
transactivate the Mdm2 gene. Hence, Mdm2 protein levels are likely to be rather low 
in cells that express only mutant p53. Indeed, ablation of endogenous Mdm2 in 
mutant p53 knock-in mice leads to a substantial increase in endogenous mutant p53 
levels [225]. Importantly, this results in an earlier age of tumour onset and a GOF 
metastatic phenotype.
Mutant p53 and Genomic instability
Human mutant p53 can increase genome instability by disrupting normal spindle 
checkpoint control, leading to accumulation of cells with polyploidy genomes [226]. 
Additional studies have revealed further manifestations of the enhancement of 
genomic instability by mutant p53, as reflected by higher mutation rates in the T-cell 
receptor of cells exposed to X-irradiation [227], increased frequency of centrosome 
amplification and aberrant mitoses in mouse mammary epithelial cells [228], as well 
as increased gene amplification in Saos2 cells [229]. This link was extended to an in 
vivo context, revealing that expression of the mouse equivalents of human “hotspot” 
p53 mutants results in tumours that exhibit a high degree of genomic instability, 
manifested by aneuploidy associated with aberrant centrosome amplification as well
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as nonreciprocal chromosome translocations without evidence of telomere erosion 
[230].
The ability of mutant p53 to disrupt mechanisms that maintain cellular' genome 
integrity might provide an appealing explanation for its impact on tumour 
progression, particularly in advanced stages of the disease in which gross 
manifestations of genomic instability are very frequent.
1.7.4 The relationship between mutant p53 expression, anti-apoptosis and 
response to adjuvant treatments.
Some p53 GOF mutants have an ability to confer on cells an elevated resistance to 
proapoptotic signals. In 1995 it was shown that mutant p53 can reduce apoptosis in 
leukemic cells [231]. Mutant p53 can also protect cells against apoptosis induced by 
growth factor deprivation [232]. The therapeutic efficacy of anti-cancer agents 
depends strongly on their ability to trigger apoptosis in target tumour cells [233]. 
Many physical and chemical DNA damaging agents used routinely in cancer therapy 
are potent p53 activators [234]. In 1999, Blandino et al studied the effects of 
exogenous mutant p53 transfection on the response to chemotherapeutic agents. 
Clonogenic survival assays revealed that cells over-expressing mutant p53 proteins 
became more refractory to the cytotoxic effects of chemotherapeutic drugs. Their 
findings suggested that over-expression of at least some forms of mutant p53, may 
directly enhance the resistance of tumour cells to anti-cancer agents and therefore 
that p53 gain-of function might contribute to failure of chemotherapy [235]. 
Increased resistance to y irradiation, doxorubicin and cisplatin was also shown in 
mouse cells expressing a murine mutant p53 isoform [236].
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1.8 RNA interference
1.8.1 The Histoiy of RNAi discovery.
As is so often the case with major scientific breakthrough; the concept of RNA 
interference was discovered by a combination of fortunate accident and clever 
interpretation of unexpected resuls. The first observation of an RNAi type 
phenomenon was made by Napoli and Jorgensen in 1990 [237]. They were studying 
the anthocyanin biosynthesis pathway, which is responsible for the deep purple 
colouration of petunias. They introduced a chimeric Chalcone synthase (CHS) gene 
and hypothesised that its over-expression would lead to deep violet colouration, as 
the enzyme was felt to be the rate limiting step in the flavonoid pathway. 
Unexpectedly white petunias were produced, which correlated with a 50 fold 
reduction in endogenous CHS mRNA expression, suggesting that the transgene was 
somehow “cosupressing” the endogenous CHS gene. In 1992 Romano and Macino 
reported a similar phenomenon in Neurospora crassa (red bread mould), noting that 
the introduction of homologous RNA sequences caused “quelling” of the 
endogenous gene [238]. The phenomenon of RNA silencing was first documented in 
animals by Guo and Kemphues in 1995 [239]. They observed that the introduction of 
sense or antisense RNA to par-1 mRNA resulted in degradation of the par-1 message 
in Caenorhabditis elegans (nematode). Previously antisense was thought to function 
by hybridisation with endogenous mRNAs resulting in double stranded RNA 
(dsRNA), which either inhibited translation or was targeted for destruction by 
cellular rlbonucleases. However, when sense par-1 transcript was used as a control, 
the message was still targeted for degradation.
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A seminal paper offering explanation for this endogenous gene silencing came from 
Fire and Mello in 1998 [240]. They reasoned that the seemingly paradoxical finding 
of sense strand silencing made by Guo and Kemphues could have been due to the 
contamination of preparations of ssRNA by dsRNA resulting from the activity of 
bacteriophage RNA polymerases They indeed found that dsRNA was substantially 
more effective at producing interference than was either purified strand individually. 
Only a few molecules of injected dsRNA were required per affected cell, arguing 
against stochiometric interference with endogenous mRNA and suggesting that there 
could be a potent amplification component in the interference process. The 
observation of gene silencing being passed from parent to progeny led to the 
hypothesis that the effect may be mediated by a stable silencing intermediate. Further 
work on drosophila demonstrated that dsRNA was converted to shorter 
intermediates, small interfering RNA’s (siRNAs), 21 -23 nucleotide lengths of RNA, 
capable of binding to their homologous target mRNA5s leading to cleavage of the 
transcript. This seminal finding of the mechanism of RNA interference has recently 
resulted in Andrew Fire and Craig Mello being awarded the Nobel Prize for 
Medicine.
1.8.2 The significance of RNA interference.
RNA interference is an evolutionary conserved cellular defence observed in nearly 
every eukaryote studied thus far, and represents a unique form of post-transcriptional 
gene silencing (PTGS), initiated by dsRNA. In nature, RNAi is initiated when the 
host cell encounters a long dsRNA transcribed from an invading virus or from an 
endogenous source such as a mobilised transposon or an inappropriately transcribed
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sequence. The discovery that delivery of siRNAs to mammalian cells caused 
sequence-specific gene silencing by RNAi has revolutionised the study of loss of 
gene functions. The ease with which genes can be silenced via the RNAi pathway 
has led to the generation and screening of genome-wide siRNA libraries in many 
organisms [241].
More recently a new class of regulatory, non-coding microRNAs (miRNAs) have 
been identified which has broadened the implications on RNAi even further. 
miRNAs are endogenously produced, short double stranded RNA molecules that can 
regulate gene expression via RNA interference. These molecules can inhibit gene 
expression by mRNA degradation or by translational inhibition of target genes. 
MiRNA genes constitute approximately 1-5% of the predicted genes in the human 
genome and bioinformatics analyses suggest that up to 30% of human genes may be 
regulated by miRNA’s [242]. It has been shown that they could act as tumour 
suppressors by inhibiting oncogenes, or function as oncogenes by inhibiting tumour 
suppressors. More than 50% of miRNA genes have been found to be localised in 
cancer-associated genomic regions or in fragile sites [243]. Studies have linked 
diseases to the loss of miRNA expression that may result from the deletion or the 
translocation of a chromosomal region. For instance, consistent down-regulation of 
miR-143 and mir-145 have been observed in advancing colorectal cancer.
1.8.3 1.7.3 RNA interference: Mechanism of action
The introduction of double-stranded RNA into cells, results in their recognition by an 
RNase III enzyme, known as dicer; which cleaves the RNA into 21-23 nucleotides
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siRNAs. This step is bypassed by using synthetic siRNAs but is utilised when short - 
hairpin sequences are used for silencing, as these are cleaved intra-cellulary by the 
Dicer enzyme into siRNA molecules. In the early years of experimentation with 
siRNA, its usage was limited to flies, worms and plants, since the introduction of 
long dsRNA into mammalian cells elicits an interferon response that causes a general 
inhibition of translation, abrogating the specificity of RNAi. The finding that short 
dsRNA could silence genes, bypassed this problem and heralded the use of RNAi in 
mammalian cells.
Once cleaved by Dicer, the 21-23 nucleotide dsRNA consequently becomes 
incorporated into a multi-protein, RNA - induced Silencing complex (RISC). This 
ternary complex consists of the Dicer enzyme, along with two other proteins; Ago 2 
and TRBP (the HIV trans-activating response RNA - binding protein). Upon 
formation of the complex, Ago2 cleaves the passenger strand of the siRNA duplex, 
which then allows the complex to associate with the target niRNA. The single- 
stranded siRNA in RISC guides sequence — specific degradation of complementary 
or near complimentary target mRNAs. RISC cleaves the target mRNA in the middle 
of the complementary region, ten nucleotides upstream of the nucleotide paired with 
the 5' end of the guide siRNA. The RISC complex catalyses hydrolysis of the target 
RNA phosphodiester linkage, yielding 5’phosphate and 3Tiydroxyl termini on the 
mRNA fragments. The cleaved mRNA sequence is therefore not translated into a 
functional protein product and the target gene has been silenced.
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Mechanism of action of RNAi.
Double stranded RNA is introduced into a cell and gets chopped 
up by the enzyme dicer to form siRNA. siRNA then binds to the 
RISC complex and is unwound. The anitsense RNA complexed 
with RISC binds to its corresponding mRNA which is the cleaved 
by the enzyme sheer rendering h inactive. 
(http://www.bioteach.ubc.ca/MolecularBiology/AntisenseRNA/)
Figure 1.13: Mechanism of action of RNAi 
Reproducedfrom wmv.bioteach.uhc.ac/MolecularBiology/AntisenseRNA
1.8.4 RNA interference and p53.
In 2002, Martinez et al, utilised siRNAs targeted against wild-type and mutant p53 
sequences. They performed their experiments on HI299, p53 null cells, transfected 
with either the wild type p53 sequence or the common R248W mutant form. They 
tested various siRNAs for their efficiency and ability to discriminate between wild- 
type and mutant p53. They found the most effective and specific mutant silencing 
occurred when the mutated base was the ninth nucleotide from the 5’ end. They 
demonstrated that their WT-siRNA inhibited the expression of the WT protein whilst
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having little effect on the mutant protein levels. Conversely their mutant siRNA 
showed high selectivity for the mutant protein over the wild type [244].
Olive et el (2004) utilised RNAi technology following their transgenic studies into 
p53 gain of function (see 1.6.4). They took cells from an osteosarcoma metastasis 
that arose from a R172H / - mouse and introduced a conditional lentiviral shRNA 
expressing construct, to knock down p53 in an endogenous setting. A proliferation 
assay confirmed that p53 shRNA expressing cells grew more slowly after 
suppression of mutant p53, than cells undergoing transfection with an empty control 
vector [214].
In 2007, Vikhanskaya et al. used siRNA against mutant p53 and also p73. They 
showed that silencing of mutant p53 expression resulted in up-regulation of p53- 
target genes in several human cancer cell lines, leading to reduced cellular colony 
growth due to the induction of apoptosis [245].
1.8.5 The use of RNA interference in colon cancer.
RNA interference has been used to study multiple aspects of the genetics involved in 
the tumourigenicity of colon cancer.
It has been demonstrated that siRNA mediated gene silencing of vascular 
endothelial growth factor (VGEF) in colon cells can produce a 67% decrease in 
cellular proliferation Hence it is suggested that RNA interference could provide a 
potential mechanism for anti-angiogenic tumour therapy in colorectal cancer [246].
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RNA interference has also been utilised to study the implications of oncogenic Ras 
mutations on levels of apoptosis, in malignant colon cells undergoing treatment with 
5 FU chemotherapeutic agents [247].
1.8.6 The pSUPER vector
In 2002, Brummelkamp et al published their first report of a new vector system 
which directed the synthesis of small interfering RNAs in mammalian cells. They 
designed a gene specific insert, such that it specified a 19 nucleotide sequence 
derived from the target sequence, separated by a short spacer from the same 19 nt 
sequence in reverse. The resulting transcript was predicted to fold back on itself 
forming a short hairpin RNA structure intra-cellularly. They demonstrated that 
siRNA expression by this vector caused efficient and specific down-regulation of 
gene expression, resulting in functional inactivation of the target gene. They also 
found that a single nucleotide mismatch in the target sequence abrogated the ability 
to suppress gene expression [248].
Brummelkamp et al went on to develop a retroviral delivery mechanism for this 
pSUPER vector and showed that it could be used to specifically and stably inhibit 
expression of the K-Ras oncogene in human tumour cells [248].
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1.8.7 pSuper used to down regulate mutant p53
Boss! et al (2006) published a paper demonstrating the use of the pSUPER retroviral 
vector against mutant p53 expressing cells. They demonstrated knock down to 20 - 
50% of original levels and showed that this resulted in a concomitant reduction in 
cell proliferation and improved cell death rates in response to chemotherapeutic 
agents [249].
1.8.8 The clinical applications of RNA interference
If RNAi is to provide future therapeutic applications then successful and safe in vivo 
delivery of siRNA sequences must be established. The most challenging issue is 
maintaining stability of the desired sequence until the active siRNA oligos reach 
their target cells. SiRNAs are unstable in the serum environment where they can be 
degraded by RNAase and are rapidly excreted in the urine if delivered systemically. 
Overcoming multiple tissue barriers and ensuring efficient endocytosis into the target 
cell are also essential to successful delivery. The use of cationic lipids and polymers 
as siRNA delivery carriers have been shown to help overcome some of these 
obstacles. Options for local delivery under consideration include: intra-tumoral, 
intra-muscular, intra-peritoneal and intra-vitreous [250].
Two phase I clinical trials have been published using intra-vitreous delivery of 
siRNA to down regulate VEGFR1 in the treatment of age-related macular 
degeneration [251, 252]. Both trials reported promising results with minimal adverse 
affects and no unwanted systemic delivery.
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1.9 Hypothesis / aims
Hypothesis - Inhibiting mutant p53 in colorectal cancer cells may reduce malignant 
potential and augment response to adjuvant therapies.
Aims: To utilise RNA interference to achieve stable knock down of mutant p53 
protein levels in a panel of colorectal cancer cell lines in culture and to consequently 
study the effects of this on cell proliferation and response to chemotherapeutic 
agents.
Transcriptional 
up-regulation of 
target genes
Tumour
Supression
X
 Dominant-negative
inhibition of wild-type
function
Gain of 
Function
J Sensitivity to 
Chemotherapy
Figure 1.14: Inhibiting mutant p53 in colorectal cancer cells may reduce malignant 
potential and augment response to adjuvant therapies.
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Chapter 2. Materials and Methods
2.1 Buffers and Solutions
All buffers and solutions were prepared in water with resistance of > 15 MCI. 
All chemicals were obtained from Sigma Aldrich unless otherwise stated.
2.1.1 SLIP (Stuart Linn immuno-precipiation) Buffer (100ml)
50ml of 0.1M HEPES (pH 7.5)
lOmls 10% (v/v) glycerol 
0.1ml 0.1% (v/v) Triton X-100 
150mM NaCl 
0.05g of BSA.
Made freshly every seven days and stored at 4°C.
2.1.2 PBS (phosphate buffered saline) / Tween (4 L)
44.8gNa2HPO4.2H20 
9.67gNaH2PO4.2H20 
17.52g NaCl
4ml 0.1% (v/v) Tween 20 (polyoxyethylene sorbiton monolaurate).
2.1.3 Tris-Glycine Electrophoresis Buffer (500ml / tank)
25mM Tris-HCl
250 mM glycine 
0.1% SDS.
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2.1.4 Electrophoresis Transfer Buffer (1L / tank) 
25mM Tris-HCl
192 mM glycine 
20% methanol.
2.1.5 4X Sample Buffer
0.25 M Tris-HCl (pH 6.8)
8% SDS
40% glycerol
4mg/ml bromophenol blue
1 % p-mercapto ethanol
Diluted to 2X and 1X with H2O as required.
2.1.6 SDS Polyacrylamide Stacking Gel (10ml) 
7.225ml H20
1.275ml 40% acrylamide mix 
1.25ml 1 M Tris-HCl (pH 6.8)
0.1ml 10% SDS 
0.1ml 10% APS 
0.01ml TEMED.
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2.1.7 SDS Polyacrylamide Seperating Gel (10ml)
Table 2.1: SDS Polyacrylamide Separating Gel Formulations.
Reproduced from Harlow and Lane(l999) Using antibodies : a laboratory manual 1253].
% Gel Concentration
6% 7.5% 10% 12% 15%
h2o 5.8ml 5.42ml 4.8ml 4.3ml 3.55ml
40% w/v
acrylamide
solution
1.5ml 1.87ml 2.5ml 3ml 3.75ml
1.5 M Tris
(pH 8.8)
2.5ml 2.5ml 2.5ml 2.5ml 2.5ml
10% SDS 0.1ml 0.1ml 0.1ml 0.1ml 0.1ml
10% APS 0.1ml 0.1ml 0.1ml 0.1ml 0.1ml
TEMED 0.008ml 0.008ml 0.008ml 0.008ml 0.008ml
2.1.1 Cryogenic preservation media
10% DMSO (dimethyl sulphoxide)
90% FBS.
2.1.2 Pepstatin (Roche Applied Science)
Stored as 1000X stock at -80°C 
1 mg/ml in 100% methanol.
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2.1.3 Leupeptin (Roche Applied Science)
Stored as 1000X stock at -80°C 
0.5mg/ml in H2O.
2.1.4 Aprotinin (Roche Applied Science)
Stored as 1000X stock at -80°C 
2mg/ml in PBS.
2.1.5 Soybean Trypsin inhibitor (Roche Applied Science)
Stored as 1000X stock at -80°C 
1 OOjig/ml in H2O.
2.1.6 Phenyl methyl sulfonyl fluoride (PMSF) (Sigma)
Fresh 100X stock of lOOmM in 100% ethanol prepared each time.
2.1.7 Ponceau S (Sigma) 10X stock
2% Ponceau S (3-hydroxy~4"[2-sulpho-4-(sulpho-phenylazo)phenylazo]-2,7 
napthalene disulphonic acid)
30% trichloroacetic acid 
30% sulphosalicylic acid.
2.1.8 Annealing Buffer
lOOmM NaCl 
50mM HEPES-pH 7.4.
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2.1.9 Agarose Gel
1 % gel = 1 gram of Seakem GTG agarose (Cambrex biosciences Rockland inc.) 
Dissolved in 100ml T.A.E. (Tris, Acetic Acid, EDTA).
0.5 gg/ml ethidium bromide added to all agarose gels (Roche)
2.1.10 Luria-Bertani Media (LB media aka LB -broth) (500ml)
12.5 grams powdered L.B. (Sigma) made to 500ml with water.
2.1.11 Luria-Bertani Agar (LB Agar) (500ml)
12.5 grams powdered L-Broth
7.5 grams Difco-bacto (or Oxoid) agar - made up to 500ml with water.
2.1.12 Orange G (Sigma)
Reconstituted in 10% glycerol with orange G powder added until appropriate orange 
colouration is achieved.
2.1.13 P-gal Fixing Buffer
0.5% glutaraldhyde in phosphate buffered saline.
2.1.14 p-Gal Substrate Buffer
3mM potassion ferrocyanide 
3mM potassium ferricyanide 
ImM MgCl2
0.5mg/mlX-gal (5-bromo-3-indoyl-P-D-galactopyranoside)
Diluted in PBS.
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2.2 Cell lines
2.2.1 Colorectal Cell lines
Unless otherwise stated, cell lines were grown from established frozen stocks 
obtained for our laboratory.
2.2.1.1 HCT116 and derivatives
This tumour cell line was derived from a male patient with colon cancer.
The p53 status is documented as wild-type.
The heterozygous +/- and the homozygous -/- cells contain a AN40 mutation, on one 
or both alleles respectively.
This cell line and its derivatives were kindly donated by Dr Lorna Warnock from 
Prof. Joe Milner’s group at the Yorkshire Cancer Research Laboratory at the 
University of York.
2.2.1.2 LoVo
LoYo was initiated in 1971 from a fragment of a metastatic tumour nodule in the left 
supra-clavicular region of a 56-year-old Caucasian male patient with a histological 
diagnosis of adenocarcinoma of the colon.
The original tumour was Duke’s C, Grade IV.
The p53 status is documented as wild-type.
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2.2.1.3 SW480
This transformed cell line was established from a Duke’s B primary adenocarcinoma 
of the colon in a 50 year old Caucasian male in 1978. The p53 status is mutant with 
the cells expressing elevated levels of p53 protein. There is a G to A mutation at 
nucleotide 14487, exon-8, codon 273, which leads to a CAT mutant codon. This 
results in an Arginine to Histidine amino acid substitution and consequently a 
missense mutation (R273H). There is also a C to T mutation at nucleotide 14686, 
exon-9, codon 309, which results in a TCC mutant codon. This leads to a Proline to 
Serine missense substitution (P309S) [173]. The SW480 cell line has been 
demonstrated, by karyotyping and sequencing, to have three copies of chromosome 
17 with all three copies of the gene containing the same two missense point 
mutations.
2.2.L4 SW620
This cell line was cultured from the metastatic lymph node of the same patient as 
SW480, 1 year after the initial colonic resection. A recurrence of the malignancy 
resulted in a wide spread metastasis from the colon to an abdominal mass. The 
established cell line consists mainly of individual, small spherical and bipolar cells 
lacking microvilli. Levels of p53 protein expression are elevated. There is the same 
G to A mutation at codon 273 as found in the SW480 cell line. Interestingly, 
although this cell line is established from a later metastasis, it only has one p53 
mutation whereas the tumour specimen cell line established on year previously 
carries two missense mutations [173].
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X2.L5 HT29
This cell line was established from the colon cancer of a 44 year old female 
Caucasian patient in 1964. The p53 gene is mutant with the same 273 Arg. to His 
(R273H) missense mutation in exon 8, as described in the SW480 and SW620 cell 
lines.
2.2.2 Other tumour cell lines
2.2.2.1 PANC1
This cell line was established from a ductal pancreatic carcinoma in a 56 year old 
Caucasian male. The cells have high levels of mutant p53 protein expression. They 
contain the same common R273H mutation, as the SW480, SW620 and HT-29 lines 
described above. They also have an additional mutation at codon 272 which is a T to 
C point mutation resulting in an alanine substitution.
2.2.2.2 H1299
A non small lung cancer cell line derived from a patient a metastatic lymph node.
The p53 status of this line is null.
2,2.23 MCF-7
A human breast adenocarcinoma cell line derived from a pleural effusion.
The p53 status of this line is wild-type.
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2.3 Tissue Culture
All tissue culture was carried out using aseptic technique and performed in a class II 
laminar flow tissue culture cabinet. Cells were cultured as a monolayer at 37°C with 
5% CO2. They were routinely maintained in 175cm2 tissue culture flasks and split 
every 48-72 hours, when at a confluence of 70-90%. Cells were cultured in either 
Dulbecco’s Modified Eagles’ Medium or RPMI - 1640, supplemented with 10% 
Foetal Bovine Serum and L-glutamine (all supplied by Sigma). All media, PBS and 
trypsin were warmed to 37°C prior to use.
Table 2.2: Cell culture Methodology for various cel! lines
Cell Line Media Routine Split Ratio TrypsinizationTime
HCT 116
(and derivatives)
DMEM -10% FBS
2mM L-Glutamine
1:8 2 minutes
L0V0
DMEM -10% FBS
2mM L-Glutamine
1:5 3 minutes
SW480
DMEM -10% FBS
2mM L-Glutamine
1:8 1 minute
SW620
DMEM-10% FBS
2mM L-Glutamine
1:8 1 minute
HT29
DMEM-10% FBS
2mM L-Glutamine
1:5 5 minutes
H1299 RPMI - 10% FBS 1:10 1 minute
Pane 1
RPMI - 10%FBS
2mM L-Glutamine
1:5 2 minutes
MCF-7
RPMI - 10%FBS
2mM L-Glutamine
1:8 1 minute
Chapter Two - Materials and Methods 86
2.3.1 Cell harvesting and passage
Culture media was removed and cells washed with sterile Dulbecco’s PBS (Sigma) 
to remove any residual media. A 0.25% Trypsin - 0.53mM EDTA solution was 
applied in a thin layer and cells incubated as above until they were no longer 
adherent to the flask base, as confirmed by light microscopy. The trypsin was 
neutralised with an equal or greater volume of the appropriate media containing FBS. 
The cells were repeatedly aspirated and released from a glass pipette to produce a 
single cell suspension and then re-plated at a density appropriate for each cell line.
2.3.2 Freezing and thawing cells
Cells were harvested with trypsin as per 2.3.1. Cells were spun in a centrifuge at 
300rcf, 4°C for 5 minutes. The pellet was then re-suspended in freezing media and 
the cryo-vial kept at -B0°C for 24 hours prior to storage in liquid nitrogen at a 
concentration of l-5xl06/ml. Cells were defrosted at 37°C and immediately 
transferred into pre-warmed culture media.
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2.4 Western Blotting
2.4.1 Cell lysate preparation
Cell pellets were lysed on ice with SLIP buffer (2.1.1) containing the protease 
inhibitors pepstatin, leupeptin, aprotinin, soybean trypsin inhibitor and PMSF (2.1.9 - 
2.1.13). SLIP buffer was added to each pellet until the dissolved solution was just 
pearlescent and left on ice for 10 minutes. Samples were then spun in the centrifuge 
at 14,000 x ref at 4°C for 10 minutes to remove any cellular debris and the 
consequent supernatant was then aspirated and retained and the pellet discarded.
2.4.2 Bradford assay to determine protein concentrations
A calibration curve of standard protein concentrations was created using bovine 
serum albumin (Sigma) made up in SLIP (with protease inhibitors as above) to 
concentrations of 20, 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0 mg/ml. Bradford protein 
assay reagent (Biorad) was diluted 1:5 with water. 2pi of each standard was added to 
1ml of the Bradford reagent and the optical density of each sample at 595nm, 
measured using a spectrophotometer. Discrepancies of <5 in the c.v. reading were 
deemed acceptable. Protein concentrations of the supernatants were determined in a 
similar fashion and then adjusted with 4X, 2X and IX sample buffer (2.1.5) to a final 
concentration of 50pg/20pl for the majority of samples. Occasionally, when protein 
yields were lower, lysates were prepared at 30pg/20pl; this is indicated where 
appropriate. Samples were either stored at -80°C until required or prepared 
immediately for resolution on an SDS Page Gel. Prior to loading, lysates were boiled 
for five minutes to denature the proteins and then spun at 14,000 x ref, at 4°C for 4 
minutes before returning onto ice immediately prior to loading.
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2.4.3 SDS-Page
0.75mm glass plates were cleaned with 70% ethanol, air dried and mounted. An SDS 
polyacrylamide separating gel (2.1.7) was poured between the plates to within 1.5cm 
of the top. The percentage of gel used was dependant on the apparent molecular 
weight of the proteins to be probed and therefore was experiment dependant. The gel 
was covered with H2O and left to set for 20 minutes before removing the water and 
adding the stacking gel (2.1.6). A 10 well comb was placed into the stacking gel and 
allowed to set for 15 minutes before removal of the comb and washing out of the 
wells with water. The gel and plates were then transferred to a Mini Protean III 
electrophoresis chamber (Biorad) and Tris-glycine electrophoresis buffer (2.1.3) 
added to fill the central chamber and half the external chamber (500ml / chamber). 
20pl of sample were loaded alongside 15 pi of broad range pre-stained molecular 
weight marker (New England Biolabs) and subjected to electrophoresis at 200V for 
55-70 minutes. The gel apparatus was dismantled, the stacking gel removed and a 
Hybond ECL nitrocellulose membrane (Amersham Biosciences) placed on the gel 
and sandwiched between 3MM Whatman chromatography paper (VWR) and 
sponges. This procedure was performed submerged in transfer buffer (2.1.4) to 
prevent air bubbles from forming within the ‘sandwich’. The nitrocellulose 
membrane was pre-soaked in the transfer buffer to ensure adequate hydration. The 
assembled transfer apparatus was then returned to the chamber, along with an ice 
block for cooling, the chamber filled with the buffer (2.1.4) and transferred for 1 
hour at 100V. The membrane was then removed, stained in Ponceau S (2.1.14) for 1 
minute, washed in water and photographed to assess evenness of loading and 
efficiency of transfer. It was cut longitudinally, at levels dictated by the apparent 
molecular weights of the proteins to be studied and using the pre-stained marker as a
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guide. The membrane underwent several washes in PBS / Tween (2.1.2) before being 
incubated overnight in 5% blotting grade non-fat dry milk powder (Biorad) in PBS / 
Tween, to block any non-specific protein binding sites.
2.4.4 Immunoblotting
The membrane was agitated at room temperature for one hour. Primary antibodies 
were diluted with 5% milk powder in PBS/ Tween, with concentrations and suppliers 
as per Table 2.3. Incubation with the primary and consequently the secondary 
antibodies, was for 1 hour each, at room temperature, with continuing agitation. The 
blot was washed in PBS / Tween for three cycles of ten minutes after each antibody 
had been removed.
Table 2.3: Primary antibodies used in immuno (ie westernj-blotting
Antibody Clone or Variant (product code) Supplier
Final
concentration Source
p53 DO-1 (Ab 6) Oncogene/Merck 0.02-3pg/ml MousemAb
p53 Ab 2433 Abeam 1:2,000 RabbitpAb
Actin C2 Insight 3f!g/ml MousemAb
MDM2 (IF-2) Ab 1 Oncogene/Merck 3pg/ml MousemAb
MDMX D19 Santa Cruz Biotechnology 1:5,000 GoatpAb
Pirh2 pAb BL588 Bethy Labs. 1:1,000 RabbitpAb
Cdkmla F5sc-6246 Calbiochem 3|ig/ml
Mouse
mAb
p!4ARF C18 Calbiochem 1:500 GoatpAb
MTBP AS-1
Manufactured from in house 
peptide raised against human 
MTBP
1:1,000 RabbitpAb
p-Gal Ab-1 Oncogene/Merck 3|ig/ml MousemAb
GFP Clones 7.1 and 13.1 Roche Applied Science 0.4pg/ml
Mouse
mAb
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Secondary antibodies.
Anti-mouse IgG, horse radish peroxidase (HRP)-linked whole antibody, Amersham 
(Img/ml used at [1:2,500] final concentration)
Anti-rabbit IgG, HRP linked whole antibody, Amersham 
(1 mg/ml used at [1:5000] final concentration).
Rabbit, anti-goat IgG, HRP conjugate, Zymed 
(1.5mg/ml used at [1:5000] final concentration)
2.4.5 Developing
Western blots were visualised using enhanced chemo-luminescence (ECL) reagent 
plus (GE Healthcare). Equal quantities of the enhanced luminal and oxidising 
reagents were combined and applied to cover the entire blot for one minute. The 
membrane was then blotted dry, reassembled, wrapped in cling film and secured in a 
Kodak light safe developing cassette. Blots were exposed to Fuji medical x-ray film 
at a range of time periods to optimise exposures for detection of the various proteins 
being studied. The film was subsequently developed in Kodak developer and fixer 
for two minutes respectively and then rinsed in water and allowed to air dry.
2.5 Luciferase reporter assay
In order to study p53 regulated transcriptional activity, a DNA plasmid luciferase 
reporter system was utilised. The pp53-TA-Luc vector (Clontech laboratories inc.) 
contains a p53 response element upstream of a herpes simplex virus thymidine 
kinase promoter (Pta). Located downstream of Pta is the firefly luciferase reporter
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gene, hence luminescence can be equated to levels of p53 mediated signal 
transduction.
luciferase
4.9 kb
a = p53 c/s-acting enhancer element 
TB = Transcription Blocker
Figure 2.1: Thepp53-TA-Luc Luciferase Reporter construct.
Puhished by Cion tech laboratories Inc. pp53-TA-Luc Vector Information, Protocol No. 
PT3511-5W2. Version No. PR19431. www.clontech.com
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2.6 SiRNA knock down experiments
2.6.1 SiRNA Oligonucleotides
The following siRNA molecules were used in this study, and were obtained from 
Dharmacon RNA technologies.
MDM2 (#1)
Sense sequence - 55 GCCACAAAUCUGAUAGUAUUU 35 
Anitisense sequence - 5’ AUACUAUCAGAUUUGUGGCUU 35
Dharmacon Cl control
Sense Sequence - 5 ’ UAGCGACUAAACACAUCAAUU 35 
Antisense Sequence - 5’ UUGAUGUGUUUAGUCGCUAUU 35
Wild Type p53 (Martinez 2002 [244])
Sense sequence - 5 ’ GCAUGAACCGGAGGCCCAUUU 3 ’
Antisense sequence - 5’ AUGGGCCUCCGGUUCAUGCUU 3’
The following siRNAs were designed by M Boyd using the online engine at the 
Whitehead Institute, http ://sirna.wi.mit.edu/
p53 R273H mutant #1
Sense sequence - 5 ’ AGCUUUGAGGUGCAUGUUUUU 3 ’
Antisense sequence - 5’ AAACAUGCACCUCAAAGCUUU 3’
p53 R273H mutant #2
Sense sequence - 5’ CUUUGAGGUGCAUGUUUGUUU 3’
Antisense sequence- 5 ’ AC A AAC AUGC ACCUC AAAGUU 35
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p53 R273H mutant #3
Sense sequence - 5’ ACAGCUUUGAGGUGCAUGUUU 3 ’
Anitsense sequence - 5’ ACAUGCACCUCAAAGCUGUUU 3’
Scrambled (‘MTBP’ siRNA sequence) [117]
Sense Sequence - 5’ GGACGCAUCCUUCUUAAUUUU 3 ’
Antisense sequence - 5’ AAUUAAGAAGGAUGCGUCCUU 3’
2.6.2 SiRNA: Methodology of basic knock-down experiments
These experiments were carried out in 6 well tissue culture plates (each well with an 
area of 9.5cm2), with each condition / treatment being applied to the 6 wells of one 
plate. Cells were harvested with trypsin from their routine culture flasks and seeded, 
in their usual media, to aim for a confluence of 40% at the start of transfection, the 
following day.
Approximately 24 hours post plating, cells were washed with sterile PBS and then 
2mls of fresh media were applied per well. The cells were then transfected with the 
luciferase reporter plasmid and a [3-galactoside expressing plasmid. The fl- 
galactoside plasmid is driven by a Simian Virus (SV40) Promoter and is utilised as a 
marker for transfection efficiency under the assumption that expression of this should 
be unaffected by the experimental conditions. It is hypothesised that the levels of the 
luciferase reporter plasmid incorporated into the cells will be proportional to the (3 
galactoside levels detectable by western-blotting.
Approximately 1.18pg of pp53-TA-Luc plasmid / well was combined with 0.42pg of 
B-Gal plasmid / well and mixed thoroughly. The transfection reagent GeneJuice
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(Novagen), was used at a volume of 3j.l1 per pg of DNA being transfected (i.e. 4.2pl 
per well). This was combined with lOOpl of serum free media (the same media used 
for the cells normal tissue culture without the FBS added) / well, mixed thoroughly 
and left at room temperature for five minutes. The two solutions were combined, 
mixed gently and left for fifteen minutes at room temperature. lOOpl of this solution 
was added to each well and the cells incubated for 4 hours before being replaced with 
1.6ml of fresh media.
The siRNA oligonucleotides were used at a final concentration of [40nM] except in 
the optimisation experiments (see 4.2). A scrambled siRNA sequence (produced 
from a rearranged MTBP siRNA) and a commercially purchased control sequence 
(Daramacon) Cl were used as negative controls, designed to be non-targeting against 
the cellular DNA and hence helping to confirm the specificity of any knock down 
effects. A lipofectamine only treatment group was also studied to account for 
transfection reagent mediated toxicity. The siRNA was added to Opti-mem media 
(invitrogen) at a volume of 200pi / well and a further 200pi of opti-mem was 
combined with 4pl /well of the transfection reagent Lipofectamine 2000 (Invitrogen). 
Both of these solutions were mixed thoroughly and left for 5 minutes before being 
combined, mixed gently and left for a further twenty minutes. 400pi was then added 
to each well and the cells incubated for a further six hours. At this stage the old 
original media was removed and fresh applied to negate the possible toxic effects of 
prolonged exposure to the Lipofectamine reagent. Typically, forty-eight hours after 
the application of the siRNA solution the cells were harvested (excluding 
optimisation experiments - see 4.2). Three wells from each condition were harvested 
using Trypsin-EDTA and spun in a centrifuge and the supernatant was subsequently
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removed by aspiration to produce a pellet for western blot analysis as described in 
section 2.4.
The remaining 3 wells were treated as separate samples for the Luciferase Reporter 
Assay (see 2.4). A Glo-lysis luciferase reporter assay kit (Promega) was used. To 
perform the assay, media was removed by aspiration and the cells were then washed 
twice with sterile PBS to remove traces of media which could interfere with the 
assay. The cells were then lysed with a specific volume of the Glo-lysis buffer at 
room temperature and agitated on a shaking table for 10 minutes. The volume of glo- 
lysis buffer necessary to lyse the cells was constant within each individual 
experiment, but varied from 300 — 500 pi, as necessary, to adequately lyse the 
specific cell line in use. Cells were harvested and transferred into 1.5ml micro­
centrifuge tubes (Eppendorf), mixed with a pipette and centrifuged at 16,100 x ref in 
a desk-top centrifuge for 3 minutes to pellet cellular debris. The supernatant was 
decanted and 50pl of this was added to 50pl of the luciferase reagent (at room 
temperature). This was immediately placed in a Turner Design 20/20 Luminometer 
and readings were taken for a thirty second period following an eight second pre- 
reading pause. Results were recorded in relative light units (RLU). The samples were 
normalised to RLU / pg protein using a Bradford assay to estimate protein 
concentrations (2.4.2). The mean of the three normalised results was plotted with the 
standard error of the mean (SEM) used and presented as the Y-axis error bars.
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2.7 In situ p Gal assay
Cells were plated the day before transfection into one 10cm dish per cell line, aiming 
for ca. 40% confluence on the day of transfection. (3-galactoside and pp53-TA~Luc 
vectors were transfected as outlined previously in section 2.6.2 . Twenty-four hours 
later the media was removed, the cells washed with sterile PBS twice and 10ml of 
fixing buffer (2.1.20) added per dish and left at room temperature for 15 minutes. 
This was removed and the cells again washed with PBS, prior to the application of 5- 
10ml per dish of substrate buffer (2.1.21). The cells were incubated at 37°C for 3-8 
hours, after which the substrate buffer was removed and the plates washed twice with 
water. Once dried, the plates were visualised by microscopy to assess the number of 
positively transfected (blue) cells and a photographic record made.
2.8 pSUPER plasmid preparation and cloning
2.8.1 The pSUPER vector
The pSUPER RNAi system (OligoEngine) is a commercially available DNA plasmid 
that directs intracellular synthesis of siRNA-like transcripts. The pSUPER vector has 
been shown to cause efficient and specific down regulation of gene expression, 
resulting in functional inactivation of the targeted genes. Stable expression of 
siRNAs using this vector mediates persistent suppression of gene expression, 
allowing the analysis of phenotypes that develop over longer periods of time.
The pSUPER vector is used with a pair of custom oligonucleotides that contain a 19- 
nuleotide sequence derived from the mRNA transcript of the gene targeted for 
suppression. The 19 nucleotide target sequence corresponds to the sense strand of the
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pSUPER-generated siRNA. In the mechanism of RNAi, the antisense strand of the 
siRNA duplex hybridises to this region of the mRNA to mediate cleavage of the 
molecule, as shown in Figure 2.2.
The designed oligonucleotides (see section 2.8.2) include the 19 base target sequence 
in sense and antisense orientation separated by a 9-nt spacer sequence that allows 
formation of a short hairpin (hence shRNA) when transcribed. The vector uses the 
polymerase-III-Hl-RNA gene promoter, as it produces a small RNA transcript 
lacking a polyadenosine tail and has a well-defined start of transcription and a 
termination sequence consisting of five thymidines in a row. Cleavage of the 
transcript (by Dicer (see section 1.7.3) occurs at the termination site after the second
uridine yielding a transcript resembling the ends of synthetic siRNAs, which also
contain two 3’ overhanging T or U nucleotides.
Hgacuccacuccuaaucuacuu
uucucagcucaccauuacaucB processed siRNA
vfGAUCCCSGACUCCAGUGGUAAUCUACi
»'«< AAAGGUUIJ iUUCUGAGGUCACCAUUAGAUG
A
U c
G A
A
A
C
transcript: 
short hairpin RNA
prefix 
fwx fGATCCCC 
rv: ronGCc!
target sequence
GACTCCAGTGGTAATCTAC
CTGACGTCACCATTAGATG
loop target seq. (anti-sense) suffix
TTCAAGAGAEEjajSlEgS^^gfrmTGGAAA r cm 
AAGTTCTCT t/V In ^»IAAAAACCTTTTCGA-. r
t pSUPER construct
Figure 2.2: Transcription of 60 base pair align udeotide into hairpin RNA and processing
to produce siRNA.
(Reproducedfrom pSUPER manual, www.oligoengine.com/products/psuper.html)
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The pSUPER vector backbone has a length of 5,429 base pairs. The vector contains a 
neomycin resistance gene allowing only stably transfected clones to survive under 
conditions of antibiotic selection, thus theoretically overcoming the problems 
associated with poor transfection efficiency observed with some cell lines. The 
pSUPER vector also has an ampicillin resistance gene which is utilised in as a 
bacterial selection marker during transformation. In addition, the plasmid contains an 
Enhanced Green Fluorescence Protein (eGFP) gene, which is fused with the 
neomycin sequence. eGFP is a gene isolated from jelly fish that allows them to glow 
luminous green in response to an ultra-violet light stimulus. The fusion gene is 
driven from a phosphoglycerate kinase (PGK) promoter. The vector contains T3 and 
Ml 3 reverse primers to allow sequence confirmation of the correct insert.
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Key Sites 
Bglll: 3181 
Hindlll: 3187 
EcoRI: 2960 
Sail: 3202 
Xhol: 3208
Vector Features
f1(+) origin: 135-441
PGK promoter 2840-2442
NeoORF: 1684-715
EGFP ORF: 2424-1691
H1 promoter: 2965-3213
Ampicillin resistance ORF: 5301-4444
T7 primer binding site (AATACGACTCACTATAG): 627-643 
T3 primer binding site (CTTTAGTGAGGGTTAAT): 3242-3258 
M13(-20) primer binding site (GTAAAACGACGGCCAGT): 600-616 
Ml3 reverse primer binding site (CATGGTCATAGCTGTT): 3276-3291
Ecl136ll
!Sacl
pSuper.gfp/neo
)00
5429 bps
Aflll
BsrGI
EGFPBspLUIII 
Aflll I
HI promoter 
PGKAcc65l
Xhol
Sail
Hindi
Accl
'Hindlll
Bglll
BstAPI
Aatll
EcoRI
Stul
Bpu 11021 
BsmBI
Sacll
Notl
Xbal
BamHI
Smal
Xmal
Figure 2.3: The pSuper GFP / Neomycin Vector.
(Reproducedfrom pSUPER manual, www.oligoengine.com/products/psuper.html
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2.8.1 The oligonucleotide sequences
Antisense sequence in RED 
Sense sequence in BLUE
pSUPER scrambled Top:
5’ - GAT CCC CGG ACG CAT CCT TCT TAA TTT TCA AGA GAA ATT 
AAG AAG GAT GCG TCC TTT TAA - 3’
pSUPER scrambled Bottom:
5’ - AGC TTA AAA AGG ACG CAT CCT TCT TAA TTT CTC TTG AAA 
ATT AAG AAG GAT GCG TCC GGG - 3’
pSUPER wild-type p53 Top:
5’ - GAT CCC CGC ATG AAC CGG AGG CCC ATT TCA AGA GAA TGG 
GCC TCC GGT TCA TGC TTT TTA - 3’ 
pSUPER wild-type p53 Bottom:
5’ - AGC TTA AAA AGC ATG AAC CGG AGG CCC ATT CTC TTG AAA 
TGG GCC TCC GGT TCA TGC GGG -3’
pSUPER p53 #3 Top:
5’ - GAT CCC CAC AGC TTT GAG GTG CAT GTT TCA AGA GAA CAT 
GCA CCT CAA AGC TGT TTT TTA - 3’ 
pSUPER p53 #3 Bottom:
5’ - AGC TTA AAA AAC AGC TTT GAG GTG CAT GTT CTC TTG AAA 
CAT GCA CCT CAA AGC TGT GGG - 3’
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2.8.2 Annealing the oligonucleotides
Oligonucleotides were dissolved in nuclease free H2O to a concentration of 3 mg/ml. 
3f.ig (l|.d) of forward and reverse oligonucleotides were added to 48j.il of Annealing 
Buffer (2.1.15). This mixture was incubated at 90°C for 4 minutes, 70°C for ten 
minutes, and then allowed to cool gradually to room temperature over the next 40 
minutes. Samples were used immediately in the ligation reaction, as outlined see 
section 2.8.5, or transfened to -20°C for storage.
2.8.3 Linearising the pSUPER vector
The pSUPER vector was linearised in sequential enzymatic digestions:
Table 2.4: Linearising the pSUPER vector: Hind III and Bgl II Digests 
Stage 1 - Digestion with Hind III (New England Biolabs) for 60 minutes at 37°C
CUT UNCUT
pSUPER Vector 5pg (10pl) 0.5pg(lpl)
Hind III enzyme (50 units)
(@ 20,000U/ml)
2.5pl N/A
Buffer No. 2
(New England Biolabs.)
5 pi 5 pi
h2o 32.5pl 44 pi
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Stage 2 - Digestion with Bgl II (New England Biolabs.) for 120 minutes at 37°C
CUT UNCUT
Bgl II (50 units)
(@10,000U/ml)
5 pi N/A
Buffer No. 3
(New England Biolabs.)
5 pi 5pl
h2o N/A 5 pi
These reactions were heat inactivated at 80°C for 20 minutes.
The linearised product was run alongside the uncut vector on a 1% agarose gel 
(2.1.16) to confirm digestion. The band corresponding to the linear backbone was 
then excised from the gel and purified using a GENECLEAN Turbo Kit (Q BlOgene) 
according to the manufacturer’s instructions. 3pl of the product of this was run again 
on a 1% agarose gel alongside a 1 Kb ladder (Invitrogen) to estimate the 
concentration of backbone DNA. Typically, 3pi of sample corresponded to 
approximately lOOng of DNA, therefore this was the quantity used in the ligation 
reaction.
2.8.4 Ligation into the pSUPER vector
The annealed oligonucleotides were used at ratios of 1:1, 1:10, and 1:100 of vector :
Oligo with lOOng of vector per ligation reaction.
i.e. (ng vector x Kb insert) / Kb vector x molar ratio = ng insert.
( 100 X 0.06 )/ 5.4 X 1 = 1.11 ng (1:1)
( 100 X 0.06 )/ 5.4 X 10 = 11.11 ng (10:1)
( 100 X 0.06 )/ 5.4 X 100 = 111.11 ng (100:1)
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The ligation reactions were run as shown in Table 2.5 and incubated overnight at 
room temperature.
Table 2.5: Annealed oligonucleotide ratios for ligation reaction into the pSUPER vector
1:1 1:10 1:100 No insert control
Backbone 3pl/100ng 3pl/100ng 3pl/100ng 3pl/100ng
Oligo
0.009ml
(Lllng)
0.09ml
(11.ling)
0.9ml
(111.ling)
N/A
T4 DNA Ligase
(Ambion)
1 pi Ipl Ipl Ip]
T4 DNA Ligase
Buffer
(Ambion)
Ipl Ipl Ipl Ipl
H20 4.991 pi 4.9 Ipl 4. Ipl 5 pi
The Bgl II site in the pSUPER backbone is destroyed upon successful insertion of the 
oligonucleotide sequence. Therefore, after cloning and prior to transformation, the 
plasmids were incubated with Bgl II 10 units/1 Opl reaction) for 30 minutes at 37°C, 
to reduce the level of background in the transformation.
2.8.5 Bacterial Transformation
L.B. agar (2.1.18) was melted and cooled until just liquid. Ampicillin [lOOpg/ml] 
was added and the mixture was then poured into 10cm bacterial plates and allowed to 
set. 5pl of each ligation reaction was added to 50pl of One Shot Top 10 chemically
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compotent E. coli (Invitrogen) and incubated on ice for thirty minutes. The cells were 
heat-shocked for 30 seconds at 42°C and returned to ice. 250j.il of SOC media 
(Invitrogen) was added and incubated at 37°C, with agitation at 225 rpm, for one 
hour. Various amounts of the cultures were then plated (typically 90% (270pi) and 
10% (30pl))5 and evenly spread across the plates before incubating overnight at 
37°C. pUC-19 plasmid (Invitrogen) was utilised as a marker of transformation 
efficiency. 29 colonies were obtained from 1.66 x 10‘7pg DNA, resulting in a 
transformation efficiency of 1.74 x 10s colonies / pg DNA.
The vector to oligo ratio of 1:10 yielded the most colonies, the 1:1 was the next 
highest, and there were relatively few colonies from the 1:100 ratio. In all cases the 
10% plate was utilised for subsequent analysis as the colonies were too confluent on 
the 90% plating. Eight colonies from the 10% plates of the 1:1 and 1:10 ligations 
respectively were selected for screening for each oligonucleotide insert. The colonies 
were inoculated aseptically into 3ml L.B. (2.1.17) with ampicillin [lOOpg/ml] and 
then incubated at 37°C overnight with agitation at 225rpm.
Plasmid DNA was purified from 2.5ml of each overnight culture using a QIAprep 
Miniprep Purification Kit (Qiagen) and then subjected to an EcoRI / Hind III double 
digest as described below, for two hours at 37°C, to identify clones containing 
inserts.
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Table 2.6: EcoRI / Hind III Digest to screen pSUPER clones
CUT UNCUT
DNA 2pl (~lpg) 2pl (~lpg)
ECO R1 (20,000U/ml)
(New England Biolabs)
0.5pl N/A
Hind III (20,000U/ml)
(New England Biolabs)
0.5pl N/A
ECO R1 Buffer
(New England Bio labs)
2pl 2pl
h2o 15 pi 16pl
Following restriction enzyme digestion samples were combined with 3pi Orange G 
(2.1.19), and analysed on a 2% agarose gel (2.1.16), by electrophoresis at 80V for 
2hours. The size of samples bands was estimated by comparison with a 100 base pair 
ladder (MBI Fermentas), as shown in Figure 2.4.
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100bpC 1 
ladder—
* * * ******
3 6 1 345678
—cut----------------- lycl------------ CUT——-------1 uch--------------- CUT —
WT p53-------------------:----- :--------- II-------------- Scrambled
— 1-1------------------ 1 |------------- J-----10:1---------------- -------^|------------------------1:1---------
* Positive clones : Vector with insert (281 bp)
(Negative clones 227bp)
1 2 3 4 5 6. 7. 8 9 10 H 12 13 14 15 16 17 18 19 20 21 22 23 .24 25 26 27 28
100 bp 
ladder
UCI-
* * * * * *
2 3 5 6 7 8
— CUT-------------|UC|-
Scrambled--------- 11—
1:10
** *  * **** ***
2 3 6 12 3 4 678
-------- CUT----------------lUCl------------- CUT--------------
------------ Mutant p53 (No. 3) ______________________
I— 1:1-------------- 1|--- |------------ 1:10---------
Figure 2.4: Agarose Gel confirming multiple clones with positive inserts for each
o/igon ucleotide sequence.
UC = Uncut (control samples with no Digestion enzymes)
C = Cut (The products of the EcoRI / Hind III digest)
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Frozen glycerol stocks were kept of all positive clones. For this 50% glycerol 
(Sigma) was sterilised by passage through a 0.2pm filter and then 500pl of this 
solution combined with 500pl of the overnight bacterial culture from which plasmid 
DNA was isolated prior to storage at -80°C.
Clones WT 1:1 No. 3, Scram 1:10 No. 2 and p53#3 1:1 No. 2 were selected to be 
amplified for transfection studies. Where possible 1:1 clones were used as these 
provided the lowest possibility of multiple inserts of the oligonucleotide sequence. 
To generate larger quantities of plasmids to be used for transfection experiments 
500pl of selected overnight cultures was added to 500ml of L.B. (2.1.17) with 
ampicillin [lOOpg/ml] and incubated overnight at 37°C with 225rpm agitation. The 
plasmid DNA was then purified using the EndoFree Mega purification kit (Qiagen) 
according to the manufacturer’s instructions. A further EcoRI / Hind III double 
digest was performed to confirm the presence of the successful oligonucleotide 
sequence insertion and the resultant samples were analysed by electrophoresis on a 
2% agarose gel. As previously shown in Figure 2.4, the sliRNA containing vectors 
produce a digest product of 281 base pairs compared with the 227 base pair parent 
vector, confirming successful insertion, as demonstrated for the large scale 
preparations in Figure 2.5.
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pSUPER wtp53 Sana p53#3
uc c uc c uc c uc c
3(H)
2(H) _ * * *
1(H)
* Positive clone (with insert) 281 bp
KH)bp
ladder - Negative for insert 227bp
Figure 2.5: Agarose get analysis of large scale preparations ofplasmid D1WA taken from 
selected bacteria! clones confirming the correct insertion of the Wtp53, mutant p53 and
scrambled sequences.
UC = Uncut (control samples with no Digestion enzymes) 
C = Cut (The products of the EcoRI / Hind III digest)
Following identification of correctly cloned inserts by restriction analysis, plasmids 
were sequenced to confirm that the shRNA sequence was inserted correctly. 
Sequencing was perfonned by MWG Eurofins.
2.8.6 Antibiotic Dose Selection
Cell lines respond differently to the same dose of antibiotics, therefore a range of 
concentrations of G418 (neomycin) were tested, to determine which provided the 
most appropriate balance between death and viability. For example, if we use a very
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high dose then all of the sensitive cells will be killed quickly. However, if the 
concentration is too high, cells that express the resistance gene, may not be able to 
proliferate. Thus a balance is required and for example using G418, in practise, this 
usually amounts to using a dose that kills the parental cells over a period of 5-10 
days. G418 Sulphate (Calbiochem) was dissolved at a concentration of 50mg/ml in 
0.1M HEPES, pH 7.3 and filter sterilised through a 0.2pm filter prior to use. Cells 
were plated into 6cm dishes, using their usual growing media, 24 hours prior to the 
first dose of antibiotics. Initial confluences of 20- 30% were recorded on Day 0 and 
the first dose of G418 was diluted in the appropriate media for each cell line and 
applied to the plates. Media was removed and antibiotic solutions replaced every 72 
hours, with the percentage of confluent, viable cells being documented on a daily 
basis. The concentration used in the subsequent transfection studies is identified by 
the red line shown in Figure 2.6.
PANC 1 - G418 antibiotic sensitivity (mg/ml) SW 480 - G418 antibiotic sensitivity (mg/ml)
Figure 2.6: G418 antibiotic sensitivity results
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HCT 116 +/+ cells continued to grow, even in the presence of high doses of G418, 
with viable cells still present following seventeen days of antibiotic treatment. 
Attempts were made to plate at lower initial confluences to hasten death of the cells, 
however, as these cells tend to grow in islands, there was a limit to how thinly they 
could be successfully plated. Therefore, it was decided to perform a puromycin kill 
curve, as the pSUPER vector is also available with a puromycin resistance gene for 
antibiotic selection. Puromycin (invitrogen) stock at lOmg/ml was diluted with tissue 
culture medium to the working concentrations in Figure 2.7.
Hct 116 +/+ Puromycin antibiotic sensitivity (mg/ml)
Time (Days)
Figure 2.7: Puromycin antibiotic sensitivity results for HCT 116 +/+ cel! line.
Figure 2.7 suggests a concentration of 0.2pg/ml would provide an appropriate 
selection for these cells. Ideally, 5-7 days to kill all cells is optimal and the doses 
0.1 and 0.25pg/ml are either side of this timescale). However, cloning of shRNA 
oligonucleotides into the puromycin pSUPER vector was not undertaken within the 
scope of this thesis due to time constraints.
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2.8.7 Transfection of p-SUPER vector into human tumour cell lines
Each cell line was transfected with pSUPER backbone alone and the pSUPER 
backbone with a scrambled sequence inserted (designed to be non-targeting against 
the cellular' DNA and hence helping to confirm the specificity of any knock down 
effects). As well as the shRNA sequences designed to suppress both mutant and wild 
type p53. Cells were plated the day prior to transfection, in three wells of a six well 
plate per condition, to aim for confluence of 90% on the following day. Prior to 
transfection, the media was removed, the cells washed twice with sterile PBS and 
1.5ml of fresh media added. 4pi of Lipofectamine 2000 (Invitrogen) was combined 
with 250pl Opti-mem (Invitogen) per well, vortexed and stored/retained/incubated at 
room temperature for five minutes. Similarly 2pg of the appropriate pSUPER vector 
was combined with a further 250pl of Opti-mem mixed thoroughly and 
stored/retained/incubated for five minutes. The plasmid and Lipofectamine solutions 
were combined, gently mixed and maintained at room temperature for twenty 
minutes, before applying 500pl per well. Twenty four hours later the cells were 
harvested with trypsin and re-seeded into three 6cm dishes per condition, aiming for 
confluences of 20-30% at the application of the first antibiotic dose as determined in 
Figure 2.6. Two non-transfected controls were also plated. The first was subjected to 
antibiotic selection to control for any spontaneous or inherent antibiotic resistant and 
to determine the effectiveness of the selection. The second control was grown 
without any antibiotic selection as a positive control for cell viability.
Media and antibiotics were changed every seventy two hours. Cells were grown until 
all of the cells in the untransfected antibiotic selection plates were dead and the
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growing colonies were big enough to be seen easily with the naked eye. In the case 
of the SW480 cells, the initial dose of G418 suggested from the antibiotic selection 
test was 1 mg/ml. However, when this dose was used, the untreated cells remained 
viable even after twenty days under selection and continued to multiply despite the 
antibiotic; therefore the selection dose was increased to 2mg/ml and the experiment 
repeated.
2.8.8 Selection of stable transfectants
To select individual colonies, media was removed from the plates and they were 
covered with a thin layer of sterile PBS. Approximately 5 pi of trypsin - EDTA was 
drawn up into a l-200pl pipette tip. Under the magnification of an inverted light 
microscope, a colony was localised, a small volume of trypsin expelled and then the 
colony gently aspirated into the pipette tip. The content of the pipette tip was 
combined with a further 100pi of trypsin and the colony gently dispersed into a 
single cell suspension by repeated gentle pipetting prior to transfer to a 24 well plate 
(1cm surface area). Cells from the colonies were gradually expanded into larger 
tissue culture flasks so that they could be harvested for western blot analysis and 
frozen for further studies. Colonies were kept under antibiotic selection until they 
were expanded into 25cm2 flasks (a minimum of seven days post colony isolation) 
and were thereafter maintained in the usual culture media for each cell line.
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2.8.9 Detection of EGFP Fluorescence
Cells were harvested in the usual maimer and then seeded into an eight chamber 
microscope slide (Lab-Tek™ - Chamber Slide™, NUNC, Fisher) at a confluence of 
approximately 25%. Twenty four hours later the chambers were removed and a 
microscope cover slip placed on the slide. Cells were visualised using a fluorescent 
inverted microscope with a FITC filter and images recorded using an attached digital 
camera.
2.9 Cell proliferation experiments
Cells were plated onto 6 well plates (area 9.5cm2 / well) in their usual growth media 
aiming for a confluence 24 hours later (Day 0) of approximately 10%. Cells were 
harvested every 24 hours and total cell count per well ascertained using a 
haemocytometer chamber and / or an automated particle analyser, aka a coulter 
counter (Beckman Coulter - Z series, Beckman Coulter Inc.).
Using the haemocytometer, the freshly harvested media (2ml per well) was pipette 
agitated and then applied to the haemocytometer slide underneath a tightly adherent 
cover slip, monitored by checking for the presence of Newton’s rings. Cell numbers 
in four separate 1mm x 1mm squares were manually counted including any cells 
overlapping the top and left borders and excluding cells crossing the bottom and right 
borders. The mean of these four totals was then multiplied by 20,000 
(haemocytometer chamber volume = 0.1mm2), providing a value for the total number 
of cells harvested from each well. Four wells were analysed for each condition and 
time period and the mean value of these plotted as a proliferation curve with the 
standard error of the mean forming the error bars.
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The coulter counter was maintained, flushed and calibrated as per manufacturer’s 
instructions. Cells were harvested in the smallest volume needed for adequate 
trypsinisation. 0.5ml of these harvested cells formed the metered volume for the 
Coulter analysis. This cell suspension was combined with 10 ml of isoton II diluent 
(Beckman Coulter inc.) to fill the accuvette (Beckman Coulter inc.) and using a 
100pm aperture tube all particles between 8 and 20 pm were filtered and counted. 
This produced a value expressed as [cells / ml] which was then multiplied by the 
appropriate total initial harvested volume (0.5ml - 5ml), as necessary. The average of 
three wells per condition was plotted with error bars as above.
For the initial proliferation experiment (see section 6.2) cell counts were performed 
using both a haemocytometer and an automated flow cytometer to ascertain the 
accuracy of the automated system for this given cell population. By comparing the 
total cell number for the same series of experimental conditions it would be possible 
to determine if the faster coulter counter method could be utilised accurately in the 
larger scale cell proliferation studies to follow (section 6.3).
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Figure 2.8: Comparison of cell number counts with the haemocytometer verses the coulter
counter method.
The graphs show that similar results are achieved with the two cell counting methods 
confirming that the coulter counter is an acceptable method counting cell numbers in 
the further proliferation experiments.
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2.10 Chemotherapeutic agent toxicity assays
5-fluoroiiracil (5-FU) (Sigma, C4H3FN202, MW = 130.8g) was dissolved in DMSO 
(0.065g /ml) [0.5M] stock and stored at 4°C. This was further diluted to [lOmM] in 
DMSO and added to the appropriate tissue culture media volume (2ml / well) to 
obtain final working concentrations of 1 to 20pM 5-fluorouraciL
In order to try and avoid any adverse effects from DMSO toxicity, the volume of 
DMSO / 5-FU added to the media was kept at a minimum (0.02%), total DMSO 
volume added was equal for all [5-FU] and a DMSO only control was also examined.
Oxaliplatin (LC Laboratories, CsHi4N204Pt, MW = 397.29g) was dissolved in H2O 
(0.4g/ml) [1M] stock and stored at 4°C. This was diluted in water to [lOmM] and 
added to the media to obtain [Oxaliplatin] 0.25pm - 10pm.
Cells were seeded in 6 well plates as previously, aiming for starting confluencies of 
10-20% 24 hours later. Tissue culture media was removed and media containing the 
chemotherapeutic agents applied and left on the cells for the duration of the 
experiment. Cells were harvested and counted at 0, 24, 48 and 72 hours using the 
Coulter analyser and cell proliferation graphed and analysed using the methods 
discussed in section 2.9.
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Chapter 3. Establishing baseline levels 
of p53 and ‘p53 pathway’ proteins
3.1 Determining the basal levels of p53 protein expression in our 
panel of colorectal cell lines
Before embarking on studies of the effectiveness of RNA interference, it was 
necessary to perform some simple and basic analyses of the colorectal cells lines to 
be studied, since this was the first time that colorectal cells had been examined in 
our laboratory. This would fulfil the dual purpose of confirming that the phenotypic 
p53 status matched the published data (see section 2.2) and allow refinement of 
tissue culture techniques with specific reference to these new cell lines, as detailed in 
section 2.3. Therefore initial experiments involved western blot analysis of basal p53 
protein expression levels in lysates prepared from a panel of colorectal cancer cell 
lines to determine the steady state levels of p53 expression.
Figure 3.1: Determination of endogenous p53 expression levels in a pane! of colorectal
cells
Figure 3. land 3.2: Cell lysates were prepared with protein concentrations of 
50pg/20pl and were analysed alongside 15pi of broad range pre-stained molecular 
weight marker (New England Biolabs) by western blot using the Ab 2433 p53 
primary antibody (Abeam), as outlined in section 2.4. Actin was used as a reference 
to confirm even sample loading. The breast cell line MCF 7 was also analysed 
alongside the colorectal samples since they have been used frequently in our 
laboratory and were known to express low levels of wild type p53 and they therefore
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provided a positive control for p53 detection. The non small cell lung cancer HI 299 
cell line was used as a negative control as they are known to be p53 null.
Figure 3.1 demonstrates very high levels of p53 protein expression in the mutant cell 
lines SW480 and SW620 consistent with their p53 point mutation(s) and over­
expression. HT-29 cells displayed relatively lower expression, despite their mutant 
status, but interestingly the band for p53 appeared at a slightly higher apparent 
molecular weight than in other cell lines. HCT-116 cells exhibited relatively high 
levels of p53 expression considering their wild-type status. In comparison, the wild- 
type LoVo cell line expresses relatively low levels of p53, comparable with MCF7 
cells. Of concern, the HI 299 cells displayed a band at approximately 53kDa, despite 
their p53 null genotype. Therefore subsequent western blots were repeated using the 
p53 primary antibody DO-1 (Ab 6), rather than AB-2433, which successfully 
eliminated this non-specific band as demonstrated in Figure 3.2.
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Figure 3.2: Determination of endogenous p53 expression levels in a panel of colorectal 
cells using primary antibody DO-1 (Ab 6)
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3.2 Basal protein levels in an array of ‘p53-pathway’ proteins
In the next set of experiments basal levels of various proteins involved in p53 
pathway were examined; genes located upstream (pi4 ARF), those involved in 
regulation of p53 stability/activity respectively (Mdm2 / MDMX) and genes encoded 
by downstream transcriptional target genes (CDKNla / PirH2) were subjected to 
western blot analysis in our panel of colorectal cells. The results of these western 
blots are summarised in figure3.2:
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Figure 3.3: Basal protein expression of a sample of f53-path way ’ proteins
Cell lysates were prepared as outlined in section 2.4.1 and 50pg/20pl of protein product was 
analysed alongside 15 pi of broad range pre-stained molecular weight marker (New England 
Biolabs), by western blot. The DO-1 p53 primary antibody (Oncogene/Merck) was utilised 
alongside the other primary antibodies detailed in Table 2.3. The approximate relative 
molecular weight of the proteins and any visualised break down products, as expected from 
the published literature is presented to the right of the displayed plot. MCF 7 and HI299 cell 
lines were added as control samples as per Figure 3.1.
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In Figure 3.3 it was notable that the wild-type LoVo cell line appeared to exhibit 
relatively high levels of MDM2 expression compared with the other cells analysed. 
MDMX protein expression appeared relatively high in both wild-type cell lines, as 
well as the mutant HT-29 cells, when compared with MCF 7 cells and our 
laboratory’s previous experience in other cell lines. There was no apparent 
correlation between p53 wild-type or mutant status and the expressed levels of pirh2, 
p21 orpl4ARF.
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Chapter 4. Evaluation of p53 siRNA 
specificity and efficacy
4.1 The effects of siRNA mediated p53 and MDM2 down regulation 
on protein expression levels and p53 mediated transcriptional 
activity.
Mutant p53 cell lines typically have very high levels of expression of the mutant 
protein and this finding has already been documented in our basal level experiments 
(section 3.1) within our chosen colon cancer cell lines. Therefore prior to targeting 
mutant p53 cell lines using RNA interference, which may prove troublesome due to 
these high protein expression levels, an initial experiment was designed that would 
target wild-type p53.
SiRNA oligonucletides, as detailed in section 2.6.1, were utilised to target wild-type 
p53 and MDM2 sequences in transient suppression experiments on three isogenic 
valiants of HCT 116 cells (+/+, +/- and -A). The p53 siRNA sequence chosen was 
selected because a previous study had suggested it had shown specificity for wild- 
type verses mutant p53 protein [244].These isogenic valiants allowed the specificity 
and magnitude of p53 suppression to be studied, since the heterozygous and null 
phenotypes could be compared against the observed effect in the parent cell line. The 
results of siRNA mediated wild-type p53 suppression in HCT 116 cells and their 
heterozygous and null phenotype derivatives, are shown in Figures 4.1 and 4.2:
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Figure 4.1: siRNA mediated suppression of p53 protein levels in HCT 116 cells and
derivatives
HCT 116 cells and their heterozygous and null derivatives underwent transfection with the 
p53 and MDM2 siRNA sequences detailed in 2.6.1. A scrambled siRNA sequence (produced 
from a rearranged MTBP siRNA) and a commercially purchased control sequence 
(Daramacon) Cl were used as negative controls. A lipofectamine only treatment group was 
also studied to account for transfection reagent mediated toxicity.
The cells were plated in 6 well tissue culture plates (each well with an area of 9.5cm:) and 
24 hours post plating (confluency -40%), the cells were underwent transfection with the 
luciferase reporter plasmid (pp53-TA-Luc) and a (i-galactoside expressing plasmid. 1.18pg 
of pp53-TA-Luc plasmid and 0.42pg of B-Gal plasmid per well was applied with the 
transfection reagent Gene Juice (Novagen), used at a volume of 4.2 pi per well. These 
reagents were combined with 100pi of serum free media and applied to the cells for 4 hours 
at which point this media was removed.
The siRNA, at [40nM], was combined with 400pi Opti-mem media (invitrogen) and 4pi 
Lipofectamine 2000 (Invitrogen) per well. 1.6mls of serum free media was added to each 
well and incubated for a further six hours. This media was replaced at 6 hours to negate the 
possible toxic effects of prolonged exposure to the Lipofectamine reagent. 48 hours after the 
application of the siRNA solution the cells were harvested with three wells per condition 
collated to allow 50pg/20pl of protein to be loaded for western blot analysis as per section 
2.4.
Figure 4.1 demonstrates that a detectable reduction in p53 protein level expression 
was obtained with the p53 targeted siRNA, in both the parent and heterozygous cell 
lines and thus the siRNA sequence appears to work in principle. MDM2 suppression 
was also visualised on the western blot, though the proportional reduction with this 
siRNA sequence appeared less then that seen with the p53 siRNA sequence. The p53 
protein levels increased in response to the suppression of MDM2 as one would 
expect in wild-type cells with negative inhibition from the p53 / mdm2 feedback 
mechanism.
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Figure 4.2: The effects of siRNA mediated suppression on p53 transcriptional activity in
HCT 116 cells and derivatives
The siRNA transfection was undertaken as detailed for Figure 4.1. 3 of the wells per 
condition were used as separate replicates for the luciferase reporter assay. A Glo-lysis 
luciferase reporter assay kit (Promega) was used. The cells were then lysed with 500pi of the 
Glo-lysis buffer and centrifuged at 16,100 x ref for 3 mins to pellet cellular debris. The 
supernatant was decanted and 50pl of this was added to 50pl of the luciferase reagent. This 
was immediately placed in a Turner Design 20/20 Luminometer and readings were taken for 
a thirty second period following an eight second pre-reading pause. Results were recorded 
in relative light units (RLU). The samples were normalised to RLU / pg protein using a 
Bradford assay to estimate protein concentrations (2.4.2). The mean of the three normalised 
results was plotted with the standard error of the mean (SEM) used and presented as the Y- 
axis error bars (see section 2.6.1). The same data from the HCT 116 -/- derivative is repeated 
in the second histogram after re-scaling to improve clarity.
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Figure 4,2 shows the p53 wild-type (+/+) cells demonstrate a high level of luciferase 
activity, concomitant with functional p53 transcriptional activity. On siRNA 
suppression of the wild-type protein, p53 transcription was reduced to 30% of 
original activity in the wild type cells. This confirms the successful suppression 
witnessed with western blot analysis as discussed in figure 4.1. The p53 
transcriptional activity is enhanced by transfection of the MDM2 siRNA as we 
would expect in a functional p53/MDM2 feedback mechanism.
The HCT 116 +/- derivative demonstrates p53 transcriptional activity at less than 
25% of the homozygous parent cell line however the pattern of response to p53 and 
MDM2 siRNA mediated down regulation is as seen and described in the +/+ cells 
above.
The basal levels of transcriptional activity in the HCT 116 -/- derivative were 
proportionally very low as expected. However, on re-scaling the data in the second 
histogram, these low protein levels still appear to be transcriptionally active, since 
they are down regulated with the p53 siRNA and upregulated with the MDM2 
siRNa, as seen in the other derivatives. The p53 homozygous -/- cells are not truly 
p53 null, rather they contain a p53 AN40 mutation on both alleles. This could 
account for the apparent residual activity seen in figure 4.2.
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The next series of experiments was designed to study the effects of siRNA mediated 
p53 down regulation on our panel of colon cancer cell lines expressing mutant p53. 
The same wild-type p53 siRNA sequence was used as outlined above (see also 
section 2.6.1).This targets a sequence outside the mutated regions of our mutant p53 
expressing cell lines [244] as cited below and hence should be able to suppress 
transcription of the mutant protein expression in these cell lines.
P53 mutations in our colon cell lines:
HT29 R273H mutation
SW480 R273H mutation
SW620 R273H and P309S mutations.
The first aim of this experiment was to see whether any detectable reduction in the 
very high levels of mutant p53 levels expressed by our cell lines, as demonstrated in 
Figure 3.1, could be achieved using siRNA mediated suppression.
The second aim of the experiment was to see if the mutant p53 cell lines retained any 
residual p53 transcriptional activity and if so would this be regulated by p53 / 
MDM2 down regulation, as witnessed previously in the HCT116 +/+ wild-type cell 
line (Figure 4.2).
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Figure 4.3: siRNA mediated knock-down of p53 in mutant colorectal cel! lines.
The siRNA mediated suppression was conducted with the same siRNA sequences and method 
previously discussed in figure 4.1. Again 50pg/20pl of protein was analysed for western blot 
analysis with results presented for the p53 and scrambled siRNA transfections alongside the 
lipofectamine only control.
In figure 4.3 two of the mutant cell lines show a demonstrable reduction in mutant 
p53 levels with siRNA transfection, though this cannot be confirmed in the SW620 
cell line due to the overexposed blot. The high levels of expression of the mutant p53 
protein in all of 3 cell lines resulted in the necessity to use very low concentrations of 
p53 primary antibody to obtain appropriate images (0.3pg/ml compared with 3pg/ml 
for wild type protein). Even with dilution the required exposure time for the western 
blots was very short. This demonstrates the magnitude of mutant p53 expression 
when compared with the wild-type p53 levels.
The proportion of suppression of p53 protein levels by the siRNA sequence appears 
less than that witnessed in the HCT 116 wild-type cells. This could represent 
saturation of the siRNA by the over-expressed mutant protein, or it could be due to 
the mutant p53 protein having a longer half life than the wild-type p53 and therefore 
being more resistant to this transient siRNA suppression. Also the mutant cell lines 
appeared quite difficult to transfect compared with the wild-type HCT116 +/+, as 
suggested by the weak p-Gal signal even on prolonged film exposures, especially in 
the SW620 and HT-29 cell lines.
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Figure 4.4: p53 transcriptional activity with p53 siRNA knock-down in SW620, SW4H0
and HT-29 cell lines
The Luciferase Reporter Assay was conducted as previously detailed in Figure 4.2 except 
that lysis of the mutant cell lines needed only 300pi of Glo-lysis buffer per condition.
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Figure 4.4 demonstrates that the level of luciferase activity and hence p53 activity is 
far lower (<3 %) in all of the mutant cell lines than in the wild-typef the Relative 
Light Units on the y axis being less than 30 in Figure 4.4 compared with greater than 
2000 in Figure 4.2. However, the results indicate that SW620 and HT-29 may retain 
a low level of p53 transcriptional activity despite their mutant p53 status. Any 
residual p53 activity in the SW480 cells is not obviously affected by p53 siRNA 
knockdown.
4.2 The effects of mutant specific siRNA nucleotides on p53 protein 
expression and transcriptional activity.
The next experiment was designed to address the question of whether any selectivity 
of mutant verses wild-type p53 suppression could be achieved by designing siRNA 
sequences against the specific R273FI mutation harboured by all 3 of our mutant p53 
colon lines, in addition to the PANC1 cells, see section 2.2.1. Hence three 19 base 
pair siRNA sequences were designed to target the specific R273H p53 DNA binding 
domain missense point mutations found in the above mentioned selected cell lines. 
These were transfected into both wild type and mutant cell lines, as previously, and 
were compared with the wild type targeting siRNA for efficacy and specificity.
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Figure 4.5: The effect of mutant p53 siRNAs on wild type and mutant p53 protein
expression
siRNA transfection was undertaken as outlined in Figure 4.1 and western blot analysis 
performed as per section 2.4.
Figure 4.5 demonstrates successful down regulation of p53 in the HCT116 +/+, 
SW480 and PANC1 cell lines, though the latter needs careful interpretation due the 
uneven actin levels and hence protein loading demonstrated. There is no visable 
suppression of p53 in the SW620 cell line, which repeats the finding suggested in 
Figure 4.3. It may be that this cell line may be inherently more difficult to transfect.
There is a suggestion of some specificity with the mutant p53 siRNA number 3 
(p53#3). It appears to reduce the p53 levels less than the wild-type p53 in the 
HCT116 wild-type cell line whilst reducing the p53 levels more in the SW480
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mutant cell line than the wild-type targeted sequence. There was no such specificity 
demonstrated for the other two p53 specific siRNAs (p53#l and p53#2).
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Figure 4.6: The effect of mutant p53 siRNAs on wild type and mutant p53 mediated
transcriptional activity
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Figure 4.6 confirms that the wild-type p53 is less suppressed in the HCT116 +/+ cell 
line with the p53 mutant specific siRNA #3, than with the wild-type p53 siRNA. 
Though this does not apply to the other two R273H specific siRNAs. In 2002, 
Martinez et al [118] showed discrimination between wild type and mutant p53 with a 
single base pair alteration in siRNA was possible. However, other groups have 
since shown that as little as 11 or even 7 bases of contiguous homology in a siRNA 
sequence may be sufficient for inhibition [119] [120], In the example of endogenous 
miRNAs only 6 or 7 bases with perfect homology are required for the seed sequence 
to enable targeting of the miRNA.
In summary, it may be possible to design an siRNA that is somewhat selective for a 
specific p53 mutant but this may not be as trivial or as reliable as some previous 
studies (Martinez) have suggested [244].
4.3 In-situ (3-galactosidase assay to assess transfection efficiency
The aim was to ascertain whether the relatively poor degree of p53 knock down 
observed in the p53 mutant colorectal cell lines thus far was the result of cells which 
are inherently resistant to transfection, rather than a deficiency in the experimental 
method. The use of a (3-galactosidase assay can only provide a general guide as to 
the ease of transfection of the cell line, since siRNA transfection rates in each cell 
line may not necessarily equate with that of (3-galactoside plasmid uptake. However 
if (3-galactosidase uptake was globally poor this may raise concerns regarding the 
experimental method.
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Figure 4.7: In situ fi-Galactosidase assays
Cells were plated the day before transfection into one 10cm dish per cell line, aiming for ca. 
40% confluence on the day of transfection, f-galactoside and pp53-TA-Luc vectors were 
transfected as outlined previously in section 2.6.2 . Twenty-four hours later the media was 
removed, the cells washed with sterile PBS twice and 10ml of fixing buffer (2.1.20) added 
per dish and left at room temperature for 15 minutes. This was removed and the cells again 
washed with PBS, prior to the application of 5-1 Oml per dish of substrate buffer (2.1.21). 
The cells were incubated at 37°C for 3-8 hours, after which the substrate buffer was 
removed and the plates washed twice with water. Once dried, the plates were visualised by 
microscopy (magnification JOOx) to assess the number of positively transfected (blue) cells 
and a photographic record made.
Figure 4.7 compares p-galactoside transfection in 3 colorectal cell lines with that of 
HI299 cells, in which transfection efficiencies of 30-40% had been achieved 
routinely by other members of our laboratory [121]. It demonstrates approximately 
30% of cells staining positively for p-galactoside in the HI299 and p53 wild-type 
HCT 116 cell lines. This suggests experimental efficiency to be comparable with 
previous expectations. However under the same experimental conditions, B-Gal
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uptake was only 5-10% in two of the mutant p53 colon cell lines (SW480 and 
SW620). This confirms that these cell lines may be more resistant to transfection 
with the p-galactoside plasmid and possibly also to siRNA transfection.
Optimisation of siRNA mediated transfection.
Due to the difficulty in obtaining efficient p53 knock down in the mutant colorectal 
cell lines, a range of experimental conditions were altered to try and optimise siRNA 
transfection efficiencies. The wild type HCT 116 +/+ were utilised as a positive 
control, since a 50% knock down in this cell had proven achievable, alongside the 
SW620 mutant, which had proven the most difficult cell line in which to knock down 
the mutant p53 protein. The variables considered were concentration of siRNA, ratio 
of transfection reagent to siRNA, the time course of knock-down effectiveness of 
siRNA and these are considered below.
1) [siRNA]
The Lipofectamine 2000 protocol (Invitrogen) suggests using 1 pi of Lipofectamine 
2000 per 20pmol siRNA as a guide ratio. It recommends further optimisation by 
considering siRNA: Lipofectamine 2000 ratios of 10 - 50 pmol siRNA: 0.5 - 1.5pi 
of Lipofectamine 2000.
The standard technique of [40mnol] of siRNA (4pi of Lipofectamine 2000 with 
80pmol siRNA in 2 mis of media = Ipl Lipofectamine 2000 per 20pmol siRNA) was 
compared against siRNA [lOOmnol] (50pmol siRNA / pi of Lipofectamine 2000).
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2) Volume of Lipofectamine 2000
Ipl and 2f.il of Lipofectamine 2000 per 20 pmol siRNA using [40nmol] siRNA
3) Duration of exposure
Cells were harvested at 24, 48 and 72 hours post transfection.
Lipofectamine 4|il / well 
[siRNA] 40 nmol
HCT116+/+
8pl / well
40 nmol
lOpl/well
100 nmol
Time 24 hr 48 hr 72 hr 24 hr 48 hr 72 hr 24 hr 48 hr 72 hr
B-Gal
Scr p53 Scrp53Scr p53 Scr p53Scrp53 Scr p53 Scr p53 Scr p53 Scr p53
p53
Actin — — ~ — — - ~ — — — — ----
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[siRNA] 40 nmol
8gl / well
40 nmol
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Figure 4.8: Western blots of siRNA delivery optimisation experiments
The effects of the wild-type p53 siRNA were compared against the scrambled control by 
analysis ofprotein concentrations on western blot for the conditions outlined in 4.2 above.
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Figure 4.9: Histograms demonstrating celt confluence with siRNA optimisation
experiments
The % cell confluence in the tissue culture flasks was studied by microscopy every 24 hours 
for the varying optimisation conditions outlined in section 4.2. This was to assess for any 
adverse toxicity reducing cell viability over the duration of the experiment, since 
lipofectamine 2000 is established as having a cytotoxic effects.
Figure 4.8 demonstrates only a marginal improvement in suppression with any of the 
variables studied. It appeared that harvesting at 48 hours post transfection gave 
maximal suppression which was consistent with previous practise. The higher siRNA 
concentrations and Lipofectamine volumes improved knock-down slightly in the 
HCT116 cells, but this was associated with reduced cell confluence, as shown in 
Figure 4.9, suggesting a higher level of toxicity and resulting in lower total protein 
yields. None of the above measures resulted in a significant p53 down regulation in 
the problematic SW620 mutant cell line (Figure 4.8), although SW620 did appear 
more resistant to the potential toxicity of higher siRNA concentrations and 
Lipofectamine 2000 volumes than the other cell lines studied.
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Chapter 5. Stable knock down with the 
pSUPER neomycin / GFP vector
5.1 Introduction
The limitations of siRNA mediated knock down are its transient nature and the fact 
that efficacy of target gene suppression is dependent on the efficiency of transfection 
achievable in any given cell line. Therefore, in order to study the effects of p53 
mediated suppression on cell growth and response to chemotherapy in the mutant 
p53 colon cancer cell lines, it was decided that stable shRNA expressing clones 
would need to be developed. These can provide for the stable suppression of the 
target gene in question (Brummelkamp)[248], rather than the limitation of a few days 
experienced with siRNA technology. The availability of a commercial vector, with a 
neomycin resistance gene, should also help overcome poor transfection efficiencies, 
since only clones with plasmid DNA integrated into their genome will survive the 
antibiotic selection process.
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5.2 Transient transfections
Prior to plating the pSUPER transfected cells for growth under antibiotic selection, 
samples of the cells were harvested for western blotting to assess whether our 
shRNA expression mechanism appeared to be functional. Levels of p53 mediated 
knock down, as well as detection of EGFP, were used to confirm that some 
functional plasmid had undergone transcection.
Actin
HCT116 +/+ SW480
Figure 5.1: Results of transient pSUPER transfection on p53 protein expression
The pSUPER empty vector and those containing the scrambled, wild-type p53 and p53#3 
mutant inserts were transfected into HCT116 +/+ and SW480 cells as outlined in sections 
2.8.1 - 2.8.6 and 2.8.8. The cells were harvested and lysed 24 hours later and 50gg/20gl of 
the protein product was run on an SDS page for western blot analysis with the DO-1 (Ab 6) 
p53 primary antibody (Section 2.4).
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Figure 5.1 demonstrates a degree of p53 knock down in the HCT 116 cell line even 
in these transient studies, along with detectable levels of GFP expression, both of 
which were reassuring that the plasmid was functioning effectively. It was also 
encouraging that the mutant targeted vector appeared to be showing some specificity, 
with less suppression of the wild type p53 protein than with the wild type shRNA 
expressing vector. The SW480 mutant cell line showed only a marginal reduction in 
p53 protein levels, but again there appeared to be potential specificity with the wild- 
type shRNA expressing pSUPER showing no demonstrable effect on the mutant p53 
protein levels.
5.3 EGFP expression in pSUPER PANG 1 clones
Initially the pSUPER plasmid and derivative constructs (expressing wild-type and 
mutant p53 shRNA or scrambled control), underwent transfection into PANG 1 cells, 
since they could undergo successful transfection more readily than the p53 mutant 
colorectal cell lines.
Once specific clones had been obtained from selected cultures by picking / isolating 
individual colonies grown under neomycin selection, it was possible to confirm true 
transfection of the plasmid, as opposed to acquisition of antibiotic resistance, by 
viewing the cells with a fluorescent microscope. Clones that had undergone positive 
transfection should be expressing the enhanced green fluorescence protein and 
therefore should glow luminescent green in response to an ultra-violet stimulus. 
Examples of PANG 1 cells exhibiting such a response are shown in Figure 5.2:
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Figure 5.2: Examples of EGFP expression from PANC1 pSUPER clones
Cells harvested after antibiotic selection (Sections 2.8.8 - 2.8.9) were seeded into an eight 
chamber microscope slide (Lab-Tek™ - Chamber Slide™, NUNC, Fisher) at a confluence of 
approximately 25%. Twenty four hours later the chambers were removed and a microscope 
cover slip placed on the slide. Cells were visualised using a fluorescent inverted microscope 
with a FITC filter and images recorded using an attached digital camera. The images are 
shown at original magnification (xlOO) and represent three of the clones that expressed high 
levels of GFP protein namely pSUPER 2, Scrambled l and wild-type p53 4. The plain 
microscopy image for each clone is displayed superiorly with the associated UV 
fluorescence image beneath. Levels of EGFP expression were variable between clones and 
within cells of one clonal population as discussedfurther in section 5.5.
5.4 Confirmation of mutant p53 knock-down in Pane 1 Clones.
Even when utilising neomycin selection and then GFP expression to detect positive 
transfectants, the levels of siRNA expression and gene knock-down could still vary 
widely among the individual clonal populations pSUPER transfected cells that 
survive antibiotic selection may not have a significant reduction in expression of the 
target gene. Instead, they may have found a way to mitigate the effects of a reduction 
in the target gene expression by compensating in another fashion, e.g. by shutting
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down expression of the shRNA or simply though rearrangement of the plasmid such 
that the neomycin cassette is retained but the shRNA cassette is disrupted. Therefore 
multiple clones were isolated for each vector; these were then screened using western 
blot analysis, to determine whether the desired reduction in target gene expression 
was observed.
RANG 1 pSUPER Clones
No Tx
p53 . 
Actin 
GFP
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Figure 5.3: p53 expression levels from the panel of pSUPER PANC1 clones.
Cells were obtained, following neomycin antibiotic selection, from PANC1 clones that had 
undergone transfection with the pSUPER plasmid and its derivatives containing the 
scrambled, wild-type p53 and p53#3 mutant inserts (Section 2.8.2 - 2.8.8). 50pg/20pl of the 
harvested protein product was analysed by western blot using the the DO-1 (Ab 6) p53 
primary antibody (Section 2.4).
Figure 5.3 demonstrates that clones 2, 4 and 5 of the wild type expressing vector and 
clones three and four of the p53 mutant expressing vector appear to show a reduction 
in p53 protein expression. The shRNA sequence designed to target wild-type rather 
than mutant p53 protein does not appear to demonstrate specificity, with protein 
knock down levels comparable with the mutant specific sequence. The proportion of 
clones screened relative to those demonstrating a reduction in protein level, as well 
as the variability of EGFP expression, suggest that as predicted, inter clone
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variability is likely to be a significant issue. Therefore, when picking colonies of 
colorectal cell lines, large number of clones would need to be screened to identify 
clones with the optimum p53 suppression.
5.5 EGFP expression in colorectal cells
Subsequently further clones were produced, using the same pSUPER / neomycin 
vector and shRNA insert derivatives as outlined in section 5.3, but using the SW620 
colonic cancer cell line. Larger numbers of colonies were picked to establish clonal 
populations than in section 5.3, in order to accommodate for the potential variability 
in p53 suppression levels seen previously within the PANC 1 shRNA expressing 
clones. EGFP expression was initially assessed visually utilising UV fluorescence 
microscopy and then quantified alongside the effect on p53 protein expression by 
western blotting.
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Figure 5.4: Examples of EGFP expression variability in a sample of SW620 clones as 
determined by UV fluorescence microscopy and western blot analysis
Cells were harvested, plated, viewed and photographed as in the Figure 5.3 legend. The 
clonal populations displayed have been selected from the large number isolated and imaged 
in order to highlight the spectrum of EGFP expression witnessed. A western blot analysis of 
50pg/20pl of the protein harvested from the lyastes of these cells is displayed concurrently. 
Due to the large number of clones processed and imaged, multiple blots were required, so 
each clonal population is displayed alongside a 'no treatment ’ control for that specific SDS 
Page gel (see section 2.4).
The fluorescence photomicrographs shown in Figure 5.4 demonstrate that whilst 
some cell clones expressed EGFP protein and hence had undergone successful 
transfection with the pSUPER plasmid, other clones e.g. pSUPER #2, were not 
expressing EGFP detectably despite having successfully grown under neomycin 
selection. This could be accounted for by the development of neomycin resistance or 
could represent clones that have stably acquired the plasmid, but due to
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rearrangement on integration, have lost the region or part thereof which encodes 
EGFP, or this may have become silenced e.g. epigenetically.
EGFP expression is seen to vary from clone to clone, for example it is much greater 
in scrambled clone #14 than in pSUPER clone #1, and the western blot reinforces 
this quantitative variability and correlates well with the visual impression from the 
photographs. There was also universal variability between levels of expression from 
neighbouring cells within a clonal population, i.e. the EGFP expression was not a 
uniform luminosity across the slide. In cell lines with no GFP demonstrable on 
western blot, there would often be a faint luminescent glow from just one or two 
cells seen on fluorescence microscopy, perhaps adding weight to mutation / silencing 
rather than antibiotic resistance as the reason for the clone survival.
Altogether GFP expression was detected by western blot in the following proportion 
of clones:
Table 5.1: Proportion of SW620 clonal populations expressing GFP protein on western
blot.
shRNA sequence 
insertion
GFP expression visible 
on western blot
Total number of clones
studied for this shRNA
insert
pSuper plasmid 5 14
Scrambled 4 19
R273H p53 mutant 9 33
Wild-type p53 19 30
All of these 97 clonal cell lines were subsequently analysed by western blot analysis 
to detennine GFP and p53 protein levels.
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5.6 Analysis of the pSUPER clonal populations generated in the 
SW620 colon cancer cell line.
Figure 5.5: SW620 pSUPER / neomycin vector only clones
(For Figures 5.5 to 5.9 the methodology of the pSUPER clones production is outlined in 
sections 2.8.2 to 2.8.8 and western blots were performed as detailed in section 2.4)
2 2 2 E E
p53 —
Figure 5.6: SW620 scrambled shRNA expressing pSUPER clones
In Figures 5.5 and 5.6 the pSUPER / GFP backbone only SW620 clones and the 
vector with the scrambled, and intended non-coding, shRNA sequence are analysed 
by western blot to assess their relative GFP and p53 protein expression. Ideally these 
negative control samples would show p53 levels comparable to the ‘no treatment’ 
parental cell line, thereby demonstrating no effect of the cloning process on p53
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levels and that any reduction in p53 levels in the p53-targeted shRNA cell lines could 
therefore be considered specific. Due to the number of clonal cell lines, multiple 
blots were required to examine this question, with each group of samples on a single 
blot being compared with a no treatment control run on the same gel, to act as a 
reference.
p53 levels in the pSUPER backbone clones seemed generally comparable with the no 
treatment control, though clones 3 and 4 and to a lesser degree clone 6, did show a 
slight reduction in p53 expression when compared with the parent cell line as 
demonstrated in Figure 5.5. Interestingly, only 5 clones displayed any detectable 
GFP expression and the p53 levels were comparable with the parental cell line in 
these clones, hence providing useful control cell lines for our subsequent 
experiments.
In Figure 5.6 it is shown that the scrambled clones showed slightly more variability 
in p53 protein expression, with p53 expression reduced in clones 3, 14 and 17 and 
increased in clone 18 when compared with the SW620 parental cell line. Of the 19 
clones, only four showed any GFP expression and unfortunately three of these 
appeared to also have altered p53 protein levels. This raises the possibility that the 
shRNA scrambled sequence could be having an unexpected (for example off-target) 
effect on the p53 pathway (though this had not been observed previously with the 
siRNA sequence which had been used routinely in our laboratory). Alternatively 
further mutations may have occurred elsewhere in the p53 pathway within these 
clonal populations, or the selection process itself may have caused an alteration in 
mutant p53 expression by up or down regulation of the intrinsic protein levels. 
Regardless of aetiology of the altered p53 levels, this would need to be considered 
when selecting appropriate control clone cell lines for future experiments.
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Figure 5.7: SW620 R273H mutant p53 shRNA expressing pSUPER clones
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Figure 5.8: SW620 wild-type p53 shRNA expressing pSUPER clones
Figure 5.7 demonstrates the p53 protein levels within the SW620 clones which 
contain the pSUPER vector expressing the shRNA sequence specifically targeted at
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the R273H mutation. In order to allow comparison of degree of p53 suppression 
between clones, the protein reduction was visually compared with the no treatment 
control group for each western blot and hence broadly categorised as shown in table 
5.2.
p53 protein reductions of >75% (based on visual categorisation) are seen in some 
clones though others show no apparent change in protein expression levels. Once 
again GFP expression was not evident in all of the clones, but reduction in p53 
steady-state levels was demonstrated independently of this, suggesting successful 
plasmid transfection, with lack of expression of the GFP component, rather than 
antibiotic resistance as the underlying mechanism.
From this data the following summary of p53 knock down within the R273H shRNA 
clones can be produced:
• 5 of the 33 clones showed a >75 % reduction in p53 expression
• 25 clones in total showed a detectable reduction in p53 protein levels
• GFP expression was detectable in 9 of the 33 clones but the level of this was 
not correlated with p53 expression levels.
Figure 5.8 demonstrates the degree of p53 suppression in the SW620 clones that 
underwent transfection with the pSUPER vector expressing the wild-type p53 
shRNA. There does not appear to be any demonstrable specificity of the shRNA 
sequences, with the wild-type sequence showing equal, if not greater, p53 
knockdown than the mutant specific sequence. This observation is not in accord with 
previous studies, which showed a single base pair alteration is sufficient for 
specificity of the shRNA [244]. I think more detailed studies and quantification, for
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example with densitometry, would be required to interpret this properly and to state 
whether these results truly contradict the previously published work.
A summary of the p53 suppression with the wild-type targeted shRNA sequence is 
summarised below:
• 12 of the 30 clones showed a >75% reduction in p53 expression
• 22 of the clones showed a detectable reduction in p53 protein levels
• GFP expression was seen to some extent in 20 of the 33 clones but again this 
showed no correlation with the degree of p53 knock down.
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Table 5.2: Summary of p53 and GFPprotein levels in the SW620 pSUPER clones
Clone
P53
expression
GFP
expression Clone
P53
expression
GFP
expression
Clone P53 expression
GFP
expression
pSUPER
1 Same None
P53 ft3
1 Increased None
WTp53
1 50 - 75% reduction Moderate
pSUPER
2 Same Moderate
P53#3
2 Same Moderate
WTp53
2 >75% reduction Low
pSUPER
3
<50%
reduction None
P53tt3
3
<50%
reduction None
WTp53
3 >75% reduction High
pSUPER
4
<50%
reduction None
P53//3
5 Same None
WTp53
4 >75% reduction None
pSUPER
5 Same None
P53tt3
6
50-75%
reduction None
WTp53
5 >75% reduction Moderate
pSUPER
6
<50%
reduction None
P53#3
7
50-75%
reduction Moderate
WTp53
6 Same Moderate
pSUPER
7 Same None
PS3#3
8 Same None
WTp53
7 <50% reduction Moderate
pSUPER
8 Same High
P53#3
9
<50%
reduction None
WTp53
8 50 - 75% reduction Moderate
pSUPER
9 Same Low
P53tt3
10
>75%
reduction None
WTp53
9 >75% reduction High
pSUPER
10 Same Moderate
P53tf3
11
>75%
reduction None
WTp53
10 50 - 75% reduction High
pSUPER
11 Same None
P53ff3
12
50-75%
reduction None
WTp53
11 Same Low
pSUPER
12 Same None
P53#3
13 Increased None
WTp53
12 >75% reduction High
pSUPER
13 Same None
P53H3
14
50-75%
reduction None
WTp53
13 Same None
pSUPER
14 Same Moderate
P53tt3
15
50-75%
reduction None
WTp53
14 >75% reduction Low
Scram
1 Same None
P53#3
16
<50%
reduction None
WTp53
15 <50% reduction None
Scram
2 Same None
P53tt3
17
<50%
reduction None
WTp53
16 Same None
Scram
3
<50%
reduction None
P53H3
18
<50%
reduction High
WTp53
17 <50% reduction None
Scram
4 Same None
P53#3
19
>75%
reduction Low
WTp53
18 Same None
Scram
5
Same None P53tt3
20
50-75%
reduction None
WTp53
19 50 - 75% reduction None
Scram
6 Same None
P53H3
21
50-75%
reduction None
WTp53
20 >75% reduction High
Scram
7 Same None
P53ft3
22 Same High
WTp53
21 50 - 75% reduction Low
Scram
8 Same None
P53tt3
23 Same Moderate
WTp53
22 Same High
Scram
9 Same None
P53tt3
24
50-75%
reduction None
WTp53
23 Same None
Scram
10 Same None
P53 ft3
25
50-75%
reduction High
WTp53
24 <50% reduction High
Scram
11 Same None
P53tt3
26
<50%
reduction Low
WTp53
25 >75% reduction High
Scram
12 Same None
P53#3
27
<50%
reduction None
WTp53
26 <50% reduction None
Scram
13 Same None
P53tt
28
<50%
reduction None
WTp53
27 Same None
Scram
14
<50%
reduction High
P53tt3
29 Same None
WTp53
28 >75% reduction High
Scram
15 Same None
P53H3
30
<50%
reduction None
WTp53
29 >75% reduction High
Scram
16 Same None
P53f*3
31
50-75%
reduction None
WTp53
30 >75% reduction High
Scram
17
<50%
reduction Moderate
P5343
32
<50%
reduction None
Scram
18 Increased Moderate
P53H3
33
>75%
reduction Moderate
Scraml9 Same High tt3 34 >75% red None
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5.7 Analysis of the pSUPER clonal populations generated in the 
SW480 colon cancer cell line.
Subsequently pSUPER plasmid containing clones were also created in the SW480 
colon cell line to see if any witnessed effects of stable p53 knock down would be 
consistent across two different cell lines. Due to time constraints, transfection was 
undertaken only with the wild-type p53 shRNA plasmid, alongside the previously 
described pSUPER and scrambled sequence controls (section 2.8.2).
The clonal populations produced from the transfection of this second colorectal cell 
line with the pSUPER vector and shRNA expressing derivatives are demonstrated 
below in figure 5.9.
p53
Actin
GFP
p53
Actin
GFP
Figure 5.9: SW480 clones containing pSUPER / neomycin vector only, scrambled and
wild-type p53 shRNA sequences
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Figure 5.9 shows steady-state p53 protein levels in all of the state SW480 cell line 
pSUPER and scrambled control clones with a large proportion of these also 
demonstrating GFP expression. Seven of the eleven wild-type clones demonstrate a 
reduction in p53 protein levels, with two of these being >75%. As the two clones 
with the greatest reduction in p53 levels also showed high levels of GFP expression, 
these would be good candidates for further investigation into the impact of this p53 
suppression, since the changes in p53 expression levels are more likely to due to 
successful transfection with the shRNA plasmid, rather than intrinsic protein level 
fluctuations, if the GFP component of the plasmid is functional.
Flaving established this array of stable clonal populations with suppressed p53 levels 
in two mutant p53 expressing colorectal cell lines, these could then be studied further 
to evaluate the impact of this protein suppression on cell proliferation rates and 
response to chemotherapeutic agents.
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Chapter 6. Studies of the impact of 
mutant p53 suppression on cell 
proliferation in the SW620 colon cancer 
cell line
My hypothesis is that colorectal cancer cells with expression of high levels of mutant 
p53 protein may display less malignant potential if the level of mutant p53 
expression were reduced, as discussed previously in section 1.7. One potential 
mechanism driving cancer disease progression is an increased rate of cell division, in 
comparison with the non-cancerous cells, allowing for tumour growth. However, it 
must also be considered that cancer cells may not divide more rapidly, but rather that 
they undergo a reduced rate of apoptosis compared with the parent cell, hence 
leading to tumour progression.
An experiment was designed to try and ascertain if the rate of cell division was 
altered by suppression of the mutant p53 protein levels in the p53 mutant SW620 
colon cancer cell line. A selection of the clonal populations containing the pSUPER 
shRNA plasmid, which had previously demonstrated a reduction of the levels of 
mutant p53 expression on western blot in the previous chapter (see section 5.6), were 
compared with the initial parent line to determine whether any alteration in cell 
division rates could be linked with the reduction in mutant p53 protein expression. 
This was studied by counting the total number of cells present in standard volume 
tissue culture and assessing the rate of increase over a measured time period and 
observing any differences between the mutant p53 clonal populations when 
compared with the parent cell line.
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6.1 Selection of the clonal populations for proliferation studies
In section 5.6 the production of an array of SW620 clonal populations containing the 
pSUPER plasmid, with shRNA expressing sequences targeted at mutant and wild- 
type p53 sequences, was discussed. The production of clones containing the empty 
pSUPER/neomycin vector and the creation of clones expressing a non-targeting, so 
called scrambled, sequence was also outlined. In this experiment a pSUPER SW620 
cell line containing the pSUPER plasmid with no insert and a representative clone 
with a scrambled shRNA sequence were selected for analysis alongside the parental 
cell line to act as controls. These were utilised as controls for the specificity of the 
shRNA mediated p53 suppression; since all of the clones contain the plasmid, this 
suggests that any difference in proliferation rates are more likely to be attributable to 
whether they harbour a p53 specific shRNA sequence, rather than a result of the 
cloning process. Hence, these were examined alongside the p53 shRNA expressing 
clones to determine whether stable reduction in p53 by shRNA altered the rate of cell 
proliferation.
As shown in Figure 6.1, the level of p53 expression in the empty vector and 
scrambled shRNA clones chosen were comparable to the parental cell line (or some 
such statement) From the collection of clones containing the empty pSUPER vector, 
one with a moderate level of GFP expression was selected for this experiment. As no 
shRNA scrambled sequence clones analysed to this point had demonstrated any GFP 
expression detectable by western blotting, the first clone obtained was selected to be 
studied. As discussed in section 5.6, mutant p53 protein expression was visualised in 
some of the clonal populations transfected with both the wild type and the R273H 
mutant targeted shRNA sequences. Initially one mutant p53 shRNA population with
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moderate suppression (50 - 75 % reduction, p53#3 25) and one with a more effective 
suppression of the mutant protein using the wild-type p53 sequence (>75% 
reduction, WTp53 3) were selected for cell proliferation analysis. These particular 
cell lines were chosen since they had retained their GFP expression as well as 
demonstrating the suppression of the mutant p53 protein levels.
The relative p53 and GFP expression profiles of the clones selected for this 
proliferation experiment are demonstrated on western blot in Figure 6.1:
p53
Actin
GFP
Figure 6.1: Western blot analysis of the pSUPER clones for the initial proliferation rate
experiment
(Summarised from previous data presented in Figures 5.5 to 5.8)
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6.2 Proliferation analysis of SW620 cell clones expressing variable 
levels of mutant p53.
pSUPER10
Scrambled 1
WTp53 3
p53#3 25
Parent cells
Figure 6.2: Proliferation analysis of SW620 cell clones expressing variable levels of
mutant p53.
Cells were plated onto 6 well plates (area 9.5ciri / well) in their usual growth media aiming 
for a confluence 24 hours later (Day 0) of approximately 10%. Cells were harvested every1 
24 hours and total cell count per well ascertained using a coulter counter (Beckman Coulter 
- Z series, Beckman Coulter Inc.) The coulter counter was maintained, flushed and 
calibrated as per manufacturer's instructions. Cells were harvested in the smallest volume 
needed for adequate trypsinisation. 0.5ml of these harvested cells formed the metered 
volume for the Coulter analysis. This cell suspension was combined with 10 ml of isoton II 
diluent (Beckman Coulter inc.) to fill the accuvette (Beckman Coulter inc.) and using a 
100pm aperture tube all particles between 8 and 20 pm were filtered and counted. This 
produced a value expressed as [cells / ml] which was then multiplied by the appropriate 
total initial harvested volume (0.5ml — 5ml), as necessary. The average of three wells per 
condition was plotted with error bars displaying the SEM.
In figure 6.2 the rate of cell proliferation appears to be comparable in the three 
control lines (parental cells, scrambled and empty pSUPER vector) but there appears 
to be a significant reduction in the growth rates of both of the populations in which 
the mutant p53 protein expression is suppressed. This appears to be proportional to 
the degree of p53 suppression, with the moderately suppressed p53#3 25 clone
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showing a moderate restriction in cell proliferation with a greater reduction noted in 
the WTp53 3 cell line which had a more marked p53 suppression.
To determine whether the observation in Figure 6.2 held true in additional clones of 
sw620 cells, the experiment was repeated with a larger selection of the shRNA 
pSUPER mutant p53 supressed cell populations. A selection of clones containing the 
pSUPER p53 wild-type and mutant targeted sequences were chosen to reflect a range 
of mutant p53 suppression levels as summarised in Table 5.2 (see also Figures 5.5 - 
5.8 for western blots). Several of the pSUPER empty vector and scrambled sequence 
clones which showed GFP expression, but minimal alteration in p53 expression 
levels, were also selected as controls, as discussed in section 6.1.
Table 6.1: Summary of relative p53 and GFP protein levels in the selected SW620
pSUPER cell lines
(Original western blot data presented in Figures 5.5 - 5.8)
Cell Line p53 expression GFP expression
pSuper 2 As per parent cell line Moderate
pSuper 8 As per parent cell line High
pSuper10 As per parent cell line Moderate
Scrambled 14 Slight reduction High
Scrambled 18 Slight increase Moderate
Scrambled 19 As per parent cell line High
WTp53 1 50-75% reduction Moderate
WTp53 3 >75% reduction High
WTp53 12 >75%) reduction High
WT p53 25 >75%) reduction High
WTp53 29 >75%) reduction High
p53#3 19 >75%) reduction Low
p53#3 22 As per parent cell line High
p53#3 25 50-75% reduction High
p53#3 33 >75% reduction Moderate
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Figure 6.3: Further proliferation experiments with an array of SW620 pSUPER cel! lines
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6.3 Calculation of Proliferation Rate using a Logarithmic Scale, 
Slope and Pearson’s Correlation Co-efficient.
These graphs demonstrate an exponential increase in cell number for any given time 
increment, with some of the curves flattening out as cell numbers increase, 
presumably as nutrients and space become an issue. We might expect the 
proliferation curves to follow a logarithmic rate of expansion based on binary cell 
division until achieving a density where further expansion is limited by competition 
for resources. Such logarithmic distributions make any visual comparison of 
proliferation rates difficult since small discrepancies in plating densities will make 
large differences to daily cell numbers, whereas the underlying rate of proliferation 
may be comparable. Therefore to allow a more accurate comparison of the cell 
populations I calculated the logio value of the cell numbers, converting the 
exponential graphs into linear ones and hence allowing rate of growth to be 
calculated by ascertaining the slope of the line (b). Where b = [LoglO(cell 
number)]/Day .The slope was ascertained by establishing a linear regression using 
the equation:
where x and y are the sample means AVERAGE(known_x’s) and AVERAGE 
(known_y5s).
To confirm that this was appropriate, the extent of a linear relationship between logio 
(cell number) and time for each population was confirmed by calculating Pearson’s 
correlation co-efficient as follows:
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where x and y are the sample means AVERAGE(arrayl) and AVERAGE(array2).
Figure 6.4: Histogram showing Proliferation Rates for an array of SW620 pSUPER
Clones
Table 6.2: Pearson's Correlation co-efficient for the Logarithmic Proliferation Linear
Regression
Cell Line Pearson’s
No Treatment 0.98
pSuper 2 0.95
pSuper 8 0.99
pSuper10 0.99
Scrambled 14 0.99
Scrambled 18 0.99
Scrambled 19 0.99
WTp53 1 1.00
WTp53 3 0.99
WTp53 12 1.00
WT p53 25 0.97
WTp53 29 0.99
p53#3 19 0.99
p53#3 22 1.00
p53#3 25 0.99
p53#3 33 0.99
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All of the Pearson’s correlation co-efficients are > 0.95 demonstrating a good linear 
regression and therefore confirming the appropriateness of comparison of 
proliferation rates by this method.
There does appear to be variability in the rates of cell proliferation between the 
pSUPER clones and the native cell line but whilst the rate of cell proliferation 
appears lower in all of the clones with suppressed p53, there are also clones 
containing the empty backbone vector and the scrambled sequence that demonstrate 
a reduction in the rate of cell proliferation. This could suggest that the process of 
clonal selection is responsible for alterations in cell proliferation rather than a 
specific effect of the reduction of mutant p53 protein expression. The scrambled 18 
clone is an exception to this finding, in that there appears to be an increase in the rate 
of cell proliferation in this population when compared with the parent cell line. 
Western blot analysis of this cell line also displayed a slight increase in p53 protein 
levels and it may be that a higher level of mutant p53 expression has been selected 
for within this clonal cell population.
Therefore in summary, these experiments provide no evidence for a role for mutant 
p53 expression in cell proliferation in the studied SW620 clones.
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Chapter 7. Studies of the impact of 
mutant p53 suppression on the 
response to chemotherapeutic agents 
in the SW620 colon cancer cell line
7.1 Hypothesis
The literature suggests that over-expression of at least some forms of mutant p53, 
may directly enhance the resistance of tumour cells to anti-cancer agents and 
therefore that p53 gain-of function might contribute to failure of chemotherapy 
[235], see section 1.1.25. The reduction of mutant p53 expression in the p53 knock 
down pSUPER clones may render them more susceptible to the effects of 
chemotherapy and therefore rates of cell proliferation may be restricted by lower 
drug concentrations. The effects of two chemotherapeutic agents 5 fluorouracil 
(5FU) and Oxaliplatin were therefore studied in these cells; since these drugs are 
commonly used in the treatment of primary and metastatic colon cancer (see 1.1.11).
7.2 Determination of IC5o for 5-fluorouracil and Oxaliplatin
IC50 (The half maximal inhibitory concentration) is a measure of the effectiveness of 
a compound in inhibiting biological or biochemical function. This quantitative 
measure indicates how much of a particular drug is needed to inhibit a given 
biological process, in this case cell proliferation, by 50 percent, at a specific time 
point. Initially the proliferation curve of the parent SW620 cell line was utilised, to 
calculate the IC50 for exposure to both chemotherapeutic drugs within this 
population. This would allow the determination of an appropriate range of 
chemotherapy agent concentrations to apply to the mutant p53 suppressed pSUPER 
clones, in order to try and calculate their IC50 in the subsequent experiments.
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Following a review of previous similar studies with the SW620 cells and these 
chemotherapeutic agents, concentrations of [l-20pM] for 5FU and [0.25-1 OpM] for 
oxaliplatin were tested to establish the IC50 for the parent population on cells 
harvested at 72 hours post exposure.
SW620 Dose Response to 5 - Fluorouracil
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Figure 7.1: Dose response curves for SW620 cells treated with 5 - Fluorouracil
5-fluorouracil (5-FU) (Sigma, C4HFN2O1, MW = 130.8g) was dissolved in DMSO (0.065g 
/ml) [0.5MJ stock and stored at 4°C. This was further diluted to [WmM] in DMSO and 
added to the appropriate tissue culture media volume (2ml / well) to obtain final working 
concentrations of 1 to 20pM 5-fluorouracil OR 5-FU. In order to try and avoid any adverse 
effects from DMSO toxicity, the volume of DMSO / 5-FU added to the media was kept at a 
minimum (0.02%). Cells were seeded in 6 well plates aiming for starting confluencies of 10- 
20% 24 hours later. Tissue culture media was removed and media containing the 
chemotherapeutic agents applied and left on the cells for the duration of the experiment. 
Cells were harvested and counted at 0, 24, 48 and 72 hours using the Coulter analyser and 
cell proliferation graphed and analysed using the methods discussed in section 2.9.
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Figure 7.2: Dose response curves for SW620 cells treated with Oxaliplatin
Oxaliplatin (LC Laboratories, C^HijN20_/Pt, MW = 397.29g) was dissolved in ILO (0.4g/tnl) 
[1M] stock and stored at 4°C. This was diluted in water to [IQtnM] and added to the media 
to obtain [Oxaliplatin] 0.25pm - 10pm. The method was otherwise as stated in Figure 7.1.
Figures 7.1 and 7.2 demonstrate a fairly clear dose : response relationship across the
\
range of chemotherapy concentrations for both agents, with cell numbers suppressed 
proportionally by the increasing drug levels. This allows calculation of the IC5o as 
follows
Maximal Cell Number = The Highest cell count at 72 hours.
Initial Cell Number = The mean cell count at 0 hours.
IC50 = The concentration of chemotherapeutic drug needed to produce a cell count 
of:
(Maximal Cell Number - Initial Cell Number)/2 + Initial Cell Number
Therefore the IC50 for 5FU = 2pm and for oxaliplatin = 0.9pm in our parent SW620
cell line.
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In the 5-FU experiments, the Maximal Cell Number was deemed to be that achieved 
with the DMSO treatment, to negate for any cytotoxicty due to this solvent rather 
than the chemotherapeutic drug being tested. This was unnecessary with oxalaplatin 
since the solvent is water.
7.3 Determination of the 5FU dose response in p53 suppressed 
pSUPER cell lines
Having established the IC50 for these two chemotherapeutic agents, this value was 
then used to guide the range of doses appropriate to study in a selection of the 
pSUPER clones. Initially 5 fluorouracil was applied at [1 — 20pM] to a sample of 
clones to see if this altered proliferation rates and hence IC50. pSUPER clones were 
selected for study which had been transfected with the p53#3 mutant specific shRNA 
and demonstrated varying degrees of mutant p53 knock down when visualised by 
western blot. Hence a cell line with no visible knock down (p53#3 22), a 50 - 75% 
reduction from baseline (p53#3 25) and two cell lines with >75% reduction in mutant 
p53 levels (p53#3 19 and p53#3 33) were selected, so that the specificity of any 
alteration in IC50 could be correlated with p53 status (as previously studied in section 
5.6). All the selected clonal lines also showed GFP expression, to help confirm that 
p53 suppression was likely due to the vector insert rather further potentially 
oncogenic, genetic or epigenetic changes resulting from clonal selection.
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c) p53#3 22 Dose Response to 
5 - Fluorouracil
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e) p53#3 33 Dose Response to 
5 - Fluorouracil
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Figure 7.3 (a-e): The 5FU dose dependant response in p53 suppressed pSUPER cell lines
The first observation from Figure 7.3a is that the dose - response relationship in the 
parental SW620 cell line differs from that previously discussed in Figure 7.1. The 
ICso dose of 2pM shows an increased amount of cell proliferation, when compared 
with the DMSO control, in this instance. This seems inconsistent with the rest of the 
experiment, which demonstrates the expected dose dependent division restriction and 
for this reason the IC50 could not be more accurately calculated then the range 2-5 
pM. It is clear that this experiment requires repeating, with the most likely 
explanation for the anomalous result being a technical error or chemo resistance.
The p53#3 19 and 22 cell lines, figures 7.3b and 7.3c demonstrate a reduction in 
proliferation in a dose related manner as expected, with IC50 value of 5pM for both
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these clonal populations. Since the p53#3 19 cell line has >75% suppression of 
mutant p53 expression, whereas the p53#3 22 cell line has no clearly detectable 
reduction in p53 level, this seems to suggest that mutant p53 suppression is not 
correlated with a reduction in cell proliferation in these particular clones.
The p53#3 25 cell line, figure 7.3d, shows a reduction in cell number with the 5pM 
dose at 48 hours, which is greater than seen with the higher doses, but this rectifies at 
72 hours producing an IC50 of 2.5pM and this is clearly a consequence of technical 
variability.
In the p53#3 33 cell line, figure 7.3e demonstrates a significant growth restriction 
across all experimental conditions at 72 hours. This correlated with a visible change 
in cell morphology, with cells appearing rounded and less cohesive than previously 
and hence the results at this time period were discarded, with the 48 hour figure used 
to calculate the ICgo value of 2.5pM.
The IC50 values of 2.5 pM for both the mutant p53 suppressed clones shown in 
Figures 7.3d and 7.3e (p53#3 25, 50-75% reduction, p53#3 33, >75% reduction), 
does suggest correlation with the hypothesised findings of reduced cell proliferation 
with mutant p53 suppression in these particular clones, but as outlined above this 
finding was not consistent across our panel of clones reviewed.
As a result of the seemingly outlying 2pM result in the parent cell line, combined 
with the discarded 72 hour results in the p53#3 33 cell line, this entire experiment 
was repeated using the same choice of p53 clones. This would also allow
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collaboration, or otherwise, of the lack of correlation between mutant p53 
suppression and the resultant IC50 dose.
In the repeat experiment the range of 5FU applied to the cells was narrowed, since 
previous values had all been IC50 < 5, it was felt the results would be more accurate 
if further values in the range 0 - 5pM were studied, whereas larger doses would add 
little more usable data. The results of this repeated experiment displayed in Figure
7.4:
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b) p53#3 19 Dose Response to 
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d) p53#3 25 Dose Response to 
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Figure 7.4 (a-e): Experiment 2: Comparison of the 5FU Response in a Selection of 
Mutant p53 SuppressedpSUPER Cell Line
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7.4 Experiment 2: The 5FU Response in a Selection of Mutant p53 
suppressed pSUPER cell lines
In Figure 7.4a the dose-response relationship in the SW620 parent cell line follows 
the expected pattern of proliferation restriction with increasing drug concentrations, 
and an approximate IC50 of 4.4pM is observed. This differs from the value of 2jiiM 
ascertained in Figure 7.1. This relatively small difference may be explained by the 
differing starting cell numbers at time zero, with a two-fold difference between the 
two experiments. Logically initial cell confluence might be expected to have an 
impact on IC50, therefore it was important to include a parental cell line control for 
each experiment and to try as far as possible to keep starting cell numbers uniform 
between serial experiments to allow valid comparisons.
The p53 suppressed pSUPER mutants all show a reduction in IC50 when compared to 
the parent cell line in this experiment with values of 1.4pM (p53#3 19,figure 7.4b), 
2.8pM (p53#3 25,figure 7.4d) and 4pM (p53#3 33, figure 7.4e). However the 
reduction was not proportional to the degree of suppression visualised by western 
blot and the cell line with no visible knock down (p53#3 22) also had a lower IC50 
than the parental cell line at 2.9pM, figure 7.4c.
7.5 The Oxaliplatin Dose Dependent Response in P53 Suppressed 
pSUPER Cell lines
The same experimental design was utilised with a second chemotherapeutic agent, 
Oxaliplatin, which was applied in the range 0-5 pM. Due to time constraints only 
two clones were studied, both with > 75% reduction in p53 expression, with the 
results demonstrated in figure 7.5:
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p53#3 33 Response to Oxaliplatin
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Figure 7.5: The Oxaliplatin Dose - Response in p53 SuppressedpSUPER Cell Lines
Figure 7.5 demonstrates an IC50 of 0.8fiM in the SW620 parent cell line, which is 
comparable to the initial value Of 0.9pM obtained previously in Figure 7.1. This 
suggests that the experimental system has some validity and that results obtained 
from these experiments are reasonably reliable.
This IC50 value is halved in both the mutant p53 suppressed cell lines studied, with 
both graphs showing good dose-response and there are no major outliers or other 
obvious anomalies.
Chapter Seven - Mutant p53 suppression and response to chemotherapeutic agents in SW620 ) 75
7.6 Summary of the IC50 values for 5 fluorouracil and oxaliplatin
Summary of ICso Values for 5FU
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Figure 7.6: Summary of drug sensitivity data for 5 -fluorouracil
Figure 7.6 summarises the results of Figures 7.3 and 7.4 alongside the p53 status ol 
each cell line and demonstrates that whilst there is a general trend towards IC50 
reduction with p53 suppression, there are anomalies and variation between the 
experiments as outlined earlier, in section 7.3.
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Figure 7.7; Summary of drug sensitivity data for Oxaliplatin
Figure 7.7 demonstrates the lower IC50 levels for oxaliplatin with both the mutant 
p53 suppressed SW620 populations studied. From these data it appears that the use 
of a lower Oxaliplatin concentration results in a comparable reduction in cell 
proliferation in the mutant p53 shRNA cell lines tested and thus it appears that 
mutant p53 may contribute to resistance to oxaliplatin in these cells. However, the 
previous experiment has demonstrated that caution is required when extrapolating 
beyond results in any given cell line and many clones must be tested with more 
replicates to confirm this finding.
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Chapter 8. Conclusions and Discussion
It was established in the introduction that colorectal cancer remains a common 
disease and even with advances in surgical techniques and adjuvant therapies, five 
year survival is still only in the region of 50%. Possible target areas for improving 
this mortality figure include: primary prevention strategies, screening programmes to 
increase early stage disease diagnosis and improved adjuvant therapies. Currently 
chemotherapy regimens are proven to confer an additional survival advantage of as 
much as 13% in node positive disease when compared with surgery alone [80]. 
Whilst chemotherapy as a palliation in advanced disease can provide three to six 
months extra life expectancy with concurrent maintenance of quality of life [87]. 
However, the current chemotherapeutic agents are recognised as having a relatively 
non-specific anti-tumour mechanism, simply targeting the rapidly dividing cancer 
cells preferentially, but also damaging healthy tissue and hence have considerable 
toxicity and side effect profiles. As knowledge of the role of genetics in 
carcinogenesis has become increasingly understood and delineated, so has the search 
for molecularly targeted ‘gene therapy5 drugs. In colorectal cancer the monoclonal 
antibody Bevacizumab (Avastin) has already been utilised clinically to confer a 4.7 
month increase in median survival compared with combination chemotherapy in the 
first line treatment of KRAS wild-type tumours [89]. Many believe the future of 
adjuvant cancer treatment lies in such targeted therapies, whereby an individual 
would have their tumour analysed for its genetic mutations and an individual therapy 
based on targeting some of these specific mutations would be administered. 
Colorectal cancer provides an attractive disease for such targeted therapies, since 
much is understood about the multiple genetic pathways that are implicated in the
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disease’s progression. The step - wise accumulation of genetic defects from early 
adenoma to late invasive and metastatic cancer provides differing known target genes 
at varying stages of the malignant process. Since p53 mutations have a vital role to 
play in the late stages of this transformation from adenoma to carcinoma, this 
obviously provides an important potential clinical target since it is at this advanced 
state of carcinogenesis that adjuvant therapies currently have their clinical role. p53 
mutations are also a relevant potential clinical target due to their frequency of 
occurrence, i.e. their presence in almost half of all colorectal cancers [172]. p53 
mutations have been linked to altered response to current chemotherapeutic agents. 
It has already been established that the effects of chemotherapy on survival are 
influenced by p53 status and that chemotherapeutic resistance is associated with 
expression of mutant p53 proteins [194, 195].
On this basis, the hypothesis, that inhibiting mutant p53 in colorectal cancers may 
reduce malignant potential and augment response to adjuvant therapies, was 
established.
The first step experimentally towards answering this question was to grow in tissue 
culture a panel of transformed colorectal cancer cell lines, expressing both mutant 
and wild-type p53, on which to test this hypothesis. Baseline p53 levels for the cell 
line cohort were studied and compared with the published data. It was demonstrated 
that p53 protein levels were many magnitudes higher in the mutant cell lines than in 
those documented to express the wild-type protein. A previously published study 
suggested that this accumulation is likely due to the prolonged half-life of the mutant 
protein, since it is outside the usual MDM2 mediated negative feedback loop [204].
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This became relevant when trying to suppress and study the effects of mutant p53 
utilising transient siRNA technology. We established that whilst wild-type p53 could 
be visibly significantly reduced, the mutant protein proved harder to down-regulate, 
probably as a result of the far greater amount of the protein product present.
In order to try and improve mutant p53 suppression using siRNA sequences, a series 
of optimisation experiments were undertaken. Despite modification of several 
variables within the transfection process, levels of down regulation of the mutant p53 
protein remained sub-optimal. This could be explained to some degree by the fact 
that even if 100% of cells underwent successful transfection with the siRNA 
sequence, the degree of suppression would still depend on the efficacy of the actual 
siRNA mediated down regulation of the target protein within any given cell. This, 
coupled with the high expression levels of the mutant protein, lead to the conclusion 
that the manufacture of stable shRNA expressing clones would be necessary to 
effectively and consistently study the effects of any down regulation of the mutant 
p53 protein.
Another consideration in our initial siRNA experiments was to ascertain whether any 
specificity could be obtained for targeting a mutant p53 sequence whilst protecting 
wild-type p53 protein production. Clinically, this is important, since ideally any 
therapy should target only the mutant protein avoiding any off target effects on 
functioning wild-type p53 within neighbouring healthy cells. In 2002, Martinez 
claimed that a single base difference in siRNAs could discriminate between mutant 
and wild-type p53 in cells expressing both forms, resulting in the restoration of wild- 
type protein function [244]. In order to confirm the specificity of siRNA targeting,
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three R273H mutant specific siRNA sequences were designed and tested alongside 
one wild-type specific sequence in cell lines expressing either mutant or wild-type 
p53 protein. This mutation was chosen since it is one of the commonest seen in 
colorectal cancer (~6% of cases) and was present in all of our p53 mutant colon 
cancer cell lines [183]. One of the three siRNA mutant sequences designed did show 
partial protection of the wild-type protein product, but this effect was not witnessed 
with the other two sequences. Therefore it may be possible to design an siRNA 
oligonucleotide that is selective for a specific p53 mutant and protective of the wild- 
type. However, our findings were not as conclusive as those presented by Martinez 
and suggested that siRNA sequence design may be crucial in conferring such 
specificity. Subsequently shRNA inserts were designed for insertion into the 
pSUPER vector from the mutant p53 siRNA sequence that had shown a degree of 
specificity.
Bmmmelkamp et al. [254] initially published in 2002 that a new vector system 
(pSUPER, oligoengine) could cause efficient and specific down regulation of genes 
by directing intra-cellular siRNA synthesis. The incorporation of antibiotic resistance 
into the plasmid allows selection of only those clones in which the plasmid had 
become successfully integrated, thus overcoming the previously discussed issues of 
transfection efficiency. Transfection followed by antibiotic selection allowed clonal 
populations of cells to be produced which had the pSUPER plasmid containing 
specific shRNA expressing sequences incorporated into their genome. It became 
apparent early in the analysis of the selected clonal populations, that not all of the 
clones grown under antibiotic selection displayed the desired down regulation of the
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target mutant p53 protein. Hence, large numbers of clonal populations had to be 
screened to compensate for this inter clonal variability.
In total over one hundred clones were produced and analysed, containing empty 
vector and scrambled sequence controls as well as those with the wild-type and 
R273H mutant specific shRNA incorporated. Clonal populations were created in 
three separate cell lines, with successful down regulation of mutant p53 protein seen 
in all. The levels of suppression achieved were far* greater than seen in our earlier 
transient studies and compared favourably with the 20-50% down regulation reported 
in similar work on mutant p53 in colon cancer published by Bossi et al in 2006 
[249].
Subsequently further experiments were conducted to assess the impact of this down 
regulation on cellular function. The effect of mutant p53 suppression on the rate of 
cell proliferation in the SW620 cell line was studied by comparing the increase in 
cell number over time of various pSUPER clones. Whilst some of the clonal 
populations with down regulation of mutant p53 expression did show a reduced 
proliferation rate, this was not consistent across all suppressed clones and some of 
the clones with no alteration in mutant p53 levels also exhibited slowed proliferation. 
This contradicts the findings of Bossi el al. who demonstrated reduction in both cell 
numbers and cell viability in all three of the mutant p53 colon lines they studied. 
However, we have previously discussed the degree of inter-clone variability 
witnessed in our studies and this may account for the discrepancies between our 
findings and those published by Bossi et al.
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Further analysis of cellular function was not possible within the time constraints of 
this study, however there is considerable scope for further assays on the down 
regulated mutant p53 clones. Alterations in cell cycle progression could be studied 
with Brd U incorporation to assess the percent of cells in S phase. FACS 
(Fluorescence Activated Cell Sorting analysis) could be utilised to study whether 
cellular apoptosis rates are affected by down regulation of the mutant p53 protein. 
The effect of down regulating the mutant protein on some of the so called ‘gain of 
function’ target genes could also be studied.
However, the primary aim of this study was to ascertain if any clinical benefit could 
be gained by reducing mutant p53 in colorectal tumours. The next set of experiments 
undertaken considered the response of the mutant p53 suppressed clones to two 
chemotherapeutic agents used currently as adjuvant and palliative treatments in the 
management of colorectal cancer (5 fluorouracil and oxaliplatin).
Two SW620 clones with significant suppression of their mutant p53 protein levels 
demonstrated IC50 levels half that of the parent population when treated with 
oxaliplatin. Thus, half the amount of chemotherapeutic agent was needed to produce 
the same effect when the mutant p53 protein had been suppressed. The results with 
the second agent, 5 fluorouracil, were less consistent. Whilst there was a general 
trend towards lower IC50 values in the down regulated clones, this was not always the 
case. The overall impression from our work is that suppression of mutant p53 may 
well improve the response of colorectal cancer cells to chemotherapy, especially 
oxaliplatin. However, these experiments show that extrapolating beyond results in
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any given clone can be misleading and that large numbers of clone replicates must be 
studied before any appropriate conclusions can be drawn.
One mechanism for confirming the specificity of any mutant p53 mediated effects 
would be to re-establish mutant p53 expression in the suppressed clones showing 
altered phenotypes and considering if the observed effect is consequently reversed. 
In order to do this, a plasmid was designed that expresses the R273H sequence, but 
has base pair mutagenesis in the region targeted by our sliRNA expressing vector, so 
that the amino acids are coded to produce the same protein product, but not targeted 
by the shRJSfA. Completion of this Polymerase Chain Reaction mediated site 
mutagenesis was not possible within the time constraints of the laboratory work, but 
its potential to confirm causality would add greater credence to the specificity of the 
described mutant p53 mediated effects. This preliminary work is detailed in 
Appendix A.
In summary, this thesis demonstrates the value of utilising the pSUPER vector to 
provide efficient and stable protein suppression, even in the context of very high 
levels of over-expression. However it also highlights that caution should be taken 
when drawing conclusions due to the variability present between clonal populations. 
This could potentially be due to further genetic mutations occurring within the clonal 
population dining the selection and culturing process.
Whilst the technology of RNA interference provides a useful tool to study gene 
silencing in the context of transformed colorectal cancer cells in culture, it is 
important to consider whether this could ever translate into a clinical therapy. The
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main issue with its use as an adjuvant therapy in colorectal cancer is the mode of 
delivery to tumour tissue. The purpose of adjuvant therapy is to ‘mop up’ any 
residual tumour cells that may reside within the draining lymph nodes, the peritoneal 
cavity or as micro-metastases, primarily within the liver. As such, any therapy should 
ideally be delivered systemically, to allow tumour cells at multiple sites to be 
targeted. Unfortunately SiRNAs are unstable in the serum environment where they 
can be degraded by RNAase and are rapidly excreted in the urine if delivered 
systemically. Overcoming multiple tissue barriers and ensuring efficient endocytosis 
into the target cell are also essential to successful delivery. The use of cationic lipids 
and polymers as siRNA delivery carriers have been shown to help overcome some of 
these obstacles but as of yet no successful systemic therapies utilising RNA 
interference are available.
There are other methods of effectively silencing gene products which are 
systemically deliverable and utilised in clinical practise at present. Monoclonal 
antibodies have already been utilised alongside adjuvant chemotherapy regimes in 
colorectal cancer in the form of the anti VEGF agent Bevacizumab (Avastin). If 
further studies were to confirm the benefits of down regulation of mutant p53, then 
manufacturing a monoclonal antibody against such proteins would seem a reasonable 
clinical target. One challenge would be the variability of mutations present, 
necessitating multiple compounds for different patients. However the presence of 
common hot-spot mutations reduces the number of alternatives required to some 
degree. Another major concern would be agent specificity; with protection of normal 
p53 function in healthy tissue whilst silencing the mutant protein within tumour cells. 
This is a difficult technical problem since most mutations have only a single base
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pair substitution from the wild-type sequence. A possible way to overcome this 
would be to look further into the mechanism of mutant p53 gain of function and in 
particular consider whether any of the target genes further down the pathway may be 
potential therapeutic targets.
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Appendix A:
Polymerase Chain Reaction mediated site 
mutagenesis
Introduction
One mechanism for confirming the specificity of any mutant p53 mediated effects 
would be to re-establish mutant p53 expression in the suppressed clones showing 
altered phenotypes and considering if the witnessed effect is reversed. A plasmid was 
designed that expresses the R273H mutant p53 sequence, but has base pair 
mutagenesis in the region targeted by our shRNA expressing vector, so that the 
amino acids are coded to produce the same protein product, but not targeted by the 
shRNA mediated suppression.
Hypothesis
Any alterations in cell proliferation, or response to chemotherapy, in cells 
transformed with the pSUPER plasmid expressing R273H shRNA, may be the result 
of the cloning process itself, rather than the specific desired shRNA effect i.e mutant 
p53 suppression. Reintroduction of the mutant R273H protein into these cells would 
permit testing of the specificity of any suppression effects, by demonstrating whether 
phenotypic reversal occurred when the same protein is transcribed from the altered 
DNA sequence.
Primer Design
To perform PCR mutagenesis four primers were designed using three sequential PCR 
reactions as outlined in Figures 0.1 to 0.6:
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5' end primer
5' Mutagen primer (5’M)
codon
Start
codon Stop
codon
Start
codon3' Mutagen primer (3'M)
3’ end primer
Wild-type 
human p5J
Figure 0.1: Target sites for the four primers
5' end primer
PC R reaction 1:
5' end primer 
3’ Mutagen primer
Start
codon
3’ Mutagen primer 
Mutagen primer (5'M)
aa
3'
5'
Figure 0.2: Strategy for PCR mutagenesis
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' V pCEP4p53
5'
“”►1
Stop |
codon I
3'—!
1(tc1^g^Eo3Ec3—3'
5'
21 nucleotide base pairs of homology
Not!
restriction site
O
■fijaitt&l
Figure 0.3: Design of the 3y end primer for pCEP4p53
pCEP4p53
I Start 
I codon
3' —fcAd Isca EraffG^ICG^ MpCldCTdGGQ £113 i^GTl CTAlGGd ICG— S'
■IfeM MMHMS—3'
5'__|g|g ||Gq ,jAQ j|j
^^□21 nucleotide base pairs of homology I ^>|
! i !Kpnl
•restriction site*
v
aMMlMili
GO 1616; II
Figure 0.4: Design of the 5’ end primer for pCEP4p53
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Codon 
Amino acid
I
l
5'
3'*
Human p53 
(section of exon
64Ci
tr
5' Mutant primer■
lAAC^GOiTTTl
‘TT^aggaag
tmtAfl cm'
TGT; GCC—3' 
5'
Region of mutagenesis
Different codons producing tfie 
same amino acid sequence 
(except our R273H mutation)
Figure 0.5: Design of the 5’ Mutant for pCEP4p53
Codon 
Amino acid aaaaai th ‘.’vrai?1
5'
3'—fCTj^Cg 
5'
[AGanii
l|TCGjAA^gg£AgGc^
Human p53 
(section of exon 8)
P = proline J
AAQ
12691 270
TGTIGCC
tr
3' Mutant primer
i—L= leuan
| F = phenylalanine |
: = gli
Region of mutagenesis
I Different codons producing the 
same amino acid sequence 
(except our R273H mutation)
I
l
C = cysteine |
A = alanine J
Figure 0.6: Design of the 3 ’ Mutant for pCEP4p53
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Terminal primers were designed containing Kpnl and Notl restriction sites as 
illustrated in Figures 0.3 to 0.7 to enable sub-cloning into an expression vector: 
pCEP4.
EcoRV
pCEP4
10.2 kb
Comments for pCEP4: 
10186 nucleotides
CMV promoter, bases 1 *588 
Multiple cloning site: bases 619-676 
SV40 pofyadenytabon signal bases 685-926 
OnP. bases 1344*3319
E0NA-1 gone (complementary strand): bases 3620-5545
Ampoillin resistance gene, bases 6171*7031
pUC on^n: bases 7040-7815
TK promoter: bases 8183-8345
Hygromyon resistance gene, bases 8409-9419
TK polyadenylation signal: bases 9431 *9702
Figure 0.7: pCEP4 vector.
Reproduced from Invitrogen,
http://tools.invitrogen.cont/cotUent/sfs/manuals/pcep4_man.pdf
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Optimisation of annealing temperature and cycle number
Firstly a range of annealing temperatures were tested for thirty cycles of PCR using 
the 5’end / 3’mutant and the 3’end / 5’mutant primers respectively as shown in 
Table 0.1:
Table 0.1: Annealing temperature samples for the 5’ end / 3’mutant and the 3* end /S’
mutant primers
Sample No. Primers DNA Temperaturerc)
1 5’end/3’M lOOng pCEPp53 53.5
2 5’end/3’M lOOng pCEPp53 55.7
3 5’end/3’M lOOng pCEPp53 59.4
4 5’end/3’M lOOng pCEPp53 63.3
5 5’end/3’M Blank 53.5
6 5’end/3’M Blank 55.7
7 5’end/3’M Blank 59.4
8 5’end/3’M Blank 63.3
9 3’end/5’M lOOng pCEPp53 53.5
10 3’end/5’M lOOng pCEPp53 55.7
11 3’end/5’M lOOng pCEPp53 59.4
12 3’end/5'M lOOng pCEPp53 63.3
13 3’end/5’M Blank 53.5
14 3’end/5’M Blank 55.7
15 3’end/5’M Blank 59.4
16 3’end/5’M Blank 63.3
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Table 0.2: The PCR reaction mix for the 5’ end/3’ mutant and the 3’ end 5’ mutant
primer
Samples
1-4
m
5x
(gl)
A
Samples
5-8
(Pi)
5x
(pl)
B
Samples
9-12
(Pi)
5x
Oil)
C
Samples
13-16
(Pi)
5x
Oil)
D
lOx AccuPrime 
Pfx Reaction 
mix
5 25 25 5 25 5 25
Accuprime Pfx 
DNA
polymerase
1 5 1 5 1 5 1 5
5’end
OligolO.lpMI
4.5 18 4.5 18
3’end
Oligo|0.1pM|
4.5 18 4.5 18
5’lMutant
lO.lpMl
4.5 18 4.5 18
3’Mutant
10.1 pM]
4.5 18 4.5 18
pCEPp53
lOOng/pI
1 5 1 5
PCR Grade
h2o
34 170 35 175 34 170 35 175
Control samples containing all of the PCR components except template DNA were 
included to detect the presence of DNA contamination. dNTP's were contained 
within the AccuPrime Pfx reaction mix (Invitrogen) and concentrations of primer and 
DNA were calculated according to the manufacturer's instructions.
Samples underwent the following regime in a thermal cycler PCR machine (Thermo- 
Fisher, Px2 thermal cycler)
Stage 1 1 cycle at 95°C for 1 minute (hot start)
Stage 2 Step 1) 94°C for 30 seconds (breaks DNA to single strands)
Step 2) Annealing Temp e.g. 53.5°C (see above)
30 seconds with 15 steps in temperature gradient
Step 3) 68°C for 1 minute (elongation)
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This initial PCR reaction was run for thirty cycles and is shown in Figure 0.8.
o o o o o o o U o U U o o oOir» Or- O OIT* oh*.
OT
*fA OIA o*T
OfA OIA O
rri LTi <r> I4*» o\ rri rr! in a> rA rA in cri <nin U*i in in in V£> in in in <£. in in in id
i 1 1 1 5’3M Blank 1 1 1 1 35M Blank
2 5 5 5 I 2 2 2 2 1/V. * . LA in IA in
Lri ir> in in r u in in in r
500
400
300
200
100
m
1111
* m
100 bp 
ladder 100ngpCEP4p53 for each condition 
30 PCR cycles.
Figure 0.8: Optimising the annealing temperatures for the 5’end / 3’mutant and the 3’end
/S’ mutant printers
Figure 0.8 demonstrates the result of PCR amplification at all temperatures for all primers, 
and with appropriately blank no-template control lanes. 20pi of the PCR products from each 
of the sixteen samples was combined with 3pi Orange G (2.1.19) and run on a 2% agarose 
gel, at 80 V for 2 hours, against 10pi of WObp ladder (MBI Fermatas). There were some non­
specific bands with the 5 ’ and / 3Mutant samples (indicated by arrows), but these were less 
pronounced at the higher annealing temperatures.
The PCR was hence repeated with the same primers and controls at 63.3°C for 5, 10, 
15 and 20 cycles. A higher annealing temperature and fewer PCR cycles reduces the 
error rate and improve the specificity of the primer-binding for the target sequence.
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35M Blank 
5-20 cycles
5'3M Blank 
5-20 cycles
100 bp 
ladder
All at63.3°C
From lOOng of pCep4p53 DNA 
lOpI run (from 50pl total PCR product)
Figure 0.9: Optimising cycle number using Timn (annealing temperature) =63.3oCfor the 
S’end / 3’mutant and the 3’end/S’ mutant primers
10pi of PCR product per condition was analysed by electrophoresis performed for 1.5 hours 
at 80 V on a 2% agarose gel. Adequate product for subsequent cloning was obtained with 20 
cycles of 5 'end / 3M only (red arrow), and with 15 cycles of the 3 'end /5M sample (black 
arrow).
The remaining 40f.il of the samples from these two conditions (S’BM - 20 cycles and 
3’5M - 15 cycles) was run on a preparative agarose gel and the resulting products 
were cut from the gel, by visualising the bands under long wave ultraviolet light, to 
use for the next stage of the mutagenesis process.
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Due to time constraints the remainder of the PCR mediated mutagenesis was 
executed by a colleague following completion of these laboratory studies. The above 
products underwent GENECLEAN (Q-BIOgene) and were then subjected to further 
PCR with the 5’end and 3’end primers. After a further GENECLEAN this product 
was then inserted into the pCEP vector at the Kpnl and Notl restriction sites as 
discussed previously in the Primer Design section.
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